NEXT Biometrics and M-Tech Join Forces on Biometric Smart Card Deployment in India

Oslo, February 11, 2019 –NEXT Biometrics (Oslo Bors: NEXT), a global leader in fingerprint sensor technology, today announced that it is partnering with M-Tech Innovations Ltd. (“M-Tech”) to develop and deploy biometric smart card solutions. The collaboration targets contact-based and dual interface biometric smart card solutions to address current and evolving banking card standards. It comprises NEXT`s sensor technology that is successfully being used in millions of devices in various industry segments worldwide. M-Tech is an accredited and certified RuPay, MasterCard and VISA card manufacturer and one of the largest smart card producers in India. In addition to the company`s strong foothold in the banking sector, M-Tech`s solutions are also used in government, access control, high-security and many more applications in India and beyond. “We are very pleased to announce the collaboration with M-Tech and the strong growth potential that this partnership offers. As outlined at the January 2019 Business Update, we are in the process of building a sustainable network with leading players in the smart card ecosystem to commercialize biometric dual interface technology in the banking sector and beyond,” said Alain Faburel, NEXT Biometrics Chief Sales and Marketing Officer. “NEXT`s flexible sensor technology offers proven high security and accuracy levels. This is particularly important for the high standards demanded in the payment sector and paramount for a secure and consistently positive user experience. The partnership with NEXT underlines our commitment to highest quality standards and continuous innovation,” said Vijay M. Gandhi, Chairman & Managing Director of M-Tech Innovations Ltd.

Ramsay Générale de Santé and Capio announce new executive committee for the combined Group

“Over the last two months, the numerous meetings I have had in each country have convinced me that our different teams share the same ambition of medical excellence, the same way of continuously improving quality of care, yet driven by different backgrounds. Our size, the diversity and complementarity of our jobs, as well as our medical innovations, are major assets that will help us transform the Group, accelerate our development and face the challenges of our changing ecosystem.”, says Pascal Roché, CEO of Ramsay Générale de Santé and Chairman of the Board of Capio AB. The Group's management structure will be based on a balance between countries’ business units, dedicated to the operational implementation of medical projects and development, and cross-borders functional units. The new Group Executive Committee comprises the following 15 people: ·  Pascal Roché, Chief Executive Officer ·  Odile Agopian, Chief Operations and Development Officer for Mental Health in France ·  Per-Helge Fagermoen, Chief Operations and Development Officer for Norway ·  Thomas Kiaer, Chief Operations and Development Officer for Denmark ·  Damien Michon, Chief Operations and Development Officer for MSO and FCR in France ·  Martin Reitz, Chief Operations and Development Officer for Germany ·  Britta Wallgren, Chief Operations and Development Officer for Sweden ·  Henrik Brehmer, Group Chief Strategy and Public Affairs Officer ·  François Demesmay, Group Chief Medical Innovation and Patient Experience Officer ·  Caroline Desaegher, Group Chief Communication and Brand Officer ·  Pierre Dupérat, Group Chief Risk, Audit and Investment Officer ·  Jean de Faultrier, Group Legal Counsel ·  Arnaud Jeudy, Group Chief Finance and Real-Estate Officer ·  Anne-Claire Liberge, Chief of Staff ·  Jamel Ouanda, Group Chief Integration and Best Practices Sharing Officer.   Pascal RochéCEO of Ramsay Générale de Santé andChairman of the Board of Capio AB

First patient treated in dose expansion cohort of Targovax's ONCOS-102 trial in melanoma

·Trial extended in checkpoint inhibitor refractory melanoma with up to 12 additional patients receiving an increased dosing regimen of 12 ONCOS-102 injections and 8 cycles of Keytruda  ·First patient in dose expansion cohort has received the first ONCOS-102 injection Oslo, Norway, 11 February 2019 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces that the first patient has received ONCOS-102 in the dose expansion cohort of the ongoing phase I trial in checkpoint inhibitor (CPI) refractory advanced melanoma, assessing ONCOS-102 in combination with the CPI Keytruda.   In September 2018, Targovax reported interim data for the first six patients of the ongoing ONCOS-102 trial in CPI refractory advanced melanoma, showing strong immune activation and one patient with a complete response (see press release here ). Results suggested that patients might benefit from more injections of Targovax’s oncolytic virus, and therefore a second dose cohort of twelve additional patients who will receive twelve, rather than three, ONCOS-102 injections has been initiated. The first patient on this extended dosing regimen has received the first ONCOS-102 injections and is ready for combination therapy with Keytruda. This also means that the first dosing cohort of the trial has been closed, with a total of nine patients enrolled. Magnus Jäderberg, CMO of Targovax, said: “We are very pleased that the proposed dose expansion cohort of our melanoma trial has been approved and is now underway. The results seen to date with only three injections of ONCOS-102 are promising, and we are confident that by increasing to twelve injections we will release the full potential of ONCOS-102 to reactivate these patients to respond to Keytruda treatment”. This phase I open label clinical trial enrolls advanced or unresectable melanoma patients who have progressed after PD-1 blockade. The trial has been extended with a new dose cohort where patients will receive four intra-tumoral ONCOS-102 over a 15-day period followed by Keytruda infusions in combination with intra-tumoral ONCOS-102 injections every three weeks for eight cycles. Up to twelve patients will be enrolled in the new dose cohort. In the first dose cohort the patients were scheduled to receive three intra-tumoral ONCOS-102 injections during the first week, followed by eight infusions of Keytruda. Nine patients were enrolled in the first dose cohort. The trial is enrolling patients at three sites in the US. 

Conference call regarding Elekta’s Q3 report for 2018/19

STOCKHOLM, February 11, 2019 – Elekta (EKTA-B.ST) will publish its Q3 report for 2018/19 on February 22, as per: · The report will be published at 07:30 CET. · Elekta will host a telephone conference starting at 10:00 CET with Richard Hausmann, President and CEO, and Gustaf Salford, CFO. To take part in the conference call, please dial in about five minutes in advance. · UK dial-in number: +44 (0) 333 300 9265 · US dial-in number: +1 646 722 4902 · Swedish dial-in number: +46 (0) 8 505 583 50 The telephone conference will also be broadcasted live online, through the following link (however, in order to ask questions, it is necessary to call in):http://event.on24.com/wcc/r/1919136-1/CA7E707987FE9817758D6C8899341F6F  # # # For further information, please contact:Oskar Bosson, Global EVP Corporate Communications and Investor RelationsTel: +46 70 410 7180, E-mail: Oskar.Bosson@elekta.comTime zone: CET: Central European Time Gunilla Öhman, Head of Investor Relations (interim)Tel: +46 70 763 8125, E-mail: gunilla.oehman@elekta.comTime zone: CET: Central European Time About ElektaFor almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com  or follow @Elekta on Twitter .

PHI and BioSpherix expand marketing partnership after scientific evaluation

In June 2018, Phase Holographic Imaging (PHI) and BioSpherix Medical entered a collaboration agreement, aiming to co-market the companies’ complementary product lines. BioSpherix  develops and market advanced hermetically sealed cell incubators for the control and optimization of cell culture environments. Since most cell analysis instruments are not adapted to cope with the demanding environment within cell incubators, analytical instruments are generally placed outside the incubator. Consequently, the cells need to be moved from the incubator into the uncontrolled laboratory environment for analysis, which currently limits the advantages of hermetically sealed incubators. PHI’s HoloMonitor® M4 time-lapse cytometer is one of the few instruments on the market that is designed to contin­u­ously operate inside a cell incubator. Together the companies’ products allow scientists to both culture and analyze living cells in an optimal cell environment. Since June, scientists at BioSpherix have successfully conducted a range of scientific experiments using Holo­Monitor. This prompted Håkan Rosvall from PHI to recently visit BioSpherix to discuss joint marketing activities, in connection with the research results being presented at scientific conferences. The first presentation will be held at the Society of Toxicology’s Annual Meeting  now in March. HoloMonitor M4 inside a BioSpherix cell incubator (top left). BioSpherix headquarters in Parish, NY USA (bottom left). Håkan Rosvall flanked by his hosts at BioSpherix (right). About BioSpherix BioSpherix Medical®, located in Parish, NY USA, designs, manufactures and sells advanced cell incubation for the control and optimization of laboratory cellular environments. Since its founding in 1982, BioSpherix has supplied equipment and systems to academic research, pharma­ceutical and bio­tech­nology organi­zations throughout the world for use in basic cell biology and stem cell research, as well as gene and cellular therapies.

Gaming Innovation Group reports Q4 2018

Gaming Innovation Group Inc. (GiG) reports €39.9 million in revenues in Q4 2018 and an EBITDA of €5.0 million. One-off items adversely impacted EBITDA by €1.8m in Q4 2018. Excluding one-off costs, EBITDA was €6.9m in Q4 and €18.9m for the full year 2018. “In Q4, we matched our previous all-time-high in revenues and for the full year 2018, we grew revenues and EBITDA with nearly 30% over 2017. After investing around €16m into tech and product development in 2018, we have now closed the circle and are offering products and services across all major verticals in the iGaming value chain. We have started our expansion into regulated markets with big brand partners, and we have launched our online and retail sports betting platform in the USA. I am really proud of what we have achieved and are looking forward to 2019.“, says Robin Reed, CEO of GiG.   Financial highlights · Operating revenues for Q4 2018 were €39.9m (39.9) in line with Q4 2017 and a 7% Q-on-Q increase. Full year 2018 revenues were €151.4m (120.4), an increase of 26% over 2017 · EBITDA in Q4 2018 was €5.0m (7.9), a decrease of 36% from Q4 2017. Full year 2018 EBITDA was €16.1m, an increase of 28% over 2017 · EBITDA in Q4 2018, excluding one-off costs, was €6.9m and €18.9m for the full year 2018 · B2B revenues in Q4 2018 were €16.4m (18.0), a decrease of 9% from Q4 2017 · Revenues for the Media vertical reached an all-time-high in Q4 2018 of €8.7m (8.5) · B2C revenues in Q4 2018 reached an all-time-high of €25.8m (25.4), +2% from Q4 2017 with an EBITDA of €0.7m (-2.1), €1.7m adjusted for one-off costs · Restructuring in the B2C segment impacted EBIT in Q4 2018 with a non-cash impairment of €13.7m · A further decrease in the number of employees in Q4 2018 resulted in an 8% decrease in other operating expenses quarter-on-quarter (adjusted for one-offs) Operational highlights · Omni-channel Sportsbook solution agreement with Hard Rock Intl., live in January 2019 · Two in-house developed games launched during Q4 2018 · Two new brands were signed to platform services in Q4 2018 and one new brand signed GiG Comply after the quarter · Awarded two licences in the newly regulated Swedish market and Spanish licence pending · New Board of Directors elected and a reversed stock split of 10:1 effective from 21 December 2018 · Applied for listing at NASDAQ Stockholm (main list) - planned for March 2019 Investor presentation and webcast: CEO Robin Reed will present the Q4 results at 10:00 CET at Helio GT 30, Grev Turegatan 30, Stockholm. The presentation will be given in English and available live via webcast and via a telephone link. Questions can be asked via the weblink. Link to the webcast: https://tv.streamfabriken.com/gig-q4-2018 Dial-in numbers for participation in the telephone conference: Norway: +4723500236 Sweden: +46856642703 United Kingdom: +443333009032 United States: +16467224904 For further information, contact: Robin Reed, CEO, +356 9999 0382 (Robin@gig.com) This information is information that Gaming Innovation Group Inc. (GiG) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on 11 February 2019. About Gaming Innovation Group Inc. (GiG): Gaming Innovation Group Inc. is a technology company providing products and services throughout the entire value chain in the iGaming industry. Founded in 2012, Gaming Innovation Group's vision is 'To open up iGaming and make it fair and fun for all'. Through our ecosystem of products and services, we are connecting operators, suppliers and users, to create the best iGaming experiences in the world. GiG operates out of Malta and is listed on the Oslo Stock Exchange under the ticker symbol GIG. www.gig.com

Johan Arvidsson appointed new CEO of Nexam Chemical

“I am very pleased to be able to present Johan Arvidsson as the successor to Anders Spetz. Johan has, during the last two years, successfully been responsible for sales within Nexam Chemical and been a member of the company´s management team. He is an experienced and engaging leader who has a deep knowledge of the company´s products and market and has a proven ability to create growth in an innovation driven business”, says Lennart Holm, Chairman of the Board. Johan Arvidsson has a degree in chemical engineering at Chalmers University of Technology. He started his professional career at Volvo and continued at the chemical group DuPont de Nemour, where he worked for 18 years. During his last years with the company, Johan was the CEO of DuPont Sverige AB. He then went on to the listed development company aXichem where he was the CEO until 2016 when Johan Arvidsson was recruited as CSO for Nexam Chemical. “I am convinced that Johan Arvidsson will be able to continue build and accelerate the growth of the company that started under the leadership of Anders Spetz. At the same time, I would like to thank Anders for a well-executed work during his four years as CEO. During these years, Nexam Chemical has grown from a promising development company to a business-driven specialty chemicals company with accelerating growth,” says Lennart Holm. The change of CEO is made in consensus between the company and Anders Spetz, who now intends to start a new chapter with his own business. “Nexam Chemical is now entering into a growth phase and it is time to hand over to Johan who has the right leadership, taking the company to the next level. I am happy and proud of what I and the team accomplished during the last four years and I wish Johan and everyone in Nexam Chemical great success. As a shareholder, I look forward to following the development of the company in the future”, says Anders Spetz. “I have, in my role as CSO, been part of the management team for two and a half years and have come to know the business very well. Nexam Chemical is now at a stage where a number of business development projects are starting to fall into place and turn into commercial sales. I look very much forward to lead the company into the next phase”, says Johan Arvidsson, new CEO of Nexam Chemical. Note: This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version. For further information please contact: Lennart Holm, Chairman of the Board, +46-706 30 85 62, lennart.holm@nexamchemical.com This information is information that Nexam Chemical Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on February 11, 2019. ___________________________________________________________________________ About Nexam Chemical Nexam Chemical develops technology and products that make it possible to significantly improve the production process and properties of most types of plastics in a cost-effective manner and with retained production technology. The improved properties include strength, toughness, temperature and chemical resistance as well as service life. The improvements in properties that can be achieved by using Nexam Chemical's technology make it possible to replace metals and other heavier or more expensive materials with plastics in a number of applications. In applications where plastic is already used, Nexam Chemicals products can improve the manufacturing process, reducing material use and enable more environmental friendly alternatives. Example of commercial applications: pipe manufacturing, foam production and high-performance plastics. More information about the business will be found on www.nexamchemical.com. The company´s Certified Adviser is FNCA Sweden AB. FNCA Sweden AB can be reached at info@fnca.se or by phone +46-8 528 00 399.

Follicum selects novel peptide drug candidate for the treatment of diabetes and protection of beta cells

Follicum AB ("Follicum" or "the company"), is a biotechnology company that develops new peptide drugs in two areas, hair loss and diabetes. In the diabetes project, peptides are being developed for the treatment of the disease itself as well as for some of the complications that are strongly over-represented in diabetics. Although several treatments are already on the market, new ones are urgently required. Furthermore, many contribute to an improved insulin release, but do not target the complications caused by the high blood sugar levels in a diabetic. These include cardiovascular disease including thrombus and myocardial infarction, fatty liver and impaired kidney function. Follicum's peptides have shown a positive effect on insulin release, an effect that is more pronounced at higher blood sugar levels. Thus, the peptides could contribute to stabilizing blood sugar levels, i.e. exactly mirroring the aim with diabetes treatment. In addition to high blood sugar levels, presence of inflammatory factors is normal in diabetic patients, which, among other things, leads to a deterioration of insulin-producing beta cell function. In addition to the effects on insulin release, Follicum's peptides have been shown to protect the beta cells when they are exposed to high sugar levels or inflammatory factors. If the function of the body’s own beta cells can be maintained, the ability of the diabetic patient to control blood sugar levels increases, and thereby, the risk of complications decreases. Additionally, the company also studies the direct effects of the peptides on various diabetes-related complications. Using an extensive selection process, the company has now chosen the most promising drug candidate for further development, initially in preclinical development by running further safetly and efficacy studies of safety. Based on the results of the preclinical program, the company will start the planning of a clinical phase I study in 2020. In addition to the selected drug candidate, three "follow-up" candidates have also been selected. These exhibit individual effect profiles that differ from the main candidate and they will be evaluated in parallel for treatment of other complications than those targeted by the main drug candidate. Jan Alenfall, CEO comments: “We are delighted to be able to select a drug candidate in the diabetes project. Several of our peptides exhibit good effects in initial studies. The peptides show different profiles between them, with effects on different types of diabetes-related complications. We now intend to evaluate this further in parallel with the preclinical development of the chosen drug candidate, not least because potential partners for the project have shown interest in the different types of complications.” For further information, please contact:Jan Alenfall – CEO, Follicum ABTelephone: +46 46 19 21 97Email: info@follicum.com This information is information that Follicum is obliged to make public according to the EU Market Abuse Regulation. The information was provided through the agency of the contact persons above, for publication on the 11th of February 2019. About DiabetesDiabetes is rapidly increasing globally. The disease is characterized by poor blood sugar control due to defective insulin signaling, which causes serious sequelae such as cardiovascular disease, renal failure, obesity, blindness and diabetic foot ulcers. Diabetes as well as it’s accompanying illnesses represent a major burden, partly for the individual patient, but also for the entire health care system. There is thus an already large and growing global need for new therapies that address effective control of glucose levels in combination with preventive effects on the various diabetic complications. Follicum's strategy is to drive a well-developed project in the diabetes field that is attractive to global partners. About Follicum’s peptidesFollicum's peptides consist of altered or unchanged fragments of human proteins. The selection of peptide sequences is based on over 20 years of academic research and the precursors of the peptides have shown good effects on the repair of tissue damage, especially in blood vessels. About Follicum ABFollicum is a biotech company focusing on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, Follicums research has resulted in a new peptide class which significantly increases the release of insulin in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Spotlight since 2014. www.follicum.com.

Scout Gaming enters Brazil with Jogajà

"We continue to build our global network and are excited about entering South America. We are experiencing a global increasing interest in Fantasy Sports gradually”, comments Scout Gaming CEO Andreas Ternström. Jogaja has recruited a team with wide experience from the gambling industry, led by Jacob Lindorff with background from Expekt, Betway and Bonnier Gaming. Jogaja is a startup backed by Swedish venture capitalists with previous experience from successful launches in Brazil. Scout Gaming's products are expected to be launched during the first half of 2019. As part of the Brazilian launch, the product range will be supplemented by local leagues. "Fantasy Sports has experienced a strong global growth with US as a leading market. The Brazilian sports betting market is the largest in South America therefore we see great potential for daily fantasy sports. Together with our partners, media companies and influencers, we will launch the coming spring and have high ambitions for the product ", comments Jacob Lindorff. For additional information, please contact:Andreas Ternström, CEO, Scout GamingTel: +46 706 770 660E-mail: andreas.ternstrom@scoutgaminggroup.com  About Scout Gaming GroupScout Gaming Group is a licensed and regulated provider of B2B Daily Fantasy Sports and pool betting. The company offers a flexible and customizable network-based Fantasy Sports solution with support for most sports and leagues through an in-house StatCenter which also provides real-time information to players. Local sports can be provided on request. The Group has approximately 70 staff and is headquartered in Stockholm, Sweden with development and operations in Bergen, Norway and Lviv, Ukraine. Sales, support and product management is handled from the office in Malta.

NeuroVive is supplied with approximately MSEK 99.0 in share issue proceeds

Approximately 55.1 percent of the Rights Issue was subscribed for on the basis of subscription rights, and the remainder, approximately 5.1 percent, without subscription rights. Furthermore, the guarantors are allocated approximately 19.8 percent of the total volume of the Rights Issue, which means that NeuroVive is provided with approximately MSEK 99.0 before issue costs, which are estimated to amount to approximately MSEK 17.7 (including compensation for the guarantee commitment of approximately MSEK 9.1, corresponding to 10 percent of the guaranteed amount of approximately MSEK 91.0).  – I would like to thank all existing shareholders who have participated in the issue for your continued support and warmly welcome our new shareholders. We are in a very exciting period in the Company's development where the financial resources now provided ensure the implementation of crucial value-creating activities in the coming year, primarily in our clinical phase projects, KL1333 for genetic mitochondrial disorders and NeuroSTAT - our brain injury project, but also in our preclinical projects, as well as in our business activities, says Erik Kinnman, CEO of NeuroVive. The allocation of shares in the Rights Issue has taken place according to the principles indicated in the prospectus dated January 22, 2019. Those who have been allocated shares without subscription rights will receive transaction notes, which are scheduled to be sent today on February 11, 2019. Those who have subscribed to shares without subscription rights through their nominees will receive notice of subscription according to their nominee's routines. Share capital and number of sharesThe Rights Issue means that the share capital increases by SEK 3,667,883.05 through the issue of 73,357,661 new shares. Following registration of the Rights Issue at the Swedish Companies Registration Office, the share capital of NeuroVive will amount to SEK 8,252,736.85 SEK, divided into 165,054,737shares, each with a quotientvalue of SEK 0.05. Trading in BTAsTrading with BTA (Paid-up subscribed shares) takes place on Nasdaq Stockholm between January 23 – February 15, 2019. The newly subscribed shares are booked as BTA on the VP account until the day before the Rights Issue has been registered with the Swedish Companies Registration Office, which is expected to take place around February 20, 2019. AdvisorsStockholm Corporate Finance AB acted as financial advisor, Cirio Advokatbyrå AB acted as legal advisor and Hagberg & Aneborn Fondkommission AB acted as issuing institution in connection with the Rights Issue. This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CET on February 11, 2019.  For more information, please contact:Catharina Johansson, CFO, IR & Communications+46 (0)46-275 62 21, ir@neurovive.com NeuroVive Pharmaceutical AB (publ) Medicon Village, 223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard)info@neurovive.com,www.neurovive.comFor news subscription, please visit http://www.neurovive.com/press-releases/subscription-page/ About NeuroVive  NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio also consists of projects for genetic mitochondrial disorders, cancer and NASH. The company advances drugs for rare diseases through clinical development into the market. For projects for common indications the goal is out-licensing in the preclinical phase. A subset of compounds under NeuroVive’s NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber’s Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).  About Stockholm Corporate Finance ABStockholm Corporate Finance is a Swedish, independent and privately owned financial advisor offering qualified transaction based advisory services by acting in capital raisings, changes in ownership, acquisition, merger and acquisitions (M&A) in listed and privately held companies. Stockholm Corporate Finance is the exclusive Swedish partner in the global network of M&A Worldwide consisting of 43 M&A advisors and investment banks in 44 countries. Stockholm Corporate Finance is an investment firm which is supervised by the FSA and is a member of the trade organization SwedSec Licensing AB. www.stockholmcorp.se. Important informationPublication or distribution of this press release in certain jurisdictions may be subject to restrictions according to law and the people in jurisdictions where this press release has been made public or distributed should inform themselves and follow such legal restrictions. This press release does not contain and does not constitute or form part of an invitation to acquire or subscribe or a solicitation of any offer to buy or subscribe for shares or other securities in NeuroVive. This press release may not be published or distributed, directly or indirectly, in or into the US, Australia, Hong Kong, Japan, Canada, New Zeeland, Switzerland, Singapore, South Africa or in any other jurisdiction where such distribution would be prohibited by applicable law. The information in this press release may not be redistributed, reproduced or passed on in ways that conflict with applicable restrictions. Failure to comply with these restrictions may constitute a violation of the United States Securities Act of 1933 or applicable laws of other jurisdictions. This press release contains certain forward-looking statements that reflect the NeuroVive's current views and expectations of future events as well as financial and operational development, including statements regarding new issues, and statements regarding guidance, planning, prospects and strategies. Words that are "referred", "expected", "expected", "planned", "estimated", "can", and other expressions that imply indications or predictions of future developments or trends, and which are not based on historical facts, are forward-looking information. Although the Company believes that these statements are based on reasonable assumptions and expectations, the Company cannot guarantee that such forward-looking statements will be implemented. As these forward-looking statements include both known and unknown risks and uncertainties, real outcomes can differ substantially from what is stated in forward-looking information. 

Presentation of Probi’s Q4 report 2018

Probi’s report for the fourth quarter 2018 will be published on Wednesday, 13 February at 8.00 a.m. CET. In conjunction with this, analysts, investors and media are invited to an audiocast telephone conference on the same day at 10.00 a.m., where CEO Tom Rönnlund and CFO Henrik Lundkvist will present and comment on the report. The presentation and presentation material can be obtained via www.probi.com  or https://tv.streamfabriken.com/probi-q4-2018 The presentation can also be followed via a telephone conference on the following telephone number:Sweden: +46 8 56 64 27 07UK: +44 33 33 00 90 31US: +1 83 35 26 83 82 After the presentation, conference participants will be able to ask questions. Questions can also be asked via the audiocast. An on-demand version of the presentation will be available at the address given above following the presentation. FOR FURTHER INFORMATION, CONTACT:Henrik Lundkvist, CFO, Probi, tel +46 46 286 89 41, e-mail: henrik.lundkvist@probi.com ABOUT PROBIProbi AB is a Swedish publicly traded bioengineering company. The vision of Probi is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research. Founded by scientists in Sweden in 1991, Probi is a multinational company with four sites, active in more than 40 markets around the world and holding over 400 patents worldwide. In 2017, Probi had net sales of MSEK 612. The Probi share is listed on Nasdaq Stockholm, Mid Cap. Probi has about 5,000 shareholders. Read more at www.probi.com

Redwood Pharma to Attend BIO-Europe 2019, Mar. 25 – 27 in Vienna for Partnering Discussions

RP101 is the Company’s lead program for the development of a novel treatment of chronic dry eye disease in postmenopausal women. The active substance is an endogenous small molecule already proven safe and effective in two Phase II clinical trials conducted in the US. The active substance is being repurposed and has been formulated in IntelliGel to control its release, reduce dosing and increase compliance. Redwood Pharma is underway with a clinical Phase II trial of RP101 in Europe. Dry eye disease is a large market with serious unmet needs – estimated to grow to USD 2.7 billion in 2022. RP101 will be the first therapy targeted towards a unique biological mechanism and the target patient population of postmenopausal women. IntelliGel is Redwood Pharma’s exclusive technology for the topical delivery of drugs to the front of the eye using a novel hydrogel based on poloxamers and water. IntelliGel is applied as an eye drop and gels upon contact with the eye. This transparent, lubricating, reversible thermogel allows for better compliance with fewer doses of medicines since the gel keeps the active substance in the eye longer; it allows for a reduction in the amount of active substance administered, a lowering of the number of doses and possible side-effects related to active substance. IntelliGel is currently used in dermatological products commercially sold in the US and China. IntelliGel can be used for both prescription-based, as well as, OTC products.

Karo Intressenter’s proposals ahead of the Extraordinary General Meeting in Karo Pharma on 14 February 2019

Karo Pharma has, at the request of Karo Intressenter, convened an Extraordinary General Meeting at 15:00 on 14 February 2019 to, inter alia, consider the election of a new Board of Directors. Karo Intressenter, which is the main shareholder of Karo Pharma and holds approximately 63 per cent of the total number of outstanding shares and votes in the company, proposes that the Board of Directors shall consist of six Board Members without any deputies, that the Board Member Håkan Åström is reelected, and that Bo Jesper Hansen, Erika Henriksson, Vesa Koskinen, Christoffer Lorenzen and Åsa Riisberg are elected as new Board Members with Bo Jesper Hansen as Chairman of the Board. Bo Jesper Hansen has indicated that he, due to his other assignments, would be willing to serve as interim Chairman of the Board until the end of the next Annual General Meeting, after which he would be available for a position as ordinary board member and vice Chairman of the Board. Marianne Hamilton, Thomas Hedner and Per-Anders Johansson will resign, and the Board of Directors will therefore, in case the Extraordinary General Meeting resolves in accordance with the proposal, consist of Bo Jesper Hansen, Erika Henriksson, Vesa Koskinen, Christoffer Lorenzen, Åsa Riisberg and Håkan Åström until the end of the next Annual General Meeting. At the Annual General Meeting 2018, it was resolved that the remuneration should be SEK 200,000 for each Board Member and SEK 500,000 for the Chairman of the Board. Karo Intressenter proposes that the remuneration for each Board Member as well as the remuneration for the Chairman of the Board shall remain unchanged until the end of the next Annual General Meeting, and that the remuneration shall be distributed pro rata between the resigning Board Members and the newly elected Board Members in relation to the amount of time the position was held. The proposal means that Håkan Åström, for the period as Chairman of the Board, shall receive remuneration equal to the amount determined by the Annual General Meeting for the Chairman of the Board (calculated pro rata for the period) and that he, for the period from the day of the Extraordinary General Meeting until the end of the next Annual General Meeting, shall receive remuneration equal to the amount determined for the other Board Members (calculated pro rata for the period). Information regarding the Board Members proposed for new election Bo Jesper Hansen, born in 1958, holds an MD PhD from the University of Copenhagen, and is, inter alia, Chairman of the Board of Laborie Inc. and vice Chairman of the Board of Orphazyme A/S. Previously, Bo Jesper Hansen was Executive Chairman of the Board of SOBI AB, Chairman of the Board of Topotarget A/S, Karolinska Development AB, and Ablynx NV, board member of Hyperion Therapeutics Inc. and Gambro AB, and served as CEO of Swedish Orphan International AB. Bo Jesper Hansen is independent in relation to Karo Pharma and its management as well as in relation to the company’s major shareholders. Bo Jesper Hansen does not hold any shares in Karo Pharma. Erika Henriksson, born in 1981, has studied business administration at the Stockholm School of Economics and is, inter alia, a board member of Eton and Director at EQT Partners and has previously been a board member of AcadeMedia and Scandic Hotels Group. Erika Henriksson is independent in relation to Karo Pharma and its management, but is not independent in relation to the company’s major shareholders. Erika Henriksson does not hold any shares in Karo Pharma. Vesa Koskinen, born in 1979, holds a M.Sc. (Econ.) from the Helsinki School of Economics and is, inter alia, Partner at EQT Partners and board member of Terveystalo Oyj, Touhula Oy and kfzteile24 GmbH. Previously he has been, inter alia, a board member of Roeser Group GmbH and Swiss Smile AG. Vesa Koskinen is independent in relation to Karo Pharma and its management, but is not independent in relation to the company’s major shareholders. Vesa Koskinen does not hold any shares in Karo Pharma. Christoffer Lorenzen, born in 1975, has studied marketing at Copenhagen Business School and is, inter alia, an Executive Vice President and a member of the Executive Board of Chr. Hansen Holding A/S, a board member of Hamlet Protein and vice Chairman of the Board of European Food & Feed Cultures Association. He has previously been Head of Corporate Strategy at H. Lundbeck A/S. Christoffer Lorenzen is independent in relation to Karo Pharma and its management as well as in relation to the company’s major shareholders. Christoffer Lorenzen does not hold any shares in Karo Pharma. Åsa Riisberg, born in 1974, holds a M.Sc in Financial Economics and Business Administration from Stockholm School of Economics and a major in International Business from Haute Etudes Commerciales (HEC) in Paris. She is a Partner at EQT Partners and a member of the Partners Committee at EQT. She has previously been a board member of, inter alia, Terveystalo Oyj, HTL-STREFA S.A., Atos Medical AB and Aleris AB. Åsa Riisberg is independent in relation to Karo Pharma and its management, but is not independent in relation to the company’s major shareholders. Åsa Riisberg does not hold any shares in Karo Pharma.       [1] The fund known as EQT VIII, comprising of EQT VIII SCSp acting by its alternative investment fund manager (gestionnaire), EQT Fund Management S.à r.l. EQT Fund Management S.à r.l. is a private limited liability company (société à responsabilité limitée), incorporated and existing under Luxembourg law, having its registered office at 26A, Boulevard Royal, L-2449 Luxembourg, registered with the Luxembourg Trade and Companies Register (Registre de Commerce et des Sociétés, Luxembourg) under number B 167.972, acting as manager (gérant) of EQT VIII SCSp, a Luxembourg special limited partnership (société en commandite spéciale) with its registered office at 26A, Boulevard Royal, L-2449 Luxembourg and registered with the Luxembourg Trade and Companies Register (Registre de Commerce et des Sociétés, Luxembourg) under number B 217.293.

Saab Receives Airbus Order for Overheat Detection Systems

The OHDS is based on new technology developed by Saab and detects bleed air leakage in an aircraft. The OHDS is set to be installed on all future A350 aircraft. “As a global leader in aeronautics, space and related services, Airbus is a very important customer for us and our commercial aircraft business. This contract is proof of the successful development of our new overheat detection system and its importance to our customers. We are proud to contribute to the A350 and see great market potential for this new system”, says Jessica Öberg, Senior Vice President and head of Saab business area Industrial Products and Services. The traditional method to detect overheating due to bleed air leakage in an aircraft, is to use a special type of electrical wiring filled with eutectic salt. The new system, introduced by Saab, uses fibre optical sensors throughout the bleed air ducts and an optical interrogator to generate and read the optical signals, leading to a system with a drastically reduced number of components. This has the benefit of installation simplicity, low weight and high reliability, while also opening up future additional measurement functions. For further information, please contact: Saab Press Centre, +46 (0)734 180 018 presscentre@saabgroup.com www.saabgroup.com www.saabgroup.com/YouTube Follow us on twitter: @saab  Saab serves the global market with world-leading products, services and solutions within military defence and civil security. Saab has operations and employees on all continents around the world. Through innovative, collaborative and pragmatic thinking, Saab develops, adopts and improves new technology to meet customers’ changing needs. 

DOCOMO Digital appoints Jonathan Kriegel as the firm’s next CEO

11th February, London  Jonathan Kriegel has been appointed as DOCOMO Digital’s next CEO, stepping up from his current role as the Chief Transformation Officer from 1st of April, to replace incumbent chief Hiroyuki Sato. Jonathan joined DOCOMO Digital in July 2018 and has been partnering with Hiroyuki Sato in driving transformation of the firm as a platform of choice in payments and digital marketing solutions for brands, merchants and telecom carriers. Prior to working with DOCOMO Digital, Jonathan served as CEO of another NTT DOCOMO group entity – DOCOMO Pacific, based in Guam. With over three decades of cross-functional leadership experience in the telecom industry with global majors such as Vodafone group, Jonathan brings deep expertise especially in shaping strategy, developing new markets and cross-border M&A. Hiroyuki Sato, an NTT DOCOMO group veteran, who has led DOCOMO Digital since inception will return to NTT DOCOMO to assume responsibility for developing new business, leveraging the experience and relationships acquired during his tenure at DOCOMO Digital.  Under his leadership, DOCOMO Digital has grown to become the preeminent mobile commerce platform enabling billions of dollars’ worth of transactions while unlocking latent value and enhancing experiences for telecom companies, merchants and their consumers around the world. “With the proliferation of connected devices and the advent of 5G, mobile commerce will continue to grow exponentially, and this presents tremendous opportunities for DOCOMO Digital as emerging markets catch-up quickly with more mature ones. I am deeply honored and excited to be entrusted with the responsibility for leading DOCOMO Digital as the payments and digital marketing spaces enter this period of accelerating growth.  With our demonstrated track record of innovation combined with the diversity embodied by our colleagues from over forty different nationalities, DOCOMO Digital has a unique opportunity to serve our partners and customers around the world with agility and at scale. I look forward to working with my DOCOMO Digital colleagues to bring our vision for DOCOMO Digital to fruition.”, Mr. Kriegel commented on his appointment.   -ENDS-

Invitation – Presentation of Sobi’s Q4/FY 2018 results

On 20 February, at 08:00 CET, Swedish Orphan Biovitrum AB (publ)  (Sobi™) will publish its report for the fourth quarter and full year 2018. Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same day at 14:00 CET. The event will be hosted by Sobi’s CEO and President, Guido Oelkers, and the presentation will be held in English. The presentation can be followed live, or afterwards on www.sobi.com. Slides used in the presentation will be made available on Sobi’s website prior to the telephone conference. To participate in the telephone conference, please call: SE: +46 8 505 583 53 UK: +44 33 330 092 73 US: +1 646 722 49 02Click here to go to the live webcast.  After the live event the webcast will be available on-demand via the same URL. --- About Sobi™Sobi™ is an international speciality healthcare company dedicated to rare diseases. Our vision is to be recognised as a global leader in providing access to innovative treatments that transform lives for individuals with rare diseases. The product portfolio is primarily focused on treatments in Haemophilia, Immunology and Specialty Care. Partnering in the development and commercialisation of products in specialty care is a key element of our strategy. Sobi has pioneered in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2017, Sobi had total revenues of SEK 6.5 billion and approximately 850 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com. For more information please contact Media relations/Investor Investor relationsrelationsLinda Holmström, Senior Jörgen Winroth, Senior IR AdvisorCommunications/IR Manager +46 708 734 095  +1 347 224 0819, +1 212 579 0506linda.holmstrom@sobi.com   jorgen.winroth@sobi.com Paula Treutiger, Head ofCommunications & InvestorRelations+46 733 666 599paula.treutiger@sobi.com

EQT acquires Kodiak Gas Services, LLC

· EQT Infrastructure has acquired Kodiak Gas Services, LLC, the fastest-growing and largest privately held contract compression business providing critical compression equipment in the US · Kodiak benefits from attractive long-term market dynamics, including growing US oil and gas production, increased centralization of compression needs and growing utilization of large compression to drive improved margins · EQT Infrastructure will support Kodiak’s growth with existing and new customers and will support the Company’s continued operational improvement by providing deep sector expertise in the Energy sector and Midstream end markets as well as its network of Industrial Advisors The EQT Infrastructure III fund (“EQT” or “EQT Infrastructure”) today announced that it has acquired Kodiak Gas Services, LLC (”Kodiak” or the “Company”) from The Stephens Group, LLC, a private investment firm representing the interests of Witt Stephens, Jr. and Elizabeth Campbell. Kodiak will maintain its corporate headquarters in Houston, Texas, under the continued leadership of President Mickey McKee, CEO David Marrs, and the Kodiak management team. Terms of the transaction were not disclosed. Founded in 2011, Kodiak is the largest privately owned contract compression company in the US; providing necessary compression equipment for the extraction of oil and transportation of natural gas in the United States. With over 1,130,000 revenue generating horsepower (“HP”) deployed across key basins, Kodiak has a differentiated offering focused on exceptional customer service and technical performance. Kodiak leverages its scale, multi-decade operational experience, strong customer relationships and leading data analytics and integration to deliver best in class service and mechanical availability. EQT will support Kodiak in its next phase of development as the Company focuses on continued expansion with existing and new customers, further strengthening its technology platform and enhancing the Company’s service offering. Moreover, EQT will leverage its bench of Industrial Advisors with extensive experience in the Energy and Midstream sectors to enhance growth and operational efficiencies. Alex Darden, Partner at EQT Partners, Investment Advisor to EQT Infrastructure, commented: “Kodiak’s differentiated service offering, strong commitment to customers and critical infrastructure at every juncture in the oil and gas value chain make the Company unique in their industry, embodying EQT Infrastructure’s approach of targeting high-quality, industry leading, stable businesses with transformation potential. We are impressed with Kodiak’s continued transformation through data implementation and strong growth and believe that the Company’s ambition and people will continue to have positive impacts going forward. We are excited to help build and shape the next phase of development for Kodiak and look forward to working with such a talented group of people and outstanding executive management team who share the same culture, values and drive as EQT.” “We are extremely excited to be partnering with EQT to continue to grow Kodiak as the premier provider of contract compression services in the US. EQT brings a wealth of knowledge to our partnership and together, we will create a platform to continue to attract the best customers, in the best basins, to provide the highest level of contract compression services in the business,” commented Mickey McKee, President of Kodiak. “With our focus on the essential, large horsepower infrastructure-type compression applications, coupled with our relentless commitment to runtime and customer service, Kodiak is well-positioned to continue to profitably grow and take market share.” “The EQT Team understands the critical nature of contract compression in serving our nation’s energy infrastructure. EQT’s partnership with Kodiak will allow us to continue achieving industry leading profitability and growth rates while continuing to provide the best service in the industry,” commented David Marrs, CEO of Kodiak. “EQT has made a substantial commitment to Kodiak and we are very excited to continue this path with their support, vast industry experience and knowledge.” Simpson Thacher & Bartlett LLP served as legal advisor to EQT Infrastructure. Jefferies LLC served as exclusive financial advisor and Kirkland & Ellis LLP acted as legal counsel to Kodiak.   ContactAlex Darden, Partner at EQT Partners, Investment Advisor to EQT Infrastructure, +1 917 281 0840 US inquiries: Stephanie Greengarten, +1 646 687 6810, stephanie.greengarten@eqtpartners.com International inquiries: EQT Press Office, +46 8 506 55, 334, press@eqtpartners.com  About EQTEQT is a leading investment firm founded in 1994, with more than EUR 50 billion in raised capital across 28 funds. EQT funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 19 billion and approximately 110,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership.  More info: www.eqtpartners.com About Kodiak Gas Services, LLCFounded in 2011, Kodiak is a market-leading provider of contract compression and related services for the oil and gas industry in North America. Servicing the producers in both the upstream and midstream segments of the value chain, Kodiak provides 24/7 access to technical and mechanical support backed by a 98% mechanical availability guarantee. With over 285 employees, Kodiak provides services in the Permian, Eagle Ford, Scoop/Stack and other basins of the United States with its headquarters located in Houston, Texas. More info: www.kodiakgas.com About The Stephens Group, LLCThe Stephens Group is a private investment firm that partners with talented management teams to help build valuable businesses. Backed by the resources of the Stephens family, it has a long history of providing sophisticated, strategic expertise and taking a partnership approach to help companies successfully achieve their strategic visions and build long-term value. With over $1 billion invested since 2006, The Stephens Group targets investments in industries across the U.S., including industrial and commercial products and services, specialty distribution, technology infrastructure and tech-enabled services, B2B food and consumer products, as well as select opportunistic situations. More info: www.stephensgroup.com

Minesto raises SEK 44.4 million from warrants program

Commenting on the outcome of the warrants program Minesto’s CEO Dr Martin Edlund said: “We are pleased that so many have chosen to exercise their warrants and subscribe for new shares in Minesto. We will use this capital injection together with our other sources of funding to continue the development of our Deep Green technology as well as existing and new projects, to establish our product on the market.” In total, 6,336,031 new shares in Minesto AB were subscribed through the warrants program, corresponding to a subscription rate of 97.8 percent. This means that Minesto will add approximately SEK 44.4 million in proceeds before deduction of issue costs. The new shares have been delivered to the subscriber's account as interim shares. Next, they will be admitted to trading on Nasdaq First North as soon as the issue has been registered with the Swedish Companies Registration Office and Euroclear, which is expected to occur about three weeks after the subscription period’s ending on 8 February. Advisor Stockholm Corporate Finance AB acted as financial advisor and MAQS Law Firm acted as legal advisor to Minesto in connection with the rights issue carried out in February 2018 and in which the warrants of series TO 2 were issued. For additional information please contact Magnus MatssonCommunications Manager, Minesto AB+46 31 774 14 89press@minesto.com The information in this press release is such that Minesto AB (publ) shall announce publicly according to the EU Regulation No 596/2014 on market abuse (MAR). The information was submitted for publication, through the agency of the contact person set out above, at 15:45 CET on 11th of February 2019. About Minesto Minesto is a marine energy technology company with the mission to minimise the global carbon footprint of the energy industry by enabling commercial power production from the ocean. Minesto’s award winning and patented product, Deep Green, is the only verified marine power plant that operates cost efficiently in areas with low-flow tidal streams and ocean currents. In May 2015, Minesto secured a €13m investment from the European Regional Development Fund through the Welsh European Funding Office, for the commercial rollout of Deep Green. Minesto was founded in 2007 and has operations in Sweden, Wales, Northern Ireland and Taiwan. The major shareholders in Minesto are BGA Invest and Midroc New Technology. The Minesto share (MINEST) is traded on the Nasdaq First North Stockholm stock exchange. Certified Adviser is G&W Fondkommission, email: ca@gwkapital.se, telephone: +46 8 503 000 50. Read more about Minesto at www.minesto.com Press images and other media material is available for download via bit.ly/minestomedia. About Stockholm Corporate Finance Stockholm Corporate Finance is an independent, privately held, financial advisor which offers financial advisory services in capital raising, ownership restructuring and M&A-services, for listed and privately held companies as well as their owners. Stockholm Corporate Finance is the exclusive Swedish partner in the global network M&A Worldwide, which consists of 51 M&A-advisors and investment banks in 45 countries. Stockholm Corporate Finance acts under the supervision of the Swedish Financial Supervisory Authority, and is a member of the licensing organization SwedSec Licensing AB. For more information, visit: www.stockholmcorp.se

ADDvise enters into an agreement to acquire Sonar Oy

ADDvise Group AB (publ) (”ADDvise”) has today entered into an agreement with the shareholders of the Finnish company Sonar Oy (“Sonar”) regarding the acquisition of all shares in Sonar. The closing is expected to take place on March 1st, 2019 (the “Acquisition”). The signing of the Letter of Intent regarding the Acquisition was made public in a press release on December 12th, 2018. · The purchase price amounts to MEUR 3.2 (corresponding to MSEK 33.6) and is based on a cash and debt free basis and will be paid in cash. · An earn-out of a maximum of MEUR 1.1 (corresponding to MSEK 11.6) may be paid out over two years and is based on that certain earning targets are met. · The fiscal year of 2018, Sonar had a revenue of MEUR 7.0 (corresponding to MSEK 73.6) and an adjusted EBITDA of MEUR 0.8 (corresponding to MSEK 8.4). Sonar in brief Sonar is operating within two business segments: Healthcare and Industry, where 60 percent of the revenue is generated from the Healthcare segment. The product portfolio consists of ultrasound and X-ray systems, among other products. The revenue for 2018 amounted to approximately MEUR 7.0 with an adjusted EBITDA of approximately MEUR 0.8.  Purchase price and financing The initial purchase price amounts to MEUR 3.2 based on a cash and debt free basis and is paid in cash. A possible earn-out of maximum MEUR 1.1 may be paid given that certain earning targets are met. The earn-out may indicatively be paid in Q2 2020 and Q2 2021. The Acquisition will be financed with own funds as well as with proceeds from the rights issue completed in February 2019. Closing is expected to take place March 1st, 2019. Advisor Mangold Fondkommission AB is the financial adviser and Krogerus is the legal advisor to ADDvise in connection with the Acquisition.  For further information, please contact: Rikard Akhtarzand, CEO. +46 765-25 90 71 rikard.akhtarzand@addvisegroup.se www.addvisegroup.se Important information   This information is required for ADDvise to disclose under the EU Market Abuse Regulation. The information was submitted for publication on February 11th 2019 at 16:15 CEST. About ADDvise  ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com

STOREBRAND ASA: Storebrand strengthens private equity position through acquisition of Cubera

Storebrand Asset Management has entered into an agreement to acquire Cubera Private Equity [Cubera]. Cubera is a Nordic firm offering investors exposure to Nordic private equity primarily through the secondary market. The firm is a leading player within Nordic private equity and has around NOK 9 billion under management, mainly from international investors. - The transaction strengthens our offering to institutional asset management clients. Storebrand is today the only provider in Norway that includes private equity in its defined contribution portfolios, says Group CEO Odd Arild Grefstad. Storebrand Asset Management is Norway's largest private asset manager with more than NOK 700 billion under management. Storebrand has more than 20 years of experience with private equity and more than NOK 19 billion invested globally for Nordic clients.  - We are building a strong Nordic private equity provider with the largest team of investment professionals in the region. This complements our private equity offering, and makes us a natural partner for international clients seeking investments in the Nordics. This supports our strategy to broaden our international client base, says EVP Asset Management Jan Erik Saugestad.   Cubera's managing partner Kine Burøy-Olsen looks forward to building a larger private equity team. - Cubera and Storebrand International Private Equity is a perfect match. We both have long experience and deep private equity expertise, but we operate in different markets and with different investors. Joining forces will strengthen our position both in the Nordics and internationally. We are proud of what Cubera has achieved so far and we look forward to exploring the opportunities arising from this merger, says Burøy-Olsen. The acquisition is in line with the strategy Storebrand communicated at its capital markets day in May 2018 – to look for bolt-on acquisitions that complement our current business to create growth. - Cubera will be run as a separate company as a part of Storebrand's multi-boutique platform. Clients demand broader and more diversified investment offerings and this strengthens our position within alternative investments, says EVP Asset Management Jan Erik Saugestad. The transaction will have limited effect on regulatory key figures and the acquisition will not affect the dividend capacity of Storebrand for the accounting year 2018. Profits from the company will back the cash generation for the Storebrand Group going forward. Cubera's adjusted pretax 2018 results are estimated to be approximately NOK 50 million. The purchase price of the acquisition is NOK 300 million. The purchase price may increase related to fundraising to new funds managed by Cubera. The transaction is contingent on regulatory approvals and certain other customary conditions. Lysaker, 11 February 2019 Contact CFO, Lars Aa. Løddesøl:  lars.loddesol@storebrand.noor (+47) 934 80 151 SVP Communications, Vibeke Hansen: vibeke.hansen@storebrand.no  or (+47) 990 13 349 Storebrand's ambition is to be the best provider of saving for pensions. Storebrand will deliver sustainable solutions adapted to the customer's individual situation, so that each person receives a better pension in a more sustainable world. Storebrand has about 40.000 corporate customers and 2 million individual customers, and is headquartered in Lysaker outside of Oslo, Norway. Storebrand manages NOK 700 bn and is Norway's largest asset manager. We work hard to reach our vision: Recommended by our customers. Storebrand (STB) is listed on Oslo Stock Exchange. Visit us at www.storebrand.no and follow us on twitter: @Storebrand_no This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

BioArctic: U.S. Food and Drug Administration Approves Investigational New Drug Applicationfor ABBV-0805

· ABBV-0805 is being evaluated as a potential disease modifying treatment for Parkinson’s Disease Stockholm, Sweden, February 11, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that AbbVie has received approval from the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for ABBV-0805. This is a requirement to start clinical trials in the U.S. ABBV-0805, previously named BAN0805, is the most advanced within the portfolio of alpha-synuclein targeting antibodies in-licensed by AbbVie from BioArctic in December 2018. The antibody is being evaluated as a disease modifying treatment for Parkinson’s disease. The first clinical study is planned to start in 2019. ABBV-0805 is a result of a strategic research alliance between BioArctic and AbbVie focused on the development of a potential immunotherapy for Parkinson’s disease. AbbVie is responsible for the clinical development of ABBV-0805. Parkinson’s disease is the second most common neurodegenerative disease in the world and is expected to grow from approximately 6.2 million patients to 12.9 million by 2040 1. Mutations in the alpha-synuclein gene are strongly linked to the development of Parkinson’s disease in a small number of patients with an inherited form of the disease. Alpha-synuclein accumulation in the form of toxic aggregates and intracellular deposits (Lewy bodies) is a key neuropathological feature of the more common sporadic Parkinson’s disease. “I am very pleased that AbbVie has received FDA approval of the IND for ABBV-0805. I see this as a result of the successful partnership and an acknowledgement of the high-quality deliveries from BioArctic. Our aim is that ABBV-0805 can continue to develop into a therapy with the potential to provide meaning advances for patients with Parkinson’s disease,” said Gunilla Osswald, Ph.D., CEO, BioArctic. For more information, please contact:Gunilla Osswald, PhD, CEO, BioArctic ABE-mail: gunilla.osswald@bioarctic.seTelephone: + 46 8 695 69 30 Christina Astrén, IR & Communications Director, BioArctic ABE-mail: christina.astren@bioarctic.seTelephone: + 46 70 835 43 36 This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, at 05.00 p.m. CET on February 11, 2019. Notes to editors About Parkinson’s diseaseParkinson’s disease is a progressive disease of the nervous system that is associated with reduced levels of dopamine in the brain. Tremor and movement disturbances are the pathological hallmarks of the disease, but it is also characterized by dementia, depression, sleep disturbance and other symptoms. As the second most common neurodegenerative disease, after Alzheimer’s disease, Parkinson’s disease affects a large number of individuals and their families. Many who fall ill are still at working age resulting in considerable financial consequences for the individual and society. Patients with Parkinson’s disease suffer from an extensive loss of nerve cells in a part of the brain associated with movement. These nerve cells contain the so-called Lewy bodies consisting of aggregated misfolded alpha-synuclein that are associated with cell loss. Alpha-synuclein aggregates can also be released from the cells and travel to neighboring cells, whereby the disease is spread from one area of the brain to another. Research has shown that mutations in the alpha-synuclein gene lead to Parkinson’s disease. 1)     Dorsey and Bloem, JAMA Neurology 2018;75:9-10 About BioArctic ABBioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential.BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B).For more information about BioArctic, please visit www.bioarctic.com.

Moberg Pharma and Bayer sign exclusive license agreement for MOB-015 in Europe

Moberg Pharma has entered into a license agreement granting the Consumer Health division of Bayer exclusive European rights to MOB-015, a new topical treatment of onychomycosis based on Moberg’s patented proprietary formulation of terbinafine. Bayer will be marketing, distributing and selling MOB-015 in Europe upon completion of Phase III clinical development and registration. “We are thrilled to partner with Bayer for the European launch, as part of our vision of making MOB-015 the leading nail fungus treatment worldwide. This is the second major agreement for MOB-015 and a further validation of the significant market potential for our asset,” says Peter Wolpert, Moberg Pharma’s CEO. Under the terms of the license agreement, Moberg Pharma will finalize the ongoing Phase III program, complete registration in Europe and provide supply for the product. Moberg Pharma is eligible to receive up to EUR 50 million in milestone payments, including EUR 1.5 million paid at signing. The majority of the milestone payments are contingent on sales targets, with the balance contingent on development and regulatory milestones.  Moberg Pharma will also receive supply fees including royalties. “We are excited about the opportunity to partner with Moberg and the potential to bring this cutting-edge technology to market in order to advance one of our key categories,’’ says Heiko Petersen, Head of Bayer’s Global Category Business Unit Dermatology. The European OTC market for onychomycosis drugs amounted to EUR 192 million in 2017, growing at 2.6%(Source: Nicholas Hall DB6 database, 2017 update, value in Euro @ MSP prices). About this informationThis information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 6.00 p.m. CET on February 11th, 2019. About MOB-015 and OnychomycosisApproximately 10% of the general population suffer from onychomycosis and a majority of those afflicted go untreated. The global market opportunity is significant with more than hundred million patients worldwide and a clear demand for better products. Moberg Pharma estimates the annual worldwide peak sales potential for MOB-015 to be in the range of USD 250-500 million. MOB-015 is an internally developed topical formulation of terbinafine based on Moberg Pharma’s experience from its leading OTC product Kerasal Nail®/Emtrix®. Oral terbinafine is currently the gold standard for treating onychomycosis but associated with safety issues, including drug interactions and liver damage. For many years, developing a topical terbinafine treatment without the safety issues of oral terbinafine has been highly desirable, but unsuccessful due to insufficient delivery of the active substance through the nail. In a previous phase 2 study, MOB-015 demonstrated delivery of high microgram levels of terbinafine into the nail and through the nail plate into the nail bed. Mycological cure of 54% and significant clear nail growth was observed in patients who completed the phase 2 study. The results are remarkable, particularly when taking into account the severity of the nails included in the study – on average approximately 60% of the nail plate was affected by the infection. Plasma levels of terbinafine with MOB-015 were substantially lower than after oral administration, reducing the risk of liver toxicities observed with oral terbinafine. MOB-015 is currently being evaluated over 52 weeks in two randomized, multicenter, controlled Phase 3 studies, including in total approximately 800 patients in North America and Europe. The primary endpoint in both studies is the proportion of patients achieving complete cure of their target nail. Topline results from the North American study are expected in the fourth quarter of 2019, followed by results in Europe in 2020.

Ericsson and Intel jointly develop next-generation software defined infrastructure for the 5G era

Ericsson (NASDAQ: ERIC) and Intel Corporation have begun a multi-year collaboration to align ongoing development efforts in software-defined infrastructure (SDI) and Intel® Rack Scale Design. The resulting next-generation infrastructure management platform will deliver a new level of cloudlike agility, transparency and efficiency required for Network Functions Virtualization (NFV), distributed cloud, and 5G. Many communications service providers have already started transitioning to standards-based servers to reduce infrastructure costs. However, others need additional management capabilities to streamline operations and fast-track delivery of new services, in order to realize the full potential of their infrastructure. Ericsson and Intel are teaming up to deliver a next-generation hardware management platform that extends the agility of the cloud to the hardware infrastructure layer. For service providers, the new infrastructure management solution will help speed time-to-market, maximize utilization, and reduce total cost of ownership. As part of the multi-faceted agreement, the companies will align development efforts of Ericsson SDI Manager software and Intel® Rack Scale Design (Intel® RSD) and extend these solutions with advanced management capabilities. These unified development efforts will allow operators to leverage multi-vendor hardware options, Ericsson’s end-to-end software solutions, and Intel’s latest architectural innovations. Lars Mårtensson, Head of Cloud & NFV infrastructure, Business Area Digital Services, Ericsson, says: “We have long history of successful collaboration with Intel. This new collaboration will focus on software in addition to hardware and we see it to be truly transformative for service providers’ ability to successfully deploy open cloud and NFV infrastructure, from centralized datacenters to the edge. Intel’s and Ericsson’s joint efforts significantly strengthens the competitiveness and roadmap of the Ericsson Software Defined Infrastructure offering.” Sandra Rivera, Senior Vice President, Network Platform Group, Intel, says: “5G will be transformative, accelerating today’s applications and triggering a wave of new usages and edge-based innovation. Our infrastructure manageability collaboration with Ericsson will help communications service providers remove deployment barriers, reduce costs, and deliver new 5G and edge services with cloudlike speed on a flexible, programmable and intelligent network.” As part of the collaboration, Ericsson and Intel will converge Ericsson SDI Manager software and Intel RSD reference software while maintaining full backward compatibility for current customers. Jointly-developed software and hardware innovations resulting from the collaboration will be offered in subsequent Ericsson hardware platforms and may also be offered with Intel’s server products which are sold through other partners and in other industry segments. Ericsson SDI system is based on Intel RSD and provides a common managed hardware pool for all workloads that dynamically scales and enables fast service rollout, performance optimization and efficient hardware utilization. Intel RSD is an industry-wide architecture for disaggregated, composable infrastructure that fundamentally changes the way a data center is built, managed, and expanded over time. The companies will show the Ericsson SDI Manager at Mobile World Congress 2019 in Barcelona, February 25-28. NOTES TO EDITORS: FOLLOW US: www.twitter.com/ericsson www.facebook.com/ericsson www.linkedin.com/company/ericsson Subscribe to Ericsson press releases here . MORE INFORMATION AT: Ericsson Newsroom   media.relations@ericsson.com (+46 10 719 69 92) investor.relations@ericsson.com (+46 10 719 00 00) About EricssonEricsson enables communications service providers to capture the full value of connectivity. The company’s portfolio spans Networks, Digital Services, Managed Services, and Emerging Business and is designed to help our customers go digital, increase efficiency and find new revenue streams. Ericsson’s investments in innovation have delivered the benefits of telephony and mobile broadband to billions of people around the world. The Ericsson stock is listed on Nasdaq Stockholm and on Nasdaq New York. www.ericsson.com Ericsson at Mobile World Congress 2019Join or follow Ericsson at MWC 2019 in Barcelona from February 25 to 28 and experience the future of 5G and IoT innovation. We will present unique insights on 5G business opportunities and showcase use cases that enhance service providers’ business and customer experiences. Take the opportunity to learn more about the latest trends and technology shaping the ICT industry, now and in the future. Join us live and online at www.ericsson.com/mwc

Moberg Pharma divests its OTC-business for USD 155 million and secures new funding for MOB-015 in transformational transaction

Summary of the transaction and its overall effects ·  The Company has entered into the following agreements regarding the divestment of the OTC-business and the funding of the MOB-015 pipeline program: · a share purchase agreement, whereby all shares in MPJ OTC AB and all units in the Company’s American subsidiary, Moberg Pharma North America LLC – which together at closing will hold Moberg Pharma’s entire Global Consumer Health Business comprising both direct and distributor sales under the over-the-counter brands Kerasal®, Kerasal Nail®, New Skin®, Dermoplast®, Domeboro®, Emtrix® and Zanmira®, including all assets and liabilities related to such business (the “OTC-business”) – will be transferred from the Company to the Purchaser for a cash consideration of USD 155 million (equivalent of SEK 1,431 million), to include a customary working capital adjustment to be determined upon closing (the “Cash Consideration”). The transaction is expected to result in a capital gain of approximately SEK 500 million. Since the transaction involves the divestiture of subsidiaries it is not expected to be subject to taxation. The Cash Consideration will be used by the Company to redeem its outstanding SEK 600 million bonds and make a payment to its shareholders of approximately SEK 43­­–45 per share; · an investment and subscription agreement, whereby the Purchaser undertakes to subscribe for newly issued series B shares, which will constitute a new class of shares, in the Company for an aggregate subscription amount of USD 2.5 million (equivalent of SEK 23 million) at a subscription price of SEK 35.16 per share, valuing MOB-015 at approximately SEK 630 million (equivalent of USD 70 million) (the “New Shares”); and · an investment and warrant instrument undertaking, whereby the Purchaser undertakes to (i) subscribe for 659,421 newly issued warrants in the Company, each of which gives the holder a right to subscribe for one ordinary share in the Company at a subscription price of SEK 35.16 per share, (the “Warrants”) and (ii) provide a loan to the Company with a principal amount of USD 2.5 million (equivalent of SEK 23 million) (the “MOB-015 Loan”). ·  In addition, the Company will prior to or upon closing of the transaction enter into: · an asset transfer agreement, whereby the OTC-business of Moberg Pharma will be separated and transferred to the special purpose vehicle MPJ OTC AB; and · a transitional services agreement, whereby Moberg Pharma will provide certain services to MPJ OTC AB with respect to the OTC-business. ·  Completion of the divestment of the OTC-business (“Closing”), including the steps described above, is expected by the end of March 2019, but conditional upon: · the passing at a general meeting in Moberg Pharma of a resolution to approve the contemplated transaction and any other steps related thereto, passed with the relevant required majority; · the waiting period (and any extension thereof) applicable to the share purchase agreement and the transaction under the HSR Act (Hart-Scott-Rodino Antitrust Improvements Act) shall have been terminated or shall have expired; · certain fundamental warranties under the share purchase agreement being true, accurate and not misleading on Closing; and · the Purchaser having received debt financing on certain specified terms. ·  The parties have agreed on a termination fee and reimbursement of expenses on a mutual basis, entailing that Moberg Pharma is entitled to a termination fee of USD 6 million (equivalent of SEK 55 million) if Closing does not take place solely due to the Purchaser’s failure to receive the relevant debt financing according to the abovementioned closing condition, whereas the Purchaser is entitled to reimbursement from the Company of any direct external expenses incurred in connection with the transaction if the transaction is not approved by the general meeting in Moberg Pharma. ·  The Company intends to announce a notice for an extraordinary general meeting in Moberg Pharma to approve the proposed transaction and any other steps related thereto. Such general meeting is expected to be held on or about March 15th, 2019 (the “Extraordinary General Meeting”). In due time before the Extraordinary General Meeting, the Company intends to make public an information document containing information regarding the transaction and its effects for Moberg Pharma. ·  Shareholders representing approximately 39% of the voting rights in the Company have entered into voting undertakings in which they commit to, at the Extraordinary General Meeting, vote in favour of the transaction as well as of electing a person suggested and nominated by the Purchaser as an ordinary board member of the Company for the period from Closing up to and including the next annual general meeting in Moberg Pharma. ·  The Company intends to use part of the Cash Consideration to redeem its outstanding SEK 600 million bonds due 2021 with ISIN SE0007953989 (the “Bonds”) in full in accordance with the terms and conditions for the Bonds. ·  The Company further intends to use the remaining part of the Cash Consideration net of the Company’s transaction expenses and cash retained for the MOB-015 development program to make a payment to its shareholders, which may include a formal dividend distribution, share split and redemption of split shares, reduction of the share capital or similar events (the “OTC-dividend”). ·  The combined value to shareholders of the transaction equals approximately SEK 78–80 per share and can be calculated as follows: · The OTC-dividend which is expected to be approximately SEK 43–45 per share to be distributed to shareholders. · Subscription in the Company for USD 2.5 million at a subscription price of SEK 35.16 per share. ·  Post-Closing, the Company will be well funded by the USD 5 million from the New Shares and the MOB-015 Loan as well as a portion of the proceeds. Rationale for the transaction ·  Realizes compelling value for the OTC-business: The Cash Consideration of USD 155 million (equivalent of SEK 1,431 million) allows shareholders to recognize the value the Company has created in developing its OTC-business over the last years. The OTC-business generated sales of SEK 434 million. The transaction implies a multiple for the entire Moberg Pharma group of 3.3x sales and 11.6x EBITDA for commercial operations (14.1x EBITDA for total Moberg Pharma). ·  Provides continued funding for MOB-015 at an attractive implied value: The Company will receive USD 5 million (equivalent of SEK 46 million) to support on-going development of MOB-015. This will include USD 2.5 million (equivalent of SEK 23 million) received from newly issued series B shares at a subscription price of SEK 35.16 per share, implying a value for MOB-015 of approximately SEK 630 million (equivalent of USD 70 million). ·  Offers shareholders meaningful near-term liquidity and preserves future upside: The transaction will allow the Company to both redeem the Bonds and distribute substantial proceeds to shareholders. In addition, the Company and Management will be focused on development and commercialization of the pipeline, with a focus on MOB-015. Shareholders will continue to benefit from future value creation associated with the MOB-015 program. Peter Wolpert, CEO Moberg Pharma, says: “We are excited to announce this transformational transaction. The transaction delivers exceptional value for the OTC-business and further validates the significant potential in MOB-015. The proceeds from this transaction offer near-term liquidity to our shareholders while preserving future upside. I would like to commend and thank our team for all of their hard work. Over the last few years we have acquired, built and generated superior performance for the company, and those efforts are reflected in this transaction.” RecommendationThe transaction is, inter alia, conditional upon shareholder approval at a general meeting in the Company. Against the background provided in this press release, the Board of Directors of the Company consider the terms of the transaction to be fair and reasonable and in the best interests of the Company and its shareholders. Accordingly, the Board of Directors unanimously recommend that the Extraordinary General Meeting approves the transaction by voting in favour of proposed resolutions to be included in the notice for the Extraordinary General Meeting. The recommendation by the Board of Directors is supported by a diligent auction process conducted by the Company’s financial advisor Sawaya Partners LLC aimed at providing the Company and the shareholders with the best possible transaction outcome in terms of value and deal certainty, where multiple third party transaction proposals and offers were evaluated, and where this transaction was compared with similar transactions, of which this transaction was determined by the Board of Directors to offer the shareholders the best value and highest level of deal certainty. The Board of Directors, accordingly, based on this process, found the current transaction to be fair and reasonable and in the best interests of the Company and its shareholders. Thomas Eklund, Chairman of the board at Moberg Pharma, added: “After a thorough process, the board is convinced that the proposed transaction is the most attractive and brings significant value to the shareholders. The combination of a premium consideration for the OTC-business, specialized U.S. Healthcare investors entering at a premium valuation, while repaying outstanding debt, is highly attractive. Shareholders benefit from receiving a significant dividend while retaining the considerable upside of the MOB-015 program.” Use of Cash Consideration for Bond redemption and OTC-dividendThe Company intends to use the increased liquidity following Closing and the receipt of the Cash Consideration to redeem the Bonds in full and pay the OTC-dividend to its shareholders. Information regarding the contemplated redemption of the Bonds is expected to be announced through a press release and sent by mail to the bondholders on or about the date of Closing.  Payment of the OTC-dividend will require that the Company has adopted an annual report for the current financial year in order to demonstrate sufficient distributable earnings. In order to carry out the OTC-dividend in 2019, the Company plans to shorten the current financial year to the period January 1st – June 30th, 2019. The resolution to change the Company’s financial year is expected to be passed at the Extraordinary General Meeting. Furthermore, the payment of OTC-dividend will be subject to shareholder approval at the annual general meeting for the shortened financial year January 1st – June 30th, 2019. For these reasons, and according to the Company’s current time plan, completion of the OTC-dividend is expected by the end of October 2019. It is the Company’s current estimate that the OTC-dividend is expected to amount to approximately SEK 43–45 per ordinary share in the Company. However, the actual and final amount of the OTC-dividend is subject to change and dependent on several different factors, such as transaction costs, expected milestone payments received, expected research and development investments, business development and administrative expenses for completing the MOB-015 development program, changes in exchange rates as well as other factors affecting the Company’s financial position at the actual time of the payment of the OTC-dividend. The final amount of the OTC-dividend will be announced at the latest when the notice for the annual general meeting for the shortened financial year is announced. In accordance with the parties’ agreement, the Purchaser will be excluded from the OTC-dividend. As a result, the New Shares will be issued as a new class of shares (class B shares) in the Company that will not be entitled to receive the OTC-dividend. The New Shares may be converted to ordinary shares in the Company after the payment of the OTC-dividend. Funding obtained for the MOB-015 pipeline programSubject to Closing taking place, the Purchaser shall subscribe and pay for the New Shares and subscribe for the Warrants in the Company and issue the MOB-015 Loan to the Company. The total subscription amount for the New Shares will amount to USD 2.5 million (equivalent of SEK 23 million), corresponding to approximately 3.6% of all shares in the Company and entailing a valuation of the Company’s MOB-015 business at SEK 35.16 per share and a total value of the MOB-015 business of approximately SEK 630 million (equivalent of USD 70 million). The MOB-015 Loan, with a principal amount of USD 2.5 million (equivalent of SEK 23 million), will be advanced to the Company promptly following Closing. The proceeds from the MOB-015 Loan will be used to fund the MOB-015 pipeline program. The MOB-015 Loan will accrue PIK interest at a rate of 3 months LIBOR + 5.50% and the loan will mature on 31 March 2023. If, prior to 31 March 2023, the Company receives milestone payments, royalties and any other similar payments from partners in excess of USD 10 million (equivalent of SEK 92 million) plus any amounts actually received from partner agreements signed to date (for the avoidance of doubt, not including payments received to cover fees, expenses and other costs), the Company will use such excess funds to repay any amount outstanding under the MOB-015 Loan in full or in part. The principal amount outstanding under the MOB-015 Loan may be reduced by way of set off against the exercise price in connection with the exercising of the Warrants to subscribe for ordinary shares in the Company. The Warrants will not be issued against payment, i.e. no subscription price will be paid in connection with the issuance and allocation of the Warrants. Each Warrant will entitle the holder to subscribe for one ordinary share in the Company at a price of SEK 35.16 per share. However, no Warrant may be exercised prior to the payment of the OTC-dividend. The Purchaser shall subscribe for such number of New Shares, at a subscription price of SEK 35.16 per share, to be issued for an aggregate subscription amount of USD 2.5 million by applying the exchange rate reported by Bloomberg one business day prior to Closing. With an application of the exchange rate reported as of February 8th, 2019 (9.27), the number of shares and votes in the Company would accordingly upon Closing increase by 656,286 from 17,440,762 to 18,097,048 shares and votes[1]. This would imply a dilution of approximately 3.6 percent of the shares and votes in the Company. In case all 659,421 Warrants are exercised, an additional 659,421 shares may be issued, corresponding to an additional dilution of approximately 3.5 percent, implying a total dilution of 7.0 percent of the shares and votes in the Company. Overall financial effects of the transaction for Moberg PharmaThe transaction will yield gross proceeds of USD 155 million (equivalent of SEK 1,431 million) for the OTC-business and a capital gain[2] of approximately SEK 500 million. The Purchaser’s undertaking to subscribe for newly issued series B shares in the Company will generate USD 2.5 million (equivalent of SEK 23 million) and MOB-015 Loan will generate USD 2.5 million (equivalent of SEK 23 million). These funds will be used for MOB-015. The Company intends to use part of the Cash Consideration to redeem its outstanding SEK 600 million Bonds. The Company intends to use remaining part of the Cash Consideration net of the Company’s transaction expenses and cash retained for the MOB-015 development program to make a payment to its shareholders.[3] Following the transaction, Moberg Pharma’s operations will change from selling products to focusing on MOB-015. The business will be operated with an organization dedicated to research and development, regulatory matters and business development. The Company’s assets following the transaction will primarily consist of balanced research and development assets, while the classes of assets data systems, goodwill, acquired product rights and stock are divested in connection with the transaction. Accounts receivable and other receivables will decrease substantially while the Company’s leverage will be significantly reduced when the Bonds are repaid. In addition, the Company’s assets will comprise cash retained from the divestment of the OTC-business, the share issue to the Purchaser and the MOB-015 Loan. As regards the Company’s revenue streams following the transaction, the revenue from the current product sales will stop, and the revenue will initially comprise milestone payments, royalties and similar payments from existing and new license partners. The Company’s costs following the transaction will be primarily comprised of research and development, business development and administrative expenses. Detailed information on the financial effects of the transaction, including certain financial information for 2018 prepared on a pro forma basis, will be included in the information document that the Company intends to make public in due time before the Extraordinary General Meeting. Indicative high-level timetable for the transaction February Announcement of transaction12th, 2019February Notice of Extraordinary General Meeting(Notice is announced on15th, 2019 February 13th, 2019)March Extraordinary General Meeting15th, 2019End of Closing, including that the Purchaser (i) pays the CashMarch 2019 Consideration, (ii) extends the MOB-015 Loan and (iii) subscribes for the New Shares and the Warrants Notice of redemption of BondsEnd of Redemption of BondsApril 2019June 30th, Last day of shortened financial year2019End of Annual general meeting for shortened financial year resolving onSeptember among other things payment of the OTC-dividend to shareholders2019End of Payment of OTC-dividend to shareholdersOctober2019 On February 12th, 2019 at 9:00 am (CET), investors, analysts and journalists are hereby invited to participate in an information meeting with the Management of the Company at the offices of Gernandt & Danielsson to receive additional detail about the transaction. Participants may also dial in to the meeting. To participate in the meeting, please visit the following address before the start of the meeting: Gernandt & Danielsson Advokatbyrå KBHamngatan 2111 47 Stockholm To participate in the conference, please dial in on any number below before the start of the call: SE: +46 8 566 427 03US: +1 646 722 49 57 On February 12th, 2019, at 3:00 pm (CET), Moberg Pharmas’s CEO Peter Wolpert will present the Year-end report 2018 and the transaction in a teleconference. The presentation will be held in English. To participate in the conference, please dial in on any number below before the start of the call: SE: +46 8 505 583 53US: +1 646 722 49 57 Advisors to Moberg PharmaSawaya Partners has been engaged as financial advisor regarding the transaction. Hansen Law has been engaged as legal advisor regarding the transfer and sale of the OTC-business and Gernandt & Danielsson has been engaged as legal advisor regarding the MOB-015 funding, public and corporate law aspects of the transaction and the redemption of the Bonds. Advisors to PurchaserSidley Austin LLP and Roschier have been engaged as legal advisors to the Purchaser in respect of the acquisition of the OTC-business and the investment in Moberg Pharma and the MOB-015 funding. About this information              This information is information that Moberg Pharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact persons set out above, at 01.00 am (CET) on February 12th, 2019. About RoundTable Healthcare Partners           RoundTable Healthcare Partners, based in Lake Forest, IL, is an operating-oriented private equity firm focused exclusively on the healthcare industry. RoundTable partners with companies that can benefit from its extensive industry relationships and proven operating and transaction expertise. RoundTable has established a successful track record of working with owner/founders, family companies, management teams, entrepreneurs and corporate partners who share a vision and believe in the value creation potential of its partnership model. RoundTable has raised USD 2.75 billion in committed capital, including four equity funds totalling USD 2.15 billion and three subordinated debt funds totalling USD 600 million. More information about RoundTable Healthcare Partners can be found at www.roundtablehp.com. About Signet Healthcare PartnersSignet Healthcare Partners is an established provider of growth capital to innovative healthcare companies. Signet invests in commercial-stage healthcare companies that are revenue generating or preparing for commercial launch. The firm's focus has primarily been on the pharmaceutical sector and medical technology companies. Signet maintains a disciplined, yet flexible investment approach. As an active investor, Signet partners closely with its companies to build their value including facilitating activities between portfolio companies. During Signet's 18-year history, it has developed a strong reputation and track record of successful investments. Signet has raised four funds with total capital commitments of over USD 400 million and has invested in more than 45 companies. For more information, visit www.signethealthcarepartners.com. About MOB-015 and OnychomycosisApproximately 10% of the general population suffer from onychomycosis and a majority of those afflicted go untreated. The global market opportunity is significant with more than hundred million patients worldwide and a clear demand for better products. Moberg Pharma estimates the annual world-wide peak sales potential for MOB-015 to be in the range of USD 250-500 million. MOB-015 is an internally developed topical formulation of terbinafine based on Moberg Pharma’s experience from its leading OTC product Kerasal Nail®/Emtrix®. Oral terbinafine is currently the gold standard for treating onychomycosis but associated with safety issues, including drug interactions and liver damage. For many years, developing a topical terbinafine treatment without the safety issues of oral terbinafine has been highly desirable, but unsuccessful due to insufficient delivery of the active substance through the nail. In a previous phase 2 study, MOB-015 demonstrated delivery of high microgram levels of terbinafine into the nail and through the nail plate into the nail bed. Mycological cure of 54% and significant clear nail growth was observed in patients who completed the phase 2 study. The results are remarkable, particularly when taking into account the severity of the nails included in the study – on average approximately 60% of the nail plate was affected by the infection. Plasma levels of terbinafine with MOB-015 were substantially lower than after oral administration, reducing the risk of liver toxicities observed with oral terbinafine. MOB-015 is currently being evaluated over 52 weeks in two randomized, multicenter, controlled Phase 3 studies, including in total approximately 800 patients in North America and Europe. The primary endpoint in both studies is the proportion of patients achieving complete cure of their target nail. Topline results from the North American study are expected in the fourth quarter of 2019, followed by results in Europe in 2020. About BUPI and oral mucositisBUPI is intended for pain relief for patients suffering from oral mucositis (OM), a serious complication of cancer treatment. OM affects approximately 400,000 patients annually in the US and may hinder completion of cancer treatment and result in expensive hospital care. BUPI is an innovative, patented formulation of the proven substance bupivacaine, in the form of a lozenge, for the treatment of pain in the oral cavity. In January 2016, Moberg Pharma reported positive results from a Phase 2 study in which BUPI was evaluated for cancer patients with oral mucositis. Based on external analysis, Moberg Pharma estimates the annual sales potential for BUPI to USD 100-200 million, assuming successful commercialization in oral mucositis and at least one further indication. Planning of regulatory development programs as well as partner discussions are ongoing. ---------------------------------------------------------------------- [1] Excluding treasury shares held by the Company. [2] The capital gain is not expected to be subject to taxation. [3] The payment may be effected through formal dividend distribution, share split and redemption of split shares, reduction of the share capital or similar events.

Lehto Group Plc: Net sales EUR 721.5 million, up 20.7%. Operating profit EUR 37.2 million, or 5.2% of net sales

Net sales EUR 721.5 million, up 20.7%. Operating profit EUR 37.2 million, or 5.2% of net sales  This report has been prepared in accordance with the IAS 34 standard. The company complies with half-yearly reporting according to the Finnish Securities Markets Act. The financial statement bulletin is unaudited. Figures in brackets refer to the corresponding period of the previous year, unless otherwise stated. Summary 2018 Group 1-12/2018 1-12/2017 10-12/2018 10-12/2017Net sales, EUR 721.5 597.6 231.6 262.2millionChange in net sales, 20.7% 74.5% -11.7% 102.1%%Operating profit, 37.2 64.6 15.3 39.1EUR millionOperating profit, % 5.2% 10.8% 6.6% 14.9%of net salesProfit for the 28.7 51.6 11.5 31.1period, EUR million Order backlog at 655.6 538.1 655.6 538.1period end, EURmillionEarnings per share, 0.49 0.89 0.20 0.53EURCash and cash 53.4 68.0 53.4 68.0equivalents, EURmillionInterest-bearing 115.9 36.9 115.9 36.9liabilities, EURmillionEquity ratio, % 42.7% 56.3% 42.7% 56.3%Net gearing ratio, % 38.5% -20.6% 38.5% -20.6% - Net sales grew by 20.7% (74.5%) in 2018 to EUR 721.5 (597.6) million. Net sales grew in the Housing, Business Premises, and Social Care and Educational Premises service areas, but declined slightly in the Building Renovation service area. - Operating profit was EUR 37.2 (64.6) million, or 5.2% (10.8%) of net sales. - The operating result was weakened especially by loss-making complete renovation projects and the weak profitability of social care and educational premises projects. - Complete renovation operations had a negative impact of about EUR 15 million on consolidated operating profit. After the end of the review period, Lehto announced that it had discontinued its Building Renovation service area and will limit its renovation operations. Profitable pipeline renovation activities have been carried out in the discontinued Building Renovation service area. This line of business has been transferred to the Housing service area, where it will be further developed and continued. - Factory production capacity was increased. Production facilities grew by about 30,000 m2. - The Board proposes a dividend of EUR 0.24 per share, representing about 48.7% of the Group’s result for the financial year. NET SALES BY SERVICE AREA, EUR million 1-12/2018 1-12/2017 ChangeBusiness Premises 231.0 181.2 27.5%Housing 301.5 232.2 29.9%Social Care and Educational Premises 117.8 109.1 8.0%Building Renovation 71.1 75.1 -5.3%Total 721.5 597.6 20.7% July–December 2018 Net sales for the second half of the year amounted to EUR 429.6 million (EUR 383.6 million in July-December 2017), substantially higher than in the first half (EUR 291.9 million). The primary reason is that projects in the Housing service area were completed and recognised as revenue in the latter half of the year. As in the previous year, net sales of the last quarter were the highest of the year, EUR 231.6 million, but lower than in the previous year (EUR 262.2 million Q4 2017). Operating profit for July-December was EUR 23.5 million (EUR 49.1 million 7-12/2017), representing 5.5% (12.8%) of net sales. The negative margins of complete renovation projects burdened operating profit particularly in the second half of the year. CEO Hannu Lehto: “We are now publishing our third financial statements as a listed company. In terms of net sales, we have made progress each year. Our average annual growth in 2016-2018 has been over 40%. We have also racked up excellent earnings during this period of strong growth. However, our earnings trend could no longer keep up the pace during the year now ended. The main reasons for this were, considering the high growth, insufficient pricing and cost control processes and the unsuccessful business development in some sectors which have also turned out to weakly fit in the Group’s strategy.   In accordance with our strategy, our key competitive factors are design management, standardised solutions and industrial manufacturing. We have found that in some business areas the adoption of these principles has not been successful and the set targets were not achieved. In complete renovation area we started many projects in 2017 – 2018.  The projects incurred significantly more costs than planned, due to which the renovation business had a substantial negative impact on the Group’s result. Profitability of projects in Social Care and Educational Premises service area has declined too as the tailored solutions have turned out to be more expensive as expected. We have analysed the factors contributing to the weaker result and taken corrective measures to improve profitability. The Building Renovation service area has been discontinued and its organisation merged into other service areas. In future, we carry out complete renovation projects selectively only as part of new construction or other larger commercial projects. We have created operating models for project design and calculation in the Social Care and Educational Premises service area that ensure project execution also on economically sustainable way. In Social Care and Educational Premises, we are continuously developing technically standardised solutions that we can use to build commercial projects that cater to the needs of the customer. Business in the Housing and Business Premises service areas has progressed as planned. Both units increased their net sales and project margins were at a good level. Based on our experiences in 2018, we have even greater confidence in our strategy and will continue to carry out development measures to enable us to even more efficiently produce high-quality solutions that meet our customers’ functional and commercial needs. According to many research institutions the growth of Finnish construction market is expected to slow down or even decline. We believe that this slowdown will facilitate availability of labour and lead to more favourable prices for raw materials and construction components.” Outlook for 2019 Lehto estimates that the Group’s net sales for 2019 will be at the level of 2018 net sales (EUR 721.5 million in 2018) and that operating profit will be approximately 5-7% of net sales (5.2% in 2018). The outlook is based on the information available to the company on the progress of ongoing construction projects and the company’s estimate of construction projects to be started and sold in 2019, and on the current outlook of the development of housing market. The most significant risks related to net sales and operating profit are the decline in the demand for apartments, the postponement of start of new care home and school projects, and the delay in starts of business premises projects currently at the negotiation phase. Press conference on the financial statements Lehto Group will hold a press conference for investors, analysts and the media on Tuesday, 12 February 2019 at 10:00 a.m. (EET). The conference will be held in the main building of Allas Sea Pool, which was built by the company. The address is Katajanokanlaituri 2a, Helsinki. CEO Hannu Lehto and CFO Veli-Pekka Paloranta will speak at the conference. The event will begin with a brief financial summary in English. The rest of the press conference will be held in Finnish. The press conference will be webcast live at lehto.fi/en/investors. The live webcast will begin at 10:00 a.m. Finnish time. A recording will be made available at the same address as soon as possible after the conference. It is also possible to participate in the press conference via a conference call. Conference call participants are requested to dial in at least five minutes prior to the start of the conference, 9:55 a.m. Finnish time. Telephone numbers: (The password is: Lehto) Finland: +358 (0) 9 2319 5437 Sweden: +46 (0) 8 5052 0424 Other/UK: +44 (0) 20 3003 2666 Business environment and business development in 2018 General market development In 2018, growth in construction continued in Finland for the fourth year running. According to estimates published in late 2018 by several financial research institutions (including the Confederation of Finnish Construction Industries RT, the Research Institute of the Finnish Economy ETLA, and the construction trends group led by the Ministry of Finance), growth in construction amounted to about 3-4%, while the Finnish economy grew at a rate of about 2.5%. It is estimated that growth of the Finnish economy will slacken in 2019 and that construction growth will slow down, and production may even decline from its 2018 level. In report, published in February 2019, the Ministry of Finance estimates that the total construction output volume is expected to decrease by 0.5 – 2.5 per cent in 2019 and further 1.5 – 3.5 per cent in 2020. Construction growth has been maintained particularly by the construction of new residential buildings. It is estimated that the construction of about 44,000 new residential units was started up in 2018. However, the number of new building permits began to decline in the second half of 2018, and it is generally expected that housing start-ups will decline in 2019.  Demand for housing has been maintained by the good availability of financing and urbanisation, which is currently seen as the main driver of housing market trends. Commercial and office construction remained more or less on a par with the previous year, but construction of industrial and warehouse buildings saw a slight year-on-year decline (RT 10/2018). The boom in construction led to a rise in the costs of labour, subcontracting, raw materials and elements. Availability of skilled labour is still the main factor that has limited production growth. Business Premises In the Business Premises service area, Lehto builds office premises, retail premises, logistics, warehouse and production facilities, leisure facilities and large shopping and activity centres. Business premises are designed according to the customers’ needs and are built using structural and spatial solutions developed or tried and tested by Lehto and Lehto’s own pre-fabricated elements. The service area serves local, national and international customers. Most of the business in the Business Premises service area comprises turnkey projects, where Lehto assumes overall responsibility for both design and construction. Lehto also builds some business premises in the form of developer contracting, which means that Lehto acquires the plot and designs and builds the property either wholly or partly at its own risk. Net sales in the Business Premises service area grew by 27.5% year-on-year to EUR 231.0 (181.2) million in 2018. A total of 31 projects were completed during the review year, the largest of which were a logistics centre for DSV in Vantaa and an office and hotel building in Tikkurila, Vantaa. In May, Lehto announced that the city council of Jyväskylä had decided, at a meeting held on 28 May 2018, to initiate the Hippos2020 project together with a consortium of Lehto Group and Fennia Asset Management Ltd and had accepted the main principles of the agreements and plans of the project. The project involves uncertainties typical of all property development projects, such as the availability of financing or finding tenants and the level of the tenants’ commitment. In June, Lehto announced that it had signed a turnkey contract with Koy Seinäjoen Ideapark, a subsidiary of Sukari Invest Oy, and had started for the construction of the Ideapark shopping centre in Seinäjoki. The value of the contract is around EUR 65 million, in addition to which Lehto will be in charge of additional and alteration work to be specified later. Lehto continued the development project of the Lippulaiva shopping centre in Espoonlahti, together with Citycon Oyj and designers, but Lehto and Citycon decided to end the negotiations on this turnkey project in October. For three years, the parties and designers sought to find a solution that would be in line with the operational and financial objectives of both Citycon and Lehto, but no such suitable solution could be found. The order backlog of the Business Premises service area grew during the review period and was EUR 134.5 million at year end (EUR 127.4 million on 31 December 2017). The order backlog does not include the possibly starting Hippo 2020 project. Social Care and Educational Premises In the Social Care and Educational Premises service area, Lehto designs and builds care homes, assisted living facilities, daycare centres and schools to meet the needs of municipalities and nationwide care and daycare service providers. The construction projects are implemented either under ordinary construction contracts or as investment transactions, where Lehto signs a lease agreement with the service operator and sells the completed property to a fund that invests in properties in the sector. Net sales of Social Care and Educational Premises grew by 8.0% from the previous year to EUR 117.8 (109.1) million in 2018. Care homes for the elderly generated the bulk of the net sales. During the review year, 28 (29) care home and assisted living units were completed, and 8 (25) were under construction at the end of the year. Two (two) daycare centres and one (one) school were completed during the review period. At the end of the review period, three (one) schools and one health centre were under construction. The majority of the properties built by the service area are 1-2-storey wooden buildings, but it is also building an increasing number of diverse and multi-storey concrete buildings.  The implementation of individualised care facility projects requires more planning and work than before, which contributed to the decrease in the project margins of this service area during the review period. The company did not estimate the cost impacts of individualised construction with sufficient accuracy in advance. Lehto continued to develop its school and daycare centre collection with its concept for the productisation of commercially configurable and technically modular solutions. There is an immediate need in the market for both temporary premises and permanent schools. The first modular daycare centres and schools will be delivered to Helsinki and the municipality of Botkyrka in Sweden. In addition to nursing homes, the service area is building assisted living housing. The number of elderly people is rising in Finland and they need diverse living solutions with care services. Lehto seeks to harness its strong expertise in housing construction in its assisted living solutions. The order backlog of the Social Care and Educational Premises service area at the end of the review period was EUR 60.0 million (EUR 100.3 million on 31 December 2017). The decline in the order backlog is due to the decrease in the number of care sector properties under construction. Housing In the Housing service area, Lehto builds new blocks of flats, balcony access houses and terraced and detached houses as part of area construction in Finland’s growth centres, especially in the Helsinki metropolitan area. The majority of Lehto’s housing projects are developer contracting projects, in which Lehto designs and builds properties on land areas that it has purchased and then sells the completed apartments to customers. Customers include private persons as well as private and institutional investors. Most housing properties are concrete apartment buildings and are built using the kitchen/bathroom modules developed by Lehto. The modules are completely prefabricated at Lehto’s own factory and transported to the construction site, where they are lowered into the building through the roof. This building method ensures rapid completion of construction, improves quality and produces cost savings. Lehto’s factories also manufacture wall elements, windows, fixtures and fittings, as well as wooden space elements that can be used to rapidly build terraced houses and balcony access blocks particularly well suited for urban environments. Net sales in the Housing service area grew by 29.9% from the previous year to EUR 301.5 (232.2) million. A total of 1,900 (2,002) apartments were sold in the review period. At the end of the period, 3,229 (2,029) new apartments were under construction, of which 1,647 (309) had not yet been sold. There were 41 (12) completed, unsold apartments. Most of the completed and ongoing housing projects are developer contracting projects located in the Helsinki Metropolitan Area and other Finnish growth centres: the Tampere, Turku, Jyväskylä and Oulu regions. The largest housing construction projects currently in progress are in Kaivoksela in Vantaa and in the centre of Oulu. The number of residential units that are under construction but which have not as yet been sold grew during the financial year. This is primarily due to the decline in demand by private investors in the latter half of the year. A larger share of apartments are sold to consumers, and thus sales are concluded closer to the completion of construction, whereas sales to investor customers have historically been made in the early phases of construction. During the financial year, Lehto made outlays on promoting sales to consumers and stepped up marketing to consumer customers. Human resources in housing sales have also been boosted significantly. Demand from institutional investors remained at a good level. In Lehto’s view, there is now greater interest in the market for acquiring large housing portfolios. Availability of financing for housing remained good during the review year and interest rates were low. However, during discussions with banks towards the end of the period, indications came to light that the terms and conditions of financing may be tightened, especially in the case of housing corporations majority-owned by investors.   Growth in housing production is also reflected in the growth in inventories, as net sales are only recognised upon delivery. To manage its balance sheet risk, Lehto continuously estimates the trend in housing sales and decides separately on the start-up of each developer-contracted housing project. The housing construction order backlog at year end was EUR 365.4 million (EUR 216.9 million on 31 December 2017). The housing production order backlog includes the proportion of started developer contracting projects that has not been recognised as net sales. A construction project is included in the order backlog once the decision to start construction has been made and the contract for a developer contracting project has been signed. Building Renovation In 2018, Lehto’s Building Renovation service area carried out pipeline renovations (renovations of apartment building plumbing), renovation contracts, developer-contracted renovation projects (an old residential or office property is renovated for use as housing) and developer-contracted projects to erect additional floors (one to two additional floors are built on top of existing buildings). Net sales in the Building Renovation service area declined by 5.3% from the previous year to EUR 71.1 (75.1) million. During the review year, 16 pipeline renovation contracts were completed in the Helsinki Metropolitan Area, and 13 were under way at year-end. The pipeline renovation business accounts for about one-third of the net sales of the service area and the project margins have been in line with Lehto’s targets. Two developer-contracted renovation projects were completed during the review year, one in Tikkurila in Vantaa and one in Hämeenlinna. At the end of the review period, Lehto had two developer-contracted renovation projects in progress in which an old residential or office building is renovated for use as housing and new apartments are built next to the renovated property. Two complete renovation projects were completed during the review period and three were under way at the end of the period with a total sales value of about EUR 56 million. The margin of these projects is deeply in the red. The projects will be completed in the first half of 2019 and the expected losses have been recognised in the 2018 financial statements. The margins of projects other than pipeline renovation have been weak or negative. The project implementation costs have been considerably higher than expected. Projects other than pipeline renovation had a negative impact of about EUR 15 million on Lehto’s operating profit for 2018. As announced in a release published on 2 November 2018, Lehto took steps to reorganise the Building Renovation service area and improve profitability. After the end of the financial year, the Building Renovation service area was discontinued and the company decided to limit its renovation operations. Building renovation functions have been merged into other service areas. The pipeline renovation business and further development of the additional floor construction concept have been transferred to the Housing service area, while other complete renovation operations have been transferred to Business Premises. Ongoing complete renovation projects will be concluded by the current project organisation. Once these projects have been completed, the project organisation will be transferred to other projects in the Business Premises service area. In the future, new complete renovation projects will only be undertaken selectively on condition that the renovation is related to new construction projects or when it is a significant part of a larger commercial entity. Lehto committed to a number of such projects even before the discontinuation of the Building Renovation service area. Lehto will also continue the development of the additional floor construction concept as part of additional and complementary construction. Lehto will continue and develop its profitable pipeline renovation operations. At the end of the financial year, Lehto launched the Lehto Total service package, which enables housing corporations to finance their plumbing renovations by selling building rights for complementary building. The order backlog of Building Renovation grew to EUR 95.7 million at year end (EUR 93.6 million on 31 December 2017). Growth in the order backlog was due particularly to an increase in orders for pipeline renovations. Swedish operations Lehto established a subsidiary in Sweden in August 2017. One business premises project was completed during the financial year. The unit is currently carrying out a daycare centre project in which three modular daycare centres will be built in the municipality of Botkyrka. The modules will be built at the Hartola factory in Finland and transported to Botkyrka for final assembly. The unit is also launching its first housing construction project in the Stockholm region. Lehto is planning measures to develop business in Sweden. In Lehto’s view, there is good demand for prefabricated modular products, especially in the market for affordably priced housing and daycare centres and schools. The Swedish unit has eight employees and its number of employees is expected to grow. Factory production Lehto manufactures a variety of building modules and elements at its own production facilities for its own use. Lehto has building element and module production units in Humppila, Oulainen, Oulu, Ii and Siikajoki. At the end of the review year, more than 400 people worked in factory operations. During the review period, Lehto continued to expand and boost the efficiency of its factory capacity. In March 2018, Lehto acquired the factory operations of Pyhännän Rakennustuote Oy in Hartola. Leased premises with about 20,000 m2 of floor area (owned and located in the Municipality of Hartola), production equipment for the manufacture of wood elements and modules, and 75 employees were transferred to Lehto in this transaction. A new 9 000 m² factory was completed in Oulainen in September. Logistics, warehouse functions, and the manufacture of bathroom modules, kitchen furniture and other fixtures and fittings are now concentrated on this factory. The total value of the investment is some EUR 8.0 million.   Balance sheet and financing The Group’s financial standing remained good. At the end of the financial period, the equity ratio was 42.7% (31 Dec. 2017: 56.3%) and net gearing was 38.5% (-20.6%). Consolidated balance sheet, EUR million 31 Dec 2018 31 Dec 2017Non-current assets 37.7 25.1Current assetsInventories 238.2 132.9Current receivables 139.0 111.2Cash and cash equivalents 53.4 68.0Total assets 468.3 337.2 Equity 162.4 150.7Financial liabilities 115.9 36.9Advances received 88.3 69.3Other payables 101.8 80.2Total equity and liabilities 468.3 337.2 Equity and liabilities Equity grew to EUR 162.4 million (EUR 150.7 million on 31 December 2017). Equity increased through earnings and the amount of equity was reduced by a dividend payout of EUR 19.8 million in April, representing 38.4% of the profit of the 1 January-31 December 2017 financial period. Financial liabilities grew to EUR 115.9 (36.9) million. Loans were withdrawn particularly for the construction-stage financing of projects in the Housing service area and to acquire plots and other building rights. Interest-bearing liabilities include normal bank loans as well as loans drawn by housing companies to the extent these are allocated to unsold apartments. Advances received grew to EUR 88.3 (69.3) million. Advances received include payments received for projects under construction to the extent these are not yet recorded in net sales. Other liabilities grew to EUR 101.8 (80.2) million. Other liabilities include trade payables of EUR 40.3 (38.9) million and VAT debt of EUR 19.7 (13.2) million. Assets Non-current assets amounted to EUR 37.7 million at the end of the review period (EUR 25.1 million on 31 December 2017). Non-current assets include goodwill of EUR 4.6 (4.6) million, EUR 12.7 (5.0) million in factory buildings and EUR 8.5 (4.4) million in machinery and equipment. Inventories grew to EUR 238.2 (132.9) million. The growth was attributable to strong business volume growth, and most of the inventories comprise costs accrued from incomplete housing construction projects. Current receivables grew to EUR 139.0 (111.2) million, including trade receivables of EUR 62.2 (65.9) million and percentage-of-completion receivables of EUR 71.1 (39.1) million. The growth in receivables is related to the increased business volume.   Cash flow statement, EUR million 1-12/2018 1-12/2017Cash flow from operating activities -18.3 -2.8Cash flow from investments -13.7 -0.3Cash flow from financing 17.5 3.4Change in cash and cash equivalents -14.5 0.3 Cash and cash equivalents at the beginning of the period 68.0 67.7Cash and cash equivalents at the end of the period 53.4 68.0 Cash and cash equivalents decreased to EUR 53.4 (68.0) million. Net cash from operating activities was EUR -18.3 (-2.8) million, which includes a negative impact of EUR 52.8 (55.5) million due to the growth in net working capital. The main factor behind net working capital growth was the increase in inventories. As a result of business growth, the costs tied to incomplete projects have increased and the Group has acquired more building rights than previously for future construction projects. The growth of inventories is also attributable to growth in factory production and the resulting increase in stock of materials. Net cash flow from investments was EUR 13.7 million negative, including EUR 14.6 million investments in tangible assets mainly relating to factory production. Investments in intangible rights amounted to EUR 1.3 million. Net cash flow from financing was EUR 17.5 million positive. A total of EUR 109.3 million was drawn in loans and EUR 72.0 million was repaid. Cash flow from financing also includes cash expenses of EUR 19.8 million due to dividends paid. On 1 November 2018, Lehto signed a EUR 50 million financing agreement with OP Corporate Bank plc and Nordea Bank plc. This financing agreement is a Revolving Credit Facility (RCF) that is valid for three years. The agreement employs the standard covenants for profitability and indebtedness. At the end of the financial year, the credit facility had not been used. Other significant events during the financial period On 15 February 2018, Lehto announced that the company’s Board of Directors has decided to continue the share-based incentive plans for Group key employees, adopted in 2016. The aim of the plans is to align the objectives of the shareholders and the key employees in order to increase the value of the company in the long term and to commit key employees to the company. On 1 March 2018, Lehto announced that major shareholders had sold a total of 7,100,000 shares in Lehto Group Plc in an accelerated book-building process, representing about 12.2% of total shares and voting rights. On 20 March 2018, Lehto announced that Pekka Korkala, M.Sc. (Tech.), in charge of factory production, has been chosen into Lehto Group’s Executive Board, effective as of 20 March 2018. Korkala has been CEO of Takuuelementti Oy (currently Lehto Components Oy), a subsidiary of Lehto Group Plc, since 10 July 2017, and will continue in this position. Korkala has long experience in business and factory production management in, for example, the vehicle industry in Finland and abroad. At the same time, it was announced that Chief Operating Officer Asko Myllymäki stepped down from the Group’s Executive Board as from 20 March 2018. On 3 May 2018, Lehto announced that it adopted the new IFRS 15 Revenue from Contracts with Customers retroactively from 1 January 2018 in accordance with IAS 8. Lehto estimates that the new IFRS 15 does not have a material impact on the recognition of net sales at Lehto. On 24 May 2018, Arto Tolonen, PhD (Tech.), Chief Development Officer (CDO), was appointed as a member of Lehto Group’s Executive Board. On 1 August 2018, Lehto reduced the operating profit forecast for 2018. Lehto estimated that net sales for 2018 will grow by 20-30% from 2017 and that operating profit will be approximately 8-9% of net sales. The decrease in the forecast was due to lower project margins than previously projected, particularly in the Social Care and Educational Premises and Building Renovation service areas, and the postponement until 2019 of the estimated date of completion of some projects that will be recognised as income upon delivery. On 5 September 2018, Lehto announced that Ville Kettunen (Civil Engineer, construction) had been appointed as Executive Vice President for the Social Care and Educational Premises service area and as a member of Lehto Group’s Executive Board. On 19 October 2018, Lehto downgraded its financial outlook for 2018. Lehto estimated that the Group’s net sales for 2018 will grow by 20-25% from 2017 and that operating profit will be approximately 5-6% of net sales. This weaker outlook stemmed from a further decline in project margins, particularly in the Social Care and Educational Premises and the Building Renovation service areas, combined with a slightly lower estimate for the Group’s total net sales. It was reported that the decline in net sales is primarily due to delays in launching Social Care and Educational Premises projects. The release noted that business in the Housing and Business Premises service areas is progressing as planned. On 2 November 2018, Lehto announced its plans to discontinue the Building Renovation service area and merge renovation functions into other service areas. It was planned that the pipeline renovation unit would be transferred to the Housing service area and other renovation operations to the Business Premises service area, where ongoing complete renovation projects would be completed by the current project organisation. Upon the completion of these projects, the project organisation would then be transferred to other projects in the Business Premises service area. The planned changes were not expected to result in a need to reduce personnel. On 2 November 2018, Lehto announced a change in Lehto Group's Executive Board as of 5 November 2018. Pekka Lindeman, Executive Vice President of the Building Renovation service area, stepped down from the Group Executive Board. The change is due to the reorganisation of the Building Renovation service area, which Lehto announced in a stock exchange release on 2 November 2018. As of 5 November 2018, the Executive Board consists of the following: · Hannu Lehto, CEO · Veli-Pekka Paloranta, CFO · Pasi Kokko, EVP, Housing service area · Jaakko Heikkilä, EVP, Business Premises service area · Ville Kettunen, EVP, Social Care and Educational Premises service area · Timo Reiniluoto, EVP, Business Support Services · Pekka Korkala, EVP, Factory production · Arto Tolonen, Chief Development Officer On 20 November 2018, Lehto Group Plc announced that three of its biggest shareholders have named their representatives for the shareholders' Nomination Committee whose job is to prepare the proposals concerning Board members and remuneration for the Annual General Meeting of 2019. The members of the Nomination Committee are Hannu Lehto, Vesa Vanha-Honko and Mikko Kinnunen. Risks and factors of uncertainty In its business operations, Lehto is exposed to operative risks as well as risks relating to the availability of financing, overall economic trends and political decision-making and other risks relating to the activities of the public sector. Lehto’s business is partly so-called traditional contracting and partly its own production, where the final customer is not always known when starting the construction project. These business models involve different risks. In traditional contracting, project income is recognised according to the degree of completion. The main risk in this model is that total costs for the project exceed the estimated costs or the completion of the project is delayed. Especially in the changing market environment the main risk in own production is that the company is not able to sell the production within the planned time schedule or at the planned price. In addition, project costs can exceed the estimated costs. Failure in project pricing, technical implementation, estimating costs and time schedule, selling the property or finding financing can have a negative impact on the company’s result and financial position. During the 2018 financial year, the number of residential units under construction that Lehto had not yet sold grew significantly. This increases the sale and price risk related to housing business. Part of Lehto’s business involves agreements according to which Lehto builds premises in line with the customer’s needs and sells the premises upon their completion or at a later stage to a fund. Although Lehto works with well-known and established funds, Lehto cannot be certain that the funds have the capacity to provide the cash required for the purchase of the premises at the agreed time of payment. The project business the Group carries out is characterised by variation, which can be significant, in profit between different reporting periods due to the accounting methods of projects. The Group’s cash flow is usually generated in step with a project’s degree of completion, however such that the last instalment payable after the completion is bigger than the other instalments. Thereby a delay of an individual large project can have an effect on the sufficiency of working capital.  Changing building regulations or zoning policies can also have significant effects on the company’s business. Lehto aims to control risks at each level of the organisation. Risk management includes risk identification, estimation and plans to avoid them. Personnel The average number of personnel during the review period was 1,457 (1,013). The number of personnel at year end was 1,552 (1,184). About 49% (49%) of the Group’s personnel are salaried employees and 51% (51%) employees working at construction sites. Lehto’s personnel grew by 368 in 2018. The major share of this increase is due to growth in the Housing service area and factory operations.  The majority of Lehto’s employees participate in the performance bonus plan, which is based on targets set on a project-specific or annual basis. In addition, no more than 70 key employees participate in a long-term share-based incentive plan with a one-year vesting period and a two-year restriction period. Targets are set for the key employees for each vesting period, and the employee’s performance bonus is calculated on the basis of the achievement of the targets. The performance bonus is converted into an increased number of shares multiplied by a bonus factor determined by the Board. The equivalent bonus is paid to the employee after the end of the two-year restriction period. The bonus is paid to the key employees after the restriction period partly in the form of shares and partly in the form of cash. Research and development Lehto develops and manufactures building modules and components, such as bathroom/kitchen modules, housing space elements, wall elements, large roof elements, technical building modules, windows and some smaller building renovation modules at its own production facilities. The purpose of developing modules is to enhance building quality and to accelerate the construction process. The development of modules, components and space concepts is part of continuing operations, and the related costs are largely recorded as an expense in the income statement. Capitalised development expenditure during the financial year amounted to EUR 0.5 million. The most significant development investments are related to product design and the development of product factory operations. Flagging notifications On 1 March 2018, it was announced that Asko Myllymäki had sold shares in Lehto in an accelerated book-building process (the "Share Sale") on 28 February 2018. Following the completion of the Share Sale, Asko Myllymäki's ownership of shares and voting rights in Lehto fell from 8.25% to 1.10%. On 2 March 2018, it was announced that the total shares and voting rights in Lehto owned by funds administered by OP Fund Management Company Ltd had exceeded the 5% threshold to 5.37%. On 7 June 2018, it was announced that the total shares and voting rights in Lehto owned by funds administered by OP Fund Management Company Ltd had risen from 5.37% to 6.27%. On 28 December 2018, it was announced that the Lehto shares and voting rights owned by OP-Suomi investment fund, which is managed by OP Fund Management Company Ltd, had fallen from 5.01% to 4.83%. The release noted that the total holding in Lehto of the investment funds managed by OP Fund Management Company Ltd still exceeds the 5% threshold. Its total holding on 21 December 2018 was 5.29%. Events after the reporting period After the end of the review period, Lehto announced that it had discontinued its Building Renovation service area and will limit its renovation operations. Annual General Meeting and Annual Report The Annual General Meeting of Lehto Group Plc will be held on Friday 29 March 2019 at 1.00 p.m. at Elektroniikkatie 8, Oulu. The Board of Directors will publish the Notice of Meeting no later than on 8 March 2019. Lehto Group Plc’s Annual Report, including the company’s financial statements, report by the Board of Directors, auditor’s report, corporate governance statement, remuneration report and responsibility report will be available on the company’s website no later than on Friday, 8 March 2019. Board proposal for the use of the profit shown on the balance sheet and for deciding on payment of dividends The parent company’s distributable funds on the balance sheet of 31 December 2018 are EUR 82,813,733.01, of which the operating profit is EUR 15,674,875.79. The Board of Directors proposes to the Annual General Meeting gathering on 29 March 2019 that the dividend payable on the basis of the balance sheet confirmed for the financial year 1 January - 31 December 2018 be EUR 0.24 (0.34) per share, total of EUR 13,980,180.48 (19,805,255.68).  The dividend shall be paid to shareholders who on the record date for the dividend payment, 2 April 2019, are recorded in the shareholders’ register held by Euroclear Finland Oy. The Board of Directors proposes that the dividend payment date be 9 April 2019. Vantaa, 11 February 2019  Lehto Group PlcBoard of Directors  TABLES The accounting policies applied in this review are mainly the same as in the latest annual report. Lehto has adopted the IFRS 15 Revenue from Contracts with Customers retroactively from 1 January 2018 in accordance with IAS 8, and presents restated comparative data for 2017. Lehto has published a stock exchange release on 3 May 2018 on the adoption of the standard. The standard does not have a material impact on the recognition of net sales. In addition, the company has adopted a new IFRS 9 standard and an IFRS 2 standard amendment. These do not have a material impact on the consolidated financial statements. IFRS 16 Leases will enter into force on 1 January 2019. As a result, all material leases are recognized in the balance sheet. The adoption of the standard will have no material impact on the company's result and equity, but it will increase the company's assets and liabilities. The most significant effect arises from leases related to leased land plots in inventories with a lease obligation of EUR 156.4 million at the end of 2018. The IAS 34 requirements have been complied with. CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME 7-12/ 7-12/ 1-12/ 1-12/EUR million 2018 2017 2018 2017Net sales 429.6 383.6 721.5 597.6Other operating income 1.1 1.4 3.0 1.5Changes in inventories 41.7 6.6 107.1 45.0Capitalised production 4.3 0.8 8.0 0.8Raw materials and consumables used -195.9 -143.6 -331.7 -245.1External services -201.1 -153.5 -359.5 -251.4Employee benefit expenses -41.4 -33.5 -82.9 -61.3Depreciation and amortisation -2.1 -1.8 -3.5 -3.2Other operating expenses -12.6 -11.0 -24.8 -19.3Operating profit 23.5 49.1 37.2 64.6Financial income 0.1 0.1 0.2 0.3Financial expenses -0.7 -0.4 -1.2 -0.7Share of associated company profits 0.0 0.0 0.0 0.0Profit before taxes 23.0 48.8 36.2 64.2Income taxes -5.0 -9.3 -7.5 -12.6Profit for the period 17.9 39.5 28.7 51.6 Profit attributable toEquity holders of the parent company 17.9 39.6 28.7 51.6Non-controlling interest 0.0 0.0 0.0 0.0 17.9 39.5 28.7 51.6 Earnings per share calculated from the profitattributable to shareholders of the parentcompany, EUR per shareEarnings per share, basic 0.31 0.68 0.49 0.89Earnings per share, diluted 0.31 0.68 0.49 0.88 CONSOLIDATED BALANCE SHEETEUR million Dec 31, 2018  Dec 31, 2017AssetsNon-current assetsGoodwill 4.6 4.6Other intangible assets 2.2 2.1Property. plant and 22.9 10.6equipmentInvestment properties 0.7 0.8Investments and receivables 1.1 2.0Deferred tax assets 6.1 4.9Non-current assets total 37.7 25.1 Current assetsInventories 238.2 132.9Trade and other receivables 139.0 111.2Cash and cash equivalents 53.4 68.0Current assets total 430.6 312.1 Assets total 468.3 337.2 Equity and liabilitiesEquityShare capital 0.1 0.1Invested non-restricted 69.2 69.2equity reserveRetained earnings 64.1 29.6Profit for the financial 28.7 51.6periodEquity attributable to 162.1 150.4shareholders of the parentcompanyNon-controlling interest 0.3 0.3Equity total 162.4 150.7 Non-current liabilitiesDeferred tax liabilities 0.7 0.4Provisions 10.4 4.1Financial liabilities 20.1 11.1Other non-current 5.6 2.5liabilitiesNon-current liabilities 36.8 18.1total Current liabilitiesFinancial liabilities 95.8 25.8Advances received 88.3 69.3Trade and other payables 85.1 73.2Current liabilities total 269.2 168.3 Liabilities total 305.9 186.4 Equity and liabilities total 468.3 337.2 CONSOLIDATEDSTATEMENT OFCHANGES INEQUITYEUR million Equity attributable to shareholders of the parent company Share Invested Retained Equity Non Equity, capital non earnings attributable -controlling total -restricted to equity shareholders interest reserve of the parent companyEquity at 1 0.1 69.2 41.6 110.8 0.0 110.9January2017ComprehensiveincomeProfit for 51.6 51.6 0.0 51.6thefinancialperiodTotal 51.6 51.6 0.0 51.6comprehensiveincomeTransactionswithequityholdersDistribution -12.8 -12.8 -12.8ofdividendsShare-based 0.9 0.9 0.9compensationOther changes -0.1 -0.1 0.3 0.2Transactions -12.0 -12.0 0.3 -11.8withequityholders,totalEquity at 31 0.1 69.2 81.2 150.4 0.3 150.7December 2017 Equity at 1 0.1 69.2 81.2 150.4 0.3 150.7January2018Effect of 2.3 2.3 2.3IFRS 2standardamendmentAdjusted 0.1 69.2 83.5 152.7 0.3 153.0equity at1 January2018ComprehensiveincomeProfit for 28.7 28.7 0.0 28.7thefinancialperiodTotal 28.7 28.7 0.0 28.7comprehensiveincomeTransactionswithequityholdersDistribution -19.8 -19.8 -19.8ofdividendsShare-based 0.5 0.5 0.5compensationOther changes -0.1 -0.1 0.0 -0.1Transactions -19.4 -19.4 0.0 -19.4withequityholders,totalEquity at 31 0.1 69.2 92.8 162.1 0.3 162.4December 2018   CONSOLIDATED CASH FLOW STATEMENT 1-12/ 1-12/EUR million 2018 2017Cash flow from operating activitiesProfit for the financial period 28.7 51.6Adjustments:Non-cash items 4.9 0.7Depreciation and amortisation 3.5 3.2Financial income and expenses 1.0 0.4Capital gains -0.4 0.0Income taxes 7.5 12.6Changes in working capital:Change in trade and other receivables -26.2 -44.1Change in inventories -105.3 -42.0Change in trade and other payables 78.7 30.6Interest paid and other financial expenses -1.0 -0.8Financial income received 0.2 0.3Income taxes paid -9.8 -15.3Net cash from operating activities -18.3 -2.8 Cash flow from investmentsInvestment in property, plant and equipment -14.6 -4.1Investment in other intangible assets -1.3 -0.4Acquisition of subsidiaries 1) 0.0 -1.1Sales of associates 0.3 0.0Proceeds from sale of tangible and intangible assets 0.0 0.0Proceeds from other investments 0.2 0.0Loans granted 0.0 -0.9Repayments of loan receivables 1.7 6.2Dividends received 0.0 0.0Net cash from investments -13.7 -0.3 Cash flow from financingLoans drawn 109.3 51.7Loans repaid -72.0 -34.9Acquisition of non-controlling interest 1) 0.0 -0.9Dividends paid -19.8 -12.8Paid share issue 0.0 0.3Net cash used in financing activities 17.5 3.4 Change in cash and cash equivalents (+/-) -14.5 0.3Cash and cash equivalents at the beginning of the year 68.0 67.7Effects of exchange rate change -0.1 0.0Cash and cash equivalents at the end of the period 53.4 68.0 1) The acquisition of non-controlling interest is due to the additional purchase prices paid to the sellers of non-controlling interest acquired in previous financial periods. KEY FIGURES 7-12/ 7-12/ 1-12/ 1-12/ 2018 2017 2018 2017Net sales, EUR million 429.6 383.6 721.5 597.6Net sales, change % 12.0 % 73.3 % 20.7 % 74.5 %Operating profit, EUR 23.5 49.1 37.2 64.6millionOperating profit, as % of 5.5 % 12.8 % 5.2 % 10.8 %net salesProfit for the period, EUR 17.9 39.6 28.7 51.6millionProfit for the period, as % 4.2 % 10.3 % 4.0 % 8.6 %of net sales Equity ratio, % 42.7 % 56.3 %Gearing, % 21.3 % 11.7 %Net gearing ratio, % 38.5 % -20.6 %Return on equity, ROE, % 18.3 % 38.8 %Return on investment, ROI, 16.1 % 40.6 %% Order backlog, EUR million 655.6 551.2Personnel during the 1,457 1,013period, averagePersonnel at the end of 1.,552 1,184periodGross expenditure on 15.9 4.5assets, EUR millionEquity / share, EUR 2.78 2.58Earnings per share, EUR, 0.31 0.68 0.49 0.89basicEarnings per share, EUR, 0.31 0.68 0.49 0.88dilutedAverage number of shares 58,250,752 58,250,752 58,250,752 58,250,752during the period, basicAverage number of shares 58,380,598 58.432.315 58.380.598 58.432.315during the period, dilutedNumber of shares at the end 58,250,752 58,250,752 58,250,752 58,250,752of the periodMarket value of share at 247.6 763.1the end of period, EURmillion Share prices, EURHighest price, EUR 14.18 14.26Lowest price, EUR 4.02 9.79Average price, EUR 9.13 11.76Price at the end of period, 4.25 13.10EUR Share turnover, shares 42,861,908 16,334,696Share turnover out of 73.6 % 28.0 %average number of shares, %Dividend / share, EUR 1) 0.24 0.34Dividend payout ratio, % 1) 48.7 % 38.4 %Effective dividend yield % 5.6 % 2.7 %1)Price / Earnings 8.64 14.33 1) For year 2018 dividendproposal LIABILITIES AND GUARANTEESEUR million Dec  Dec 31, 2017 31, 2018Loans covered by pledges onassetsLoans from financial 65.8 28.2institutionsDebts on shares in unsold 48.9 7.3housing and real estate companysharesInstalment debts 0.8 1.1Total 115.6 36.6 GuaranteesCorporate mortgages 1.8 1.8Real-estate mortgages 4.9 4.6Pledges 65.4 12.9Absolute guarantees 0.3 0.3Total 72.4 19.6 Contract guaranteesProduction guarantees 49.9 33.8Warranty guarantees 14.3 10.4RS guarantees 36.8 29.3Payment guarantees 10.5 14.2Rent guarantees 0.0 Total 111.5 87.7 Rent liabilitiesWithin one yearPremises rents 1.5 2.0Rents related to plots in 156.4 N/AinventoriesOther rents 0.7 0.5Within 1-5 yearsPremises rents 4.5 4.3Other rents 0.8 0.8Over 5 yearsPremises rents 0.2 0.7Other rents 0.1Total 164.1 8.3 Contract guaranteesProduction guarantees 3.2 1.4 The collateral for instalmentdebt is the financed equipment.Absolute guarantees includecontract guarantees given onbehalf of another Group companyand loan guarantees for housingcompanies under construction.Pledges are inventory items andother financing assets pledgedas collateral for financialinstitution loans and loans forhousing companies underconstruction. Pledges arepresented at carrying amount.Furthermore, a right of claim toa lease agreement entered intoby the company was given as acollateral for a loan to asubsidiary.   REVENUE ANALYSISEUR million 1-12/2018 1-12/2017Revenue recognised over time 463.6 459.0Revenue recognised upon delivery 257.4 137.8Rental income 0.5 0.7Total 721.5 597.6 SEGMENT INFORMATION The Group has one operating segment, Building Services. The segment’s operations consist of providing new construction and renovation services. The Group's management monitors the entire Group, and the segment figures are consistent with the Group figures. RELATED PARTIES The Group’s related parties include Group companies, members of the Board of Director and the Group’s top management as well as entities on which related parties have influence through ownership or management. Related parties also include associated companies and joint ventures. Transactions withrelated parties Sales Purchases Sales PurchasesEUR million 1-12/2018 1-12/2018 1-12/2017 1-12/2017Associated companies 0.0Key personnel and 56.3 5.2 77.5 3.9their controlledentitiesTotal 56.3 5.2 77.5 3.9 Receivables Liabilities Receivables LiabilitiesEUR million  Dec 31, Dec 31, 2018  Dec 31, 2017 Dec 31, 2017 2018Associated companies 0.0Key personnel and 7.8 0.1 2.2 0.2their controlledentitiesTotal 7.8 0.1 2.2 0.2 A major part of related party transactions are connected with purchase of apartments and other premises from the company. The transactions are valued at the debt-free selling price of the completed site. Purchases are mainly equipment rents and other service purchases.

Fourth quarter concludes an extraordinary year for Elkem

Oslo, 12 February 2019: Elkem completes a strong 2018, but fourth quarter earnings hampered by weaker market sentiment, especially in China. Sales prices and volumes in China have been affected by lower demand and maintenance stops. Considering the challenging market conditions the result was relatively strong. Total operating income for the fourth quarter 2018 was NOK 6,265 million, which was in line with fourth quarter 2017. EBITDA for the quarter amounted to NOK 974 million, down from NOK 1,078 million in the corresponding quarter last year. Earnings per share (EPS) was NOK 0.64 in fourth quarter, giving accumulated EPS of NOK 5.74 in 2018. The board has proposed a dividend of NOK 2.60 per share, which amounts to 45% of the profit for 2018 in line with Elkem’s policy and based on an extraordinary strong year with leverage is below target. “Weaker market conditions in China have resulted in lower sales prices and lower volumes for core silicone products. Therefore, Xinghuo Silicones has been operating below full capacity rate in the quarter. As announced, Yongdeng Silicon Materials have completed technical upgrades of two furnaces resulting in lower production and sales. The average sales prices in the fourth quarter have generally been higher than the corresponding quarter last year, but this has been offset by higher raw material costs and lower sales volumes. The fourth quarter was also negatively affected by special items and one-off effects of approx. NOK 55 million,” says Helge Aasen, CEO of Elkem ASA. Elkem raised new financing of NOK 1,750 million in the Norwegian bond market and EUR 215 million in the German Schuldschein market during the fourth quarter. The new loans have maturities ranging from three to seven years and have partly been used to refinance local bank debt in China. Recapitalisation of Xinghuo Silicones and Yongdeng Silicon Materials were completed in December 2018 and January 2019. The group’s equity as at 31 December 2018 amounted to NOK 13,722 million, giving a ratio of equity to total assets of 44%. Net interest-bearing debt was NOK 3,264 million, which gave a ratio of net debt to EBITDA of 0.6 times. The group has a strong liquidity position and a well distributed loan maturity profile. The company’s fundamental position continues to be strong based on favourable market positions and strong financials. The current market sentiment is weak, partly due to seasonality in sectors such as construction. Market prices have however, stabilised and are likely to increase after first quarter. First quarter 2019 is expected to be weaker than fourth quarter 2018, mainly due to temporary production curtailments, and lower average realised sales prices due to time-lag and effects of Chinese New Year. Subsequent quarters in 2019 likely to improve based on expected higher sales volumes, price recovery, lower raw material costs and accelerated improvement programmes. Contact information: +---------------------------+-----------------------------------------------------+|Morten Viga CFO |Odd-Geir Lyngstad ||Phone: +47 416 09 752 |VP Finance & Investor Relations Phone: +47 976 72 806||Email: morten.viga@elkem.no|Email: odd-geir.lyngstad@elkem.no |+---------------------------+-----------------------------------------------------+ About Elkem ASAFounded in 1904, Elkem is one of the world's leading suppliers of silicon-based advanced materials with operations throughout the value chain from quartz to specialty silicones, as well as attractive market positions in specialty ferrosilicon alloys and carbon materials. Elkem is a publicly listed company on the Oslo Stock Exchange, and is headquartered in Oslo. The company has 6200 employees with 27 production sites and sales offices in a total of 28 countries worldwide. In 2018 Elkem had revenues of 25.9 billion NOK. To learn more, please visit www.elkem.com

BerGenBio ASA: Results for the Fourth Quarter and Full Year 2018

Bergen, Norway, 12 February 2019 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces its results for the fourth quarter and full year 2018. A presentation of the results by the Company’s management will take place today at 10.00 am CET in Oslo – details below. Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “BerGenBio made important progress in 2018 and met all its key operational milestones. The strength of the clinical data coupled with correlation with AXL biomarker expression has allowed us to confirm our clinical development strategy in AML and NSCLC. In 2019 we will focus on initiating late stage clinical trials in these indications and we look forward to providing further details and updates during the coming year.” Highlights – Fourth Quarter 2018 Superior monotherapy efficacy of bemcentinib in relapsed/refractory (R/R) AML/MDS patients reported at ASH 2018 – a possible first registration path · 43% ORR with bemcentinib monotherapy in AXL-biomarker-positive R/R AML/MDS patients · Enrolment complete into the phase II combination cohort of the study testing bemcentinib and decitabine in first-line AML, top-line results anticipated in 1Q 2019 Superior progression-free-survival (PFS) and response rate (ORR) in AXL positive advanced NSCLC patients receiving bemcentinib/ KEYTRUDA® combination presented as late breaking abstract at SITC 2018  · 5.9 months median PFS in AXL-positive vs. 3.3 months in AXL-negative patients  · 40% ORR & 70% clinical benefit rate in AXL-positive patients, including PD-L1 negative patients for whom KEYTRUDA monotherapy is not expected to work · Stage 2 of the two-part trial open and enrolling Novel tissue- and blood-based biomarkers of AXL expression identified and qualified across multiple clinical trials with bemcentinib: potential for development as companion diagnostics · Selected as a poster discussion at ESMO and presented as poster at SITC 2018  Clinical development team strengthened  · Team strengthened and expanded, particularly in key medical, clinical operations and regulatory functions in preparation for advancing bemcentinib into the next stages of clinical development Financial Highlights (Figures in brackets = same period 2017 unless otherwise stated) · Total operating expenses for the fourth quarter were NOK 53.2 million (NOK 47.5 million). Total operating expenses for the full year 2018 amounted to NOK 196.9 million (NOK 183.7 million) · Research and development expenses accounted for 78.1 % of total operating expenses in Q4, and 73.7 % for the full year 2018  · Comprehensive loss for the fourth quarter amounted to NOK 51.1 million (loss of NOK 47.6 million). Comprehensive loss for the full year 2018 was NOK 191.7 million (loss of NOK 182.2 million)  · Cash and cash equivalents amounted to NOK 360.4 million at the end of December 2018 (NOK 398.2 million at 30 September 2018 and NOK 370.3 million at 31 December 2017) Presentation and Webcast Details A presentation by BerGenBio’s senior management team will take place at 10.00 am CET at: Hotel Continental, Stortingsgaten 24/26, 0117 Oslo The presentation will webcast live and the link will be available at www.bergenbio.com in the section Investors/ Financial Reports. A recording will be available shortly after the webcast has finished. The results report and the presentation will be available at www.bergenbio.com in the section: Investors/ Financial Reports from 7:00 am CET the same day. -End- About AXL  AXL kinase is cell membrane receptor and an essential mediator of the biological mechanisms that drive aggressive and life-threatening diseases. In cancer, AXL drives tumour survival, treatment resistance and spread, as well as suppressing the body’s immune response to tumours. AXL expression has been established as a negative prognostic factor in many cancers. AXL inhibitors, therefore, have potential value at the centre of cancer combination therapy, addressing significant unmet medical needs and multiple high-value market opportunities.  About BerGenBio ASA  BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for advanced and aggressive cancers.  The company’s proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme. Ongoing clinical trials are investigating bemcentinib in multiple solid and haematological tumours, in combination with current and emerging therapies (including immunotherapies, targeted therapies and chemotherapy), and as a single agent.  In parallel, BerGenBio is developing companion diagnostics test to identify patient populations most likely to benefit from bemcentinib; this is expected to facilitate more efficient registration trials and support a precision medicine-based commercialisation strategy.  BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). www.bergenbio.com  Contacts  Richard Godfrey CEO, BerGenBio ASA +47 917 86 304  Rune Skeie, CFO, BerGenBio ASA rune.skeie@bergenbio.com +47 917 86 513  Media Relations in Norway  Jan Petter Stiff, Crux Advisers stiff@crux.no +47 995 13 891  International Media Relations  Mary-Jane Elliott, Chris Welsh, Nicholas Brown, Carina Jurs, Consilium Strategic Communications bergenbio@consilium-comms.com +44 20 3709 5700 Forward looking statements  This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements   This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. 

Fourth quarter and year-end report - 31 December 2018

MUSD (unless Fourth Third Fourth Full Fullspecifically quarter quarter quarter year yearstated) 2018 2018 2017 2018 2017Net daily 11,898 11,857 11,726 11,767 12,261production fromOman,Blocks 3&4 beforegovernment take(bbl)Net barrels 569,177 567,258 556,729    2,233,323    2,308,342produced, after        government take(bbl)Net barrels sold, 542,596 579,360 617,577    2,163,148    2,316,404after government        take (bbl) Average selling 77.9 74.3 53.9 70.5 51.8price per barrel,USD Revenue and other 44.4 42.3 30.1 157.3 119.3incomeEBITDA 30.8 30.1 19.7 106.6 78.2Operating result 19.1 18.5 9.9 60.7 38.4Result for the 19.9 18.2 11.0 62.2 33.1periodEarnings per 0.58 0.53 0.32  1.82 0.97share (afterdilution), USD Net cash 73.1 63.7 42.0 73.1 42.0Investments in  16.2 12.6 8.2  55.8 40.4oil and gasproperties Letter to shareholders Dear Friends and Investors, We are delighted to report record financial numbers for both the fourth quarter and the full year 2018. Our revenues and other income increased 32 percent to MUSD 157.3 and our EBITDA increased 36 percent and amounted to MUSD 106.6. We are equally delighted to report a 2P reserve replacement ratio of 177 percent for 2018 – the highest for three years and the 7thconsecutive year of increasing our 2P reserves. So our main asset, Blocks 3&4 onshore Oman certainly continues to confirm its growth potential! Production has been very stable both for the quarter and for the year, although delays in the development of the discoveries from 2017 has pushed our expected production increase into the first quarter of 2019. The fourth quarter saw intense activity on Block 49 where several hundred kilometres of seismic was collected on time. Processing is ongoing and over the next couple of months, processed data will be ready for interpretation and mapping. In December 2018, we attempted to increase our presence in Oman further by entering into an agreement to acquire two percent of the Mukhaizna field. Unfortunately, Tethys Oil was informed by the seller that partner pre-emption rights had been exercised, preventing us from completing the transaction. This slight setback does not, however, diminish our ambition to grow in Oman and elsewhere. Year end 2018 reserves and the appraisal/development programme The discoveries we made in 2017 continue to have a great impact on our reserves, contingent resources and our reserve replacement. In 2018, we produced 4.3 million barrels and we added 7.6 million barrels of 2P reserves. The additions and revisions include maturation of Contingent Resources to reserves and upside revisions of the Farha South, Shahd and Erfan fields. The appraisal of the Ulfa and Samah discoveries has been one of the central components of the work programme during 2018. Appraisal and development of the Ulfa, Samah and Erfan fields will continue in 2019, now with the Ulfa production facilities fully up and running. With the continued appraisal programme, and a remaining resource base of 2C Contingent Resources of 12.5 million barrels, we are in a good position to continue to replace and increase our reserves in 2019. Exploration A significant amount of new seismic data was acquired in 2018 – 2,750 km23D seismic on Blocks 3&4 and 253 km2of 3D and 299 km of 2D on Block 49. But with so much focus on the appraisal of our 2017 discoveries we did not see much exploration drilling for most of 2018, apart from the Tibyan discovery in the first quarter 2018. The exploration programme did not get under way until late in the year and currently two wells that spudded in the fourth quarter are in progress. In 2019 we will see the results from these wells as well as additional seismic and the drilling of at least three new exploration wells. All new seismic data will guide our exploration drilling on our blocks in the years to come. So 2019 looks like it could be quite an active year from the exploration perspective. Oil price environment We started the year with an average selling price of USD 63.7 per barrel for the first quarter, which increased quarter by quarter during the year. We achieved an average selling price per barrel of USD 77.9 for the fourth quarter of 2018, which is the highest oil price we have achieved since 2014. Towards the end of the year, international prices fell about 40 percent down to about USD 50 per barrel. As Tethys Oil’s oil sales price is calculated with an effective two-month lag to spot prices, we will see the lower prices in our sales during the first quarter 2019. In January 2019 the prices have rebounded somewhat. However, what we have shown in previous years is that Tethys Oil is profitable even at lower oil prices. Fourth quarter in focus We produced 1.1 million barrels of oil in the fourth quarter of 2018, corresponding to 11,898 barrels of oil per day, which was slightly higher than the annual average. Our average selling price in the fourth quarter amounted to USD 77.9 per barrel, an increase of five percent compared to the third quarter 2018. Following the higher oil price combined with a stable production, our quarterly results are again on par with our best quarters in 2014. For the quarter, we report revenues and other income of MUSD 44.4, up five percent compared with the third quarter. Our EBITDA amounted to MUSD 30.8, up two percent compared with the third quarter. During the fourth quarter 2018, cash flow from operations amounted to MUSD 29.3 and investments in oil and gas amounted to MUSD 16.2. Our net cash position increased from MUSD 63.7 to MUSD 73.1. The result for the period amounted to MUSD 19.9, up nine percent compared with MUSD 18.2 in the third quarter. Outlook The annual average net production from the company’s existing operations on Blocks 3&4 in Oman during 2019 is expected to amount to between 12,000-13,000 barrels of oil per day. Reflecting the strong operational and financial position of Tethys Oil, the board of directors is proposing an ordinary dividend of SEK 2.00 per share. Further, in line with Tethys Oil’s long-term capital structure target, the board of directors is proposing an extraordinary distribution of SEK 6.00 per share. Under current market conditions and production assumptions, Tethys Oil expects its 2019 investments for the company’s existing operations on Blocks 3&4 and Block 49 in Oman to amount to MUSD 50-55. Focus of the work programme in Blocks 3&4 is continued development and appraisal drilling, upgrading of production facilities and other infrastructure, new seismic acquisition and drilling of exploration wells. Focus on Block 49 is to continue the exploration programme. The new seismic data acquired in 2018 will be processed and interpreted in order to further define possible oil traps and to enhance the understanding of the deeper parts of the block in general. Preparations for exploration drilling will be carried out. So, to sum up our plans for 2019: we still have over 12 million barrels of Contingent Resources to mature to Reserves; we expect the results of three to five exploration wells on Blocks 3&4; and on Block 49 prospect maturation will get seriously under way. Not to mention anything else that may come our way. So stay with us – it will be an exciting year! Stockholm in February 2019 Magnus NordinManaging Director For further information, please contact: Magnus Nordin, managing director, phone: +46 8 505 947 00 Jesper Alm, CFO, phone: +46 8 505 947 00 Conference call Date: 12 February 2019 Time: 10.00 CET To participate in the conference call, you may choose one of the following options: Link to webcast: https://edge.media-server.com/m6/p/d7v8nv9y To participate via phone, please call: Sweden: +46 8 505 564 74Switzerland: +41 225 675 541UK: +44 203 364 5374North America: +1 855 753 2230 This information is information that Tethys Oil AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 7:30 CET on 12 February 2019.

Year-end report 2018: Wihlborgs posts record strong results and continued growth

“We close the books on another record year. Each year since we first listed on the stock exchange in 2005 has been a record year — irrespective of whether one looks at rental income, operating surplus or income from property management. This shows that our constant desire to strive to take responsibility for what we have and to develop it further is deeply rooted in our culture,” says Ulrika Hallengren, CEO of Wihlborgs Fastigheter. “We have noted continued healthy demand for office space. Our net lettings remain strong, SEK 85 million for the full year, and our office vacancies are at very low levels. Given the healthy level of regional demand, it is critical that we continue to develop new space in all our cities. Our project portfolio is at an all-time high, with decided investments in excess of SEK 2 billion. We are creating new business opportunities with our development projects that, in combination with the low vacancy levels in existing properties, will comprise the foundation of our continued growth.” “We have also grown through acquisitions. We have increased our presence in Lund through the acquisition of the Nya Vattentornet 3 property in the fourth quarter of 2018, and we acquired the adjacent properties, Nya Vattentornet 2 and 4, last week. Altogether, this means that we are well-positioned to develop the company and the region.” Wihlborgs Fastigheter AB (publ) This information is of such a kind that Wihlborgs Fastigheter AB (publ) is legally required to disclose pursuant to the EU’s Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication through the agency of the above contact people on 12 February 2019, at 7:30 a.m. CET. At 12:00 noon today, CEO Ulrika Hallengren and CFO Arvid Liepe will present the interim report at Operaterrassen in Stockholm. The presentation can be followed by webcast  or telephone +46 8 519 99 383 or +44 333 30 09 268 (UK) Link to webcast 

Report for the fourth quarter 2018 and preliminary year end accounts

Financial and operating highlights 4Q 2018 (4Q 2017 in brackets) · Operating revenues were NOK 1 854 million (NOK 1 660 million) · EBITDA (operating result before depreciation, impairment, result from associates, finance and tax) was NOK 470 million (NOK 399 million) · Depreciation was NOK 267 million (NOK 221 million) · EBIT (operating result) was NOK 202 million (NOK 163 million)     · Deconsolidation of Dolphin Drilling ASA, segment Offshore drilling derecognized,Re-presentation of the income statement · Net result after tax from continuing operations was NOK 68 million (NOK 30 million  Post quarter event: Dividend proposal NOK 4.00 per share  Renewable energy · EBITDA NOK 433 mill. (NOK 336 mill.) · Total generation up 7% · Like-for-like generation down 5.5% · Increasing electricity prices in all markets · Investment decision on Högaliden wind farm in Sweden, approx. SEK 1.2 billion. · Verkanliden in Sweden consented and expanded, pipeline development Shipping / Offshore wind · EBITDA NOK 40 mill. (NOK 32 mill.) · Utilization for installation vessels 79% (59%). · Contract pipeline to 4Q 2019 covered 52% by firm contracts · High activity in Global Wind Service · Acquisition of an indirect 51% shareholding in a company owning the Offshore Transport & Installation vessel Blue Tern (ex.Seafox 5). Total investment of USD 73.6 million Cruise · EBITDA NOK 9 mill. (NOK 29 mill.) · Net ticket income per diems unchanged · Passenger days increased 6% · Higher share of revenues from fly cruises · Increase in fuel costs Financial information The unaudited Group accounts for 4 quarter 2018 comprise Bonheur ASA (the “Company”) and its subsidiaries (together the “Group of companies”) and the Group of companies’ ownership in associates. The main business segments of the Group of companies are Renewable energy, Shipping / Offshore wind, Cruise and Other investments. The investment in Dolphin Drilling ASA (DD) is deconsolidated from November 2018. From the same date the investment will be reported as a separate line item in the consolidated income statement and derecognized from the Group of companies’ statement of financial position. From the same date, the investment in DD is assessed as a financial investment. For further details see note 10 Discontinued operations. The Group of companies’ operating revenues in the quarter amounted to NOK 1 854 million (NOK 1 660 million). Renewable energy had operating revenues of NOK 570 million (NOK 467 million), Shipping / Offshore wind NOK 413 million (NOK 364 million), Cruise NOK 527 million (NOK 476 million). Within Other investments NHST Media Group had operating revenues of NOK 331 million (NOK 349 million). EBITDA in the quarter was NOK 470 million (NOK 399 million). Renewable energy achieved EBITDA of NOK 433 million (NOK 336 million), Shipping/Offshore wind NOK 40 million (NOK 32 million), while Cruise achieved EBITDA of NOK 9 million (NOK 29 million). Within Other investments EBITDA was NOK - 12 million (NOK 2 million), of which NHST was NOK 10 million (NOK 21 million). Depreciation in the quarter was NOK 267 million (NOK 221 million). No impairment was recognized in the quarter (NOK 16 million). EBIT in the quarter was NOK 202 million (NOK 163 million). Net financial items in the quarter were NOK - 94 million (NOK - 14 million). Net interest expenses were NOK 74 million (NOK 74 million) and net currency gain amounted to NOK 118 million (NOK 74 million). Net unrealized loss related to fair value adjustment of financial instruments were NOK 57 million (gain NOK 9 million), whereof the major part was related to forward fuel hedging within Cruise. In the quarter, an unrealized loss of NOK - 101 million was recognized on financial assets. Other financial expenses amounted to NOK - 6 million (NOK 14 million). Net result in the quarter from continuing operations was NOK 68 million (NOK 30 million), while net result from discontinued operations (Dolphin Drilling) was NOK 181 million (NOK - 509 million). This includes the net result from Dolphin Drilling for a period of 1 month (NOK -128 million), net balance sheet effect from deconsolidation (NOK 260 million) and fair value of the Company’s shares in DD (NOK 48 million). Net Result in the quarter was NOK 249 million (NOK - 479 million), of which NOK 236 million (NOK - 271 million) are attributable to the shareholders of the parent company. The non-controlling interests´ share of the net result from continuing operations in the quarter was NOK 13 million (NOK - 208 million). Revenues for the year were NOK 6 787 million (NOK 6 325 million) while EBITDA year to date was NOK 1 484 million (NOK 1 570 million). Operating result (EBIT) year to date was NOK 438 million (658 million). Net financial items were NOK - 362 million (NOK - 120 million). Net result after estimated tax from continuing operations was NOK - 23 million (NOK 367 million), while net result from discontinued operations was NOK - 2 675 million (NOK -2 144 million). For further information see note 10. Net result for the year was NOK - 2 698 (NOK - 1 777 million), of which NOK - 1 381 million (NOK - 864 million) are attributable to the shareholders of the parent company. The non-controlling interests´ share of net result from continuing operations was NOK - 1 318 million (NOK - 913 million). Annual General meeting / Dividend With regard to the Annual General Meeting 2018 the board will, subject to no diverging position taken by the Shareholders’ Committee, propose a dividend of NOK 4.00 per share. For the company NOK 170 million. The annual general meeting is scheduled for Wednesday 29 May 2019.

Year-End Report 1 January - 31 December 2018

"Acquisition-intensive quarter"1 OCTOBER – 31 DECEMBER 2018 (3 MONTHS) · Net sales increased by 3 percent to SEK 685 million (668). · EBITA amounted to SEK 74 million (79), corresponding to an EBITA-margin of 10.8 percent (11.7), including acquisition costs of SEK 6 million. · Profit after tax increased by 9 percent and amounted to SEK 44 million (40). · Earnings per share amounted to SEK 1.83 (1.67). · Cash flow from operating activities amounted to SEK 92 million (97). 1 JANUARY – 31 DECEMBER 2018 (12 MONTHS) · Net sales increased by 6 percent to SEK 2,482 million (2,333). · EBITA amounted to SEK 245 million (234), corresponding to an EBITA-margin of 9.9 percent (10.0), including acquisition costs of SEK 8 million. · Profit after tax increased by 7 percent and amounted to SEK 129 million (120). · Earnings per share amounted to SEK 5.36 (4.95). · Cash flow from operating activities amounted to SEK 177 million (208). · The equity ratio amounted to 35 percent (40). · Return on working capital (P/WC) amounted to 62 percent (63). · During the financial year five acquisitions have been completed, with a combined annual sale of about SEK 750 million. · The Board of Directors proposes a dividend of SEK 2.20 per share. Stockholm, 12 February 2019AddLife AB (publ) For more information, contact;Kristina Willgård, CEO, kristina.willgard@add.life, +46 70 510 12 23Martin Almgren, CFO, martin.almgren@add.life, +46 70 228 15 45www.add.life  TeleconferenceInvestors. analysts and the media are invited to a teleconference at which CEO Kristina Willgård and CFO Martin Almgren will present the interim report. The presentation will be given in English and take about 20 minutes. after which there will be an opportunity to ask questions.The teleconference will be at 10:00 a.m. on 12 December 2019The presentation will be available via the following link: https://5569958126.globalmeet.com/MartinAlmgrenPlease call on: +46 8 22 90 90 code: 113242 AddLife is an independent player in the Life Science industry that offers high-quality products, services and advice to both the private and public sectors, mainly in the Nordic region. AddLife has about 900 employees in some 40 operating subsidiaries. The Group currently has net sales of around SEK 2.5 billion. AddLife shares are listed on Nasdaq Stockholm.This information is information that AddLife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 12 February 2019 at 08:00 a.m. CET.

The Nomination Committee proposal to Swedbank AGM 2019

At the AGM 2018, it was decided to increase the number of Board members from nine to ten. In January 2019, one Board member announced that, due to another assignment, the member was prevented from continuing the assignment in Swedbank’s Board of Directors. The Nomination Committee assesses that the remaining members together have required experience and expertise to lead Swedbank into the future. Remuneration of the Board of Directors and Auditors.The Nomination Committee proposes to raise the remuneration to the Board of Directors calculated on an annual basis as follows, corresponding to an average raise of 5 percent (calculated on proposed number of members): SEK 2,630,000 (presently 2,540,000) to the Chair of the Board of Directors; SEK 885,000 (850,000) to the Deputy Chair of the Board of Directors; SEK 605,000 (570,000) to each of the ordinary members of the Board of Directors; SEK 395,000 (360,000) to the Chair of the Board’s Audit Committee; SEK 240,000 (232,500) to each of the other members of the Board’s Audit Committee; SEK 430,000 (410,000) to the Chair of the Board’s Risk and Capital Committee; SEK 250,000 (230,000) to each of the other members of the Board’s Risk and Capital Committee; SEK 105,000 (102,500) to the Chair of the Board´s Remuneration Committee; SEK 105,000 (102,500) to each of the other members of the Board’s Remuneration Committee. The Nomination Committee proposes that the external auditor’s fee, shall be payable by approved account. In accordance with the recommendation and preference of the Board´s Audit Committee, the Nomination Committee proposes that PwC Sverige AB is elected as external auditor for a period of four years, until the end of the AGM 2023. The Nomination Committee proposes the lawyer (Sw. advokat) Wilhelm Lüning as Chair of the 2019 AGM. The Nomination Committee comprises of the following members: Lennart Haglund, Chair, appointed by Sparbankernas Ägareförening, Jens Henriksson, appointed by the owner-group Folksam, Ramsay Brufer, appointed by Alecta, Johan Sidenmark, appointed by AMF, Peter Karlström appointed by the owner-group Sparbanksstiftelserna and Lars Idermark, Chair of the Board of Directors of Swedbank AB (publ). The entire proposal of the Nomination Committee will be included in the AGM notice and also be available on Swedbank’s website. Swedbank AB’s AGM will take place on the 28 March 2019 at Oscarsteatern, Kungsgatan 63, in Stockholm. For further information, please contact:Lennart Haglund, Chair of the Nomination Committee, telephone: +46 70 557 51 29Gabriel Francke Rodau, Head of Communication, Swedbank, telephone: +46 70 144 89 66

LeoVegas AB: Q4 report and financial targets pushed one year to 2021

”After a challenging 2018 we now see improved momentum with a record strong December and a positive start to 2019. Entering the new year we have full focus on expansion, cost control, increased profitability and to continue building the world’s best mobile casino.” - Gustaf Hagman, Group CEO Fourth quarter 2018: 1 October– 31 December 2018[1]   · Revenue increased by 25% to EUR 84.5 m (67.8). · Organic growth in local currencies was 7%. Organic growth in local currencies excluding the UK was 14%. · EBITDA was EUR 8.1 m (6.1), corresponding to an EBITDA margin of 9.6% (9.0%). · Net Gaming Revenue (NGR) from regulated markets was 33% (29%) of total NGR. · The number of depositing customers was 327,156 (253,299), an increase of 29%. · The number of returning depositing customers was 181,747 (124,890), an increase of 46%. · Earnings per share were EUR 0.22 (0.02) before dilution and EUR 0.22 (0.01) after dilution. Events during the quarter · LeoVegas has applied for a gambling licence for the Spanish market. Approval and implementation are expected during the first or second quarter of 2019. · LeoVegas was one of the first operators to receive a licence for both casino and sports betting in Sweden. Events after the end of the quarter · LeoVegas has postponed its financial targets from 2020 to 2021 due to developments in the UK market. However, the direction remains unchanged with financial targets in absolute numbers to reach EUR 600 m in revenue and EUR 100 m in EBITDA. · The Group’s Pixel.bet brand was granted a licence for online casino and sports betting in Sweden. · The Board proposes a total dividend of SEK 1.20 per share (1.20), to be paid out on two occasions during the year. · Revenue amounted to EUR 28.7 m (24.8) in January, representing growth of 16%. Comment from Gustaf Hagman - Group CEO 2018 – an educational year for a seven-year old2018 was the most challenging year in LeoVegas’ history. We bumped into challenges that we have not previously encountered and saw a slowdown in growth as a result. It was also a year in which we carried out a number of strategically crucial projects that have taken us large steps forward on our growth journey. There is much left to do, and there’s no doubt we can and will improve in many areas. We have learned a lot, and our position for achieving our long-term vision – to be the global market leader in mobile casino – is good. Today we are already the most appreciated brand in our home market in Sweden, and we are live in more markets than ever before. We are well-invested with our own technology, which makes us scalable and flexible, and we have taken large leaps in responsible gaming and compliance. Our multibrand strategy is in place, enabling us to rapidly launch new casino brands, and we are ready to expand in more markets in 2019 with an overall focus on cost control and increased profitability. During the fourth quarter we also returned to sequential growth following a slowdown during the third quarter, and we ended the year with all-time high revenues in December, and with record-high customer activity. The new year has also started on a promising note – for example, our depositing customer base was up 42% in January. LeoVegas has just celebrated seven years as a company. We have achieved a lot in a short period of time, but we are still just at the start of our growth journey. Fourth quarter figuresRevenue during the fourth quarter amounted to EUR 84.5 m (67.8), an increase of 25%. Organic growth in local currencies was 7%. As in the preceding quarter, growth during the period was affected by weak performance in the UK. Excluding the UK, organic growth for the Group was 14% during the quarter, which shows healthy underlying growth. October was the weakest month during the quarter, and December the strongest. EBITDA totalled EUR 8.1 m (6.1), corresponding to an EBITDA margin of 9.6% (9.0%). We increased our investments in marketing during the quarter, among other things to reassure our leading position in Sweden ahead of the market’s regulation, but also in other key markets. Marketing costs amounted to 37.9% during the fourth quarter, compared with 35.6% during the third quarter. Our personnel costs in relation to revenue remained at a higher level than we are pleased with. We will thus now focus on cost control, improving efficiency in our ways of working, and increase automation in our operations. This is also necessary in order to adapt our cost base to rising tax pressure in our regulated markets. Sweden – finally a regulated marketThe day we have been waiting for has finally arrived, when Sweden became a regulated market. We were among the first companies to be granted a licence, which is a quality seal and confirms our position as a leading, long-term and serious player in the industry. In January, LeoVegas’ Pixel.bet brand also received a licence in Sweden for casino and sports betting. Pixel.bet has the ambition to take the leading brand position in esports betting. A regulated market has extensive guidelines for responsible gaming. We have good experience from other regulated markets, and we have developed the organisation and our marketing methods to offer our games in the best, sustainable way. We look forward to working side-by-side the Swedish Gambling Authority and our licensed competitors to ensure a sound and responsible market that impedes the presence of unlicensed actors. With regulation of the market, all licensed gaming companies are now free to operate in stores. LeoVegas was the first one to grasp this opportunity in January. There is important symbolic value in having a physical presence at betting agents in connection with the implementation of the new gambling law in Sweden. We will now be able to truly challenge to the old monopoly through a greater exposure of our LeoVegas brand with an even closer presence to our customers in a new type of environment. Regulation of the market in Sweden also made it possible for us to launch the popular Swish mobile payment method in the Swedish market. Swish both strengthens our customer offering and is expected to significantly lower our transaction costs. Improvements in the product combined with increased marketing led to a strong fourth quarter in Sweden, with 18% sequential growth, which affirms our position as the leading casino brand. The new year has also started on a positive note for LeoVegas in Sweden. We have seen record-high customer activity, with 28% growth of our Swedish depositing customer base compared with the same period a year ago. At the same time, revenue is down somewhat compared with the same period a year ago, which is partly due to many customers initially using their welcome bonuses, but also to some trim-in challenges during the first two weeks following the start of regulation, and to the fact that players are getting accustomed to certain modifications in the gaming experience. It is still hard to accurately predict the market dynamics in Sweden in the near term, but with a record-large active customer base and a large number of exciting product and marketing initiatives under way during the year, we are well positioned in our home market. As previously, we are confident that our product, customer experience, competence in responsible gaming, very strong brand and data-driven marketing will lead to higher market shares in Sweden. UKThe UK is Europe’s largest gambling market and a market in which LeoVegas sees continued major growth potential in the long term. Together with our brands in Rocket X, LeoVegas and Royal Panda we have a unique multibrand position in casino. In the near term the market continues to be challenging, and after a transitional period we are now working from a new, lower level on which to grow. Our revenue continued to decrease sequentially during the fourth quarter, but with gradual improvements in both revenue and KPIs. This positive development continued on Group level during January. It is still too early to declare that we have turned the corner yet in the UK, but we are confident with the plan we have charted out. Scale-up marketsWe are satisfied with our performance in most of our markets during the fourth quarter. Germany continues to be a strong growth market and once again delivered a record quarter with growth of more than 200%. In addition to Germany – Finland, Denmark and Canada amongst other markets delivered good results during the quarter. Changes in Group Management teamAs previously communicated, Richard Woodbridge has been recruited as our new Chief Operating Officer. He took up his position on 7 January and has overarching responsibility for operations in LeoVegas. Richard is based at LeoVegas’ offices in Malta. Group Management has also been reinforced with Avshalom Lazar, who we recruited as Chief Compliance & Legal Officer. Avshalom, who is based in Malta, will strengthen the Group Management team with relevant knowledge about the industry and an understanding of and experience in the higher requirements that are placed on companies in regulated markets. We are also adding a new role to the Group Management, Chief Product and Technical Officer (CPTO), where we are combining the CTO and CPO roles. Mattias Wedar has been recruited to this new position and will begin at LeoVegas during the spring. Mattias joins us most recently from a similar role and has solid experience in product development and keen industry knowledge. With this new position, the product and technology organisation will have a single leader, which will increase its effectiveness and cooperation within the Group. Tech updateWe have previously presented the upgrade of our technical front-end platform, which took place during the second quarter. This has improved our organic search capabilities and during the fourth quarter we saw an increase in organic traffic by more than 70% compared to the same period last year. We expect to see continued positive effects from this combined with our data-driven marketing. The Rocket X managed UK brands encountered certain technical issues that impacted the site performance during part of the fourth quarter. The issues are now to a large extent solved which is confirmed by a higher revenue and customer activity in January compared to December. Our technology organisation has been through an intensive period, and during the fourth quarter, three parallel platform adaptations were made to the locally regulated markets in Sweden, Germany and Spain – an impressive record for LeoVegas. We are now beginning to gradually free up resources for a renewed focus on product innovation, new brands and markets – areas that are expected to drive our growth going forward. Financial targets and focus on growth with profitabilityFollowing a year burdened by a number of external factors and large internal projects, we are now well prepared for the future with a renewed focus on growth. Our direction remains firm, with financial targets in absolute figures to reach EUR 600 m in revenue and EUR 100 m in EBITDA. However, we have decided to push back these targets one year, until 2021, as our adaptation to the increased regulatory requirements in the important UK market caused us to temporarily lose our tempo compared with the previous business plan. It is also increasingly clear for us that the coming years will be decisive for who will be the long-term winners in our industry and who will not be able to cope with the increased complexity, compliance, technological development and higher tax burden. We are therefore currently in a very exciting period in the gaming industry, and we are well prepared. As more markets become locally regulated – with more regulatory requirements and higher tax pressure – it is important to be a company that is both agile and of a size that enables economies of scale. We are convinced that this requires proprietary technology and a world-class user experience while at the same time being well invested in responsible gambling and compliance – and having a diver­sified operation both geographically and in terms of brands. Moreover, we will continuously evaluate our marketing and our organisational set-up, all in line with our focus on growth with increased profitability in an increasingly complex business environment. We have also decided to conduct a strategic evaluation of our portfolio companies within LeoVentures, with the intention to further intensify focus within the Company on our end goal – to be the market-leading mobile casino operator globally. At the same time, we believe that the years ahead will offer a number of new growth opportunities within casino for operators with the strength and ability to act quickly, as smaller actors have a hard time adapting to the growing requirements and complexity. Comments regarding Q1 20192019 has begun on a good note for LeoVegas, with Revenue of EUR 28.7 m (24.8) in January, representing growth of 16%. Underlying customer activity remains strong, with 42% growth in depositing customers compared to the same period last year. We have now forged ahead through both an eventful and challenging year with several acquisitions, accolades, higher regulatory requirements, a number of major platform projects and a change in listing to the Stockholm Stock Exchange’s main market list. We at LeoVegas now look forward to 2019, where we have put casino front and centre and have our full focus on profitable growth. Presentation of the report - today at 09:00 CETTo participate in the conference call, and thereby be able to ask questions, please call one of the following numbers: SE: +46 (0) 8 56 61 84 67, UK: +44 (0) 84 44 81 97 52, US: +1 64 67 41 31 67, Confirmation code: 9775259 or join at the web https://edge.media-server.com/m6/p/jtyut9im This information is information that LeoVegas AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was submitted for publication, through the agency of the contact person set out below, at 08:00 CET on 12 February 2019. For further information, please contact:Gustaf Hagman, Group CEO: +46 (0) 8 410 367 66, gustaf.hagman@leovegas.comStefan Nelson, CFO, +46 (0) 8 410 367 66, stefan.nelson@leovegas.comPhilip Doftvik, Director of Investor Relations and Corporate Finance: +46 73 512 07 20, philip.doftvik@leovegas.com  (philip.doftvik@leovegas.com)About the LeoVegas mobile gaming groupLeoVegas’ passion is “Leading the way into the mobile future”. LeoVegas is the premier GameTech company and is at the forefront of using state-of-the-art technology for mobile gaming. A large part of this success can be credited to an extreme product and technology focus coupled with effective and data-driven marketing. Technology development is conducted in Sweden, while operations are based in Malta. LeoVegas offers casino, live casino and sports betting, and operates two global and scalable brands – LeoVegas and Royal Panda – as well as a number of local brands in the UK. The company’s shares are listed on Nasdaq Stockholm. For more about LeoVegas, visit www.leovegasgroup.com. ---------------------------------------------------------------------- [1]  Throughout this report, figures in parentheses pertain to the same period a year earlier. 

CONTINUED EFFORTS WITHIN NEW PRODUCT AREA DIGITAL IDENTITY

YEAR-END REPORT FOR THE PERIOD JANUARY TO DECEMBER 2018 FOURTH QUARTER  · Net sales for the remaining operation totaled SEK 13.9 (14.2) million. · The operating profit/loss for the remaining operation totaled SEK -14.3 (-5.3) million.  · The profit/loss for the remaining operation totaled SEK -15 (-12.0) million.  · Earnings per share for the remaining operation totaled SEK -0.04 (-0.03).  · Earnings per share for the total operation totaled SEK -0.04 (-0.03). · Cash flow from total operating activities totaled SEK -9.1 (3.1) million. FULL-YEAR PERIOD, JANUARY-DECEMBER  · Net sales for the remaining operation totaled SEK 67.6 (61.0) million. · The operating profit/loss for the remaining operation totaled SEK -20.0 (-13.9) million.  · The profit/loss for the period for the remaining operation totaled SEK -22.2 (-22.7) million.  · Earnings per share for the remaining operation totaled SEK -0.06 (-0.06).  · Earnings per share for the total operation totaled SEK -0.06 (-0.05). · Cash flow from total operating activities totaled SEK -26.1 (22.8) million. · Cash and cash equivalents were SEK 79.5 (117.0) million at the end of the period. SIGNIFICANT EVENTS DURING THE QUARTER  · A revised strategy was presented and the company started to develop solutions to secure digital identity. · A planned reorganization of the business was initiated with the aim of improving customer service and enabling growth in new areas. SIGNIFICANT EVENTS SINCE THE END OF THE FULL-YEAR PERIOD  · A new office was established in Shanghai. FINANCIAL DATA AND KEY INDICATORS     As a result of the Mobile Smart Card Solutions business area having been disposed of as of January 1, 2018, previously reported figures have been restated in order to improve comparability. The business area was reported as a business held for sale starting in the interim report for the second quarter of 2017. In order to obtain comparable historical data, previously reported figures have only been adjusted for the expenses relating directly to the discontinued business area, which will no longer affect the company’s remaining operation. The discontinued operation’s impact on the financial position has not been reported separately, as the company does not consider it possible to report the discontinued operation’s impact on cash flow. Cash flow is instead reported for the total operation.Unless otherwise specified, reported figures in the year-end report relate to the remaining operation.  KEY INDICATORS  Amounts in SEK thousand 2018  2017  2018  2017 unless otherwise stated    Q4  Q4  Full year  Full year Net sales   13,948  14,181  67,645  61,039 Net sales growth, %  -1.6%  -31.8%  10.8%  -26.7% Gross margin, %  80.5%  91.7%  85.2%  93.3% Operating profit/loss  -14,261  -5,279  -19,958  -13,936 Operating margin, %  -102.2%  -37.2%  -29.5%  -22.8% Cash flow from operating  -9,067  3,093  -26,055  22,788 activities Cash and cash 79,543  116,955  79,543  116,955 equivalents, totaloperation  PRESENTATION OF THE YEAR-END REPORTIn connection with today’s year-end report, we issue an invitation to an information event today at 10:00 AM. Please see the last page of the year-end report for further information about participation.THE CEO’S COMMENTS During the year we have initiated a journey towards moving Precise Biometrics to a position in which we will come closer to the end customer. Precise Biometrics has for a long time been active primarily in the mobile market, where the customer was a long way from the end customer and there was a high degree of volatility. Since we announced the company’s updated strategy on October 12, we have made a lot of progress in developing our new product, Precise YOUNiQ, which secures digital identity by combining different kinds of biometrics, such as face, fingerprint, iris and voice together with geodata.   The product simplifies people’s everyday lives in a revolutionary way by means of simple onboarding, smooth and secure authentication and unique personalization of digital services. Precise YOUNiQ takes us higher up the value chain, closer to the end customer. Precise Biometrics currently operates its business in three main business areas: digital identity, smart cards and mobile devices, and it is also engaged in initiatives such as cars and door locks. During the first half of 2019, pilot tests will be initiated in the field of digital identity, which will involve conducting tests together with customers up to and including the summer, before moving into a commercial phase during the second half of 2019. We do not, however, expect this to generate any significant revenue this year, but the focus during the year will be on preparing the product ahead of next year.  Contactless payments are currently permitted only for amounts up to SEK 200 without verification; for higher amounts a PIN code is required for security reasons. The introduction of contactless payment cards with fingerprint sensors will increase the security of contactless payments and enable bigger purchases without a PIN code, improving convenience and security for both end user and card issuer.   In the field of smart cards we have a number of strong partnerships, including NXP and other partners and sensor suppliers, together we supply a product that both improves convenience for the user while at the same time being the most secure solution for biometric payment cards. We are expecting modest initial volumes in the field of smart cards during the second half of 2019, with volumes increasing during 2020 and 2021.  The mobile devices business area will account for the biggest proportion of revenue in 2019. The journey towards having the fingerprint sensor over the entire display is continuing, and the first phone with this technology will probably be launched during the second half of 2019. This means that the user can be verified regardless of where the finger is placed on the display, which enhances the experience and the security of the phone.  We continue to have strong collaboration within the mobile area with actors such as Qualcomm and a number of sensor partners in China and Korea. During the quarter a subsidiary of Xiaomi in China released an electronic door lock for domestic use with a fingerprint sensor that uses our algorithm. The launch had a big impact in the media in China, indicating the interest in new biometric solutions for consumers.  The reorganization of the business that was initiated during the quarter continues, and a new office with a handful of employees has been established in Shanghai. The office in Karlstad is closing in the middle of the first quarter, which means that work is proceeding ahead of plan. A total one-off cost of SEK 5.4 million was incurred in 2018 for the internal reorganization.  The new office in Shanghai will play an important role for the business area mobile, as the local presence is being reinforced in a key market.  The journey to move Precise Biometrics to a higher level in the value chain will be our primary focus during 2019. We are convinced that the reorganization of the business, which will soon be completed, will make a positive contribution to our development and financial results. With continued high volatility in the mobile market, 2019 may be a challenging year from a financial perspective. Precise Biometrics does, however, have a secure financial position, which makes the initiatives we have undertaken possible and which we are convinced will contribute to an improved financial result in future years.  This information is information that Precise Biometrics Biometrics AB is obligated to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8:00 AM on February 12, 2019. FOR MORE INFORMATION, PLEASE CONTACTStefan K Persson, CEO, Precise Biometrics AB Tel. +46 707 920831E-mail stefan.k.persson@precisebiometrics.com  ABOUT PRECISE BIOMETRICSPrecise Biometrics is a market leading supplier of solutions for convenient and secure authentication of people’s identity using biometrics. Our solutions are used hundreds of millions of times every day by people all over the world and are marketed together with strong business partners. For more information, please visit www.precisebiometrics.com

YEAR-END REPORT, January–December 2018

A solid quarter and best year ever Fourth quarter of 2018 · Consolidated net sales increased by 24 percent to SEK 692 m (558), of which organic growth amounted to 6 percent. Acquisitions contributed by 14 percent and currency by 4 percent · Net sales in Products & Solutions amounted to SEK 516 m (382) and Installation Services to SEK 198 m (192) · EBITDA before items affecting comparability increased by 16 percent to SEK 66 m (57) · Operating profit (EBIT) before items affecting comparability increased by 18 percent to SEK 52 m (45) · Operating profit (EBIT) amounted to SEK 47 m (43) · Operating cash flow amounted to SEK 89 m (89) · Earnings per share before and after dilution were SEK 1.03 (0.95) January–December 2018 · Consolidated net sales increased by 23 percent to SEK 2,680 m (2,187), of which organic growth amounted to 3 percent. Acquisitions contributed by 15 percent and currency by 5 percent · Net sales in Products & Solutions amounted to SEK 2,023 m (1,568) and Installation Services to SEK 752 m (714) · EBITDA before items affecting comparability increased by 16 percent to SEK 286 m (248) · Operating profit (EBIT) before items affecting comparability increased by 8 percent to SEK 224 m (208) · Operating profit (EBIT) amounted to SEK 212 m (194) · ROCE before items affecting comparability was 14.8 percent (15.5) · Operating cash flow amounted to SEK 192 m (164) · Earnings per share before and after dilution were SEK 6.30 (5.71) · The Board proposes a cash dividend of SEK 4.00  (3.75) per share Message from the CEOA solid quarter and best year ever  I am proud to report our best year ever, in terms of both sales and financial results. Consolidated net sales for the year was SEK 2,680 m, an increase by 23 percent, and EBITDA before items affecting comparability increasing by 16 percent to SEK 286 m. Consolidated net sales for the fourth quarter rose by 24 percent compared with last year, from SEK 558 m to SEK 692 m. Acquisitions contributed by 14 percent, organic growth was strong at 6 percent and currency exchange rate effects was 4 percent. At SEK 52 m, EBIT before items affecting comparability was above last year’s profit of SEK 45 m, an increase of 18 percent. At the same time, EBITDA increased 16 percent to SEK 66 m compared with SEK 57 m in the corresponding period in the preceeding year. All of our acquisitions this year - Ugilt, RVT and Veg Tech – have performed well and contributed to the growth of Nordic Waterproofing’s sales and results. During the autumn, RVT has finalized its façade element deliveries to Mjöstornet, the highest wooden structure in the world. The mild weather and late winter arrival allowed Veg Tech to deliver green vegetation solutions almost the entire fourth quarter, following the challenges after the warm and unusually dry summer. The consolidated net sales growth of 24 percent in the fourth quarter was driven by strong sales in roofing and infrastructure in Sweden, Norway and Denmark, but also the prefabricated elements business in Norway. While our Products & Solutions operating segment reported a sales increase of 35 percent, our Installation Services operating segment increased 3 percent. Within our Products & Solutions segment, Sweden, Norway and Denmark showed a strong development and positively affected by mild weather. The second sales price increases for our bitumen based products which were implemented after summer, have started to show effect in the fourth quarter. The prefabricated elements business in Norway continues to develop well and enjoys strong order intake, while we have continued to experience some delays from our customers in Denmark. Although deliveries and production efficiency has increased in the quarter, we still experience some challenges in optimizing our production planning. The profit improvement program within our flat roof installation services business in Finland has continued also during the fourth quarter. Our efforts, including a more selective approach towards roofing projects and the efficient execution of the projects, have shown positive financial effects as of mid-2018. At the same time, we have experienced a somewhat weaker development of our floor coating business, where a profit improvement program has now been started. Our Danish franchise companies continued to perform well also during the fourth quarter, with strong order books and an EBIT contribution above the preceding year. In 2019 we will continue to focus on organic growth, profitability and selective acquisitions. Organic growth is expected to come particularly from the development of our recent acquisitions, building on our new platforms in prefabricated elements, Taasinge group, and green roofs and surfaces, Veg Tech. Regarding acquisitions, we maintain our focus on small to medium sized companies presenting good synergistic potential with our existing businesses. Vejen, 12 February 2019 Martin Ellis,President and CEO Conference call A conference call for investors, analysts and media will be held today, 12 February 2019, at 10:00 a.m. CET and can be joined online at www.nordicwaterproofing.com . Presentation materials for the call will be available on the website one hour before the call. To participate, please dial:From the United Kingdom:       +44 33 3300 9263From Denmark: +45 78 15 01 07From Sweden: +46 8 566 427 05 Further information can be obtained from Martin Ellis, President and CEO tel: +45 31 21 36 69Jonas Olin, CFO & Investor Relations      tel: +46 708 29 14 54 This information is information that Nordic Waterproofing Holding A/S is obliged to make public pursuant to the EU Market Abuse Regulation.The information was submitted for publication, through the agency of the contact persons set out above, at 12 February 2019, 08:00 a.m. CET.

Year-end report 2018

JANUARY–DECEMBER 2018 (compared with JANUARY–DECEMBER 2017)  · Revenue increased by 20 percent, amounting to SEK 2,321 million (1,933)  · Earnings after tax (EAT) before extra provisions under IFRS 9 rose by 17 percent, amounting to SEK 602 million (517) · Earnings after tax (EAT) increased by 10 percent, amounting to SEK 566 million (517)  · Return on equity (RoE) was 17.6 percent (18.1)  · Earnings per share increased to SEK 5.51 (5.03)  · Continued favourable growth with increased quality in the credit portfolio, SEK 26,104 million (19,507), up 34 percent · Strong growth for all products in the Corporate segment  · Acquisition strengthens position in the Payments segment  · Good growth in private loans  · Martin Nossman appointed CEO in August 2018 THE FOURTH QUARTER OF 2018 (COMPARED WITH THE FOURTH QUARTER OF 2017)  · Revenue increased by 30 percent, amounting to SEK 690 million (530)  · Earnings after tax (EAT) before extra provisions under IFRS 9 rose by 48 percent, amounting to SEK 191 million (129) · Earnings after tax (EAT) increased by 20 percent, amounting to SEK 154 million (129)  · Earnings per share increased to SEK 1.50 (1.26)  · C/I ratio 0.43 (0.49)  · Growth of SEK 3.0 million for the quarter, both through acquisitions and growth in the underlying business  · Good growth in the Corporate segment  · The Board of Directors proposes that no dividends be paid for the financial year 2018, which is in line with the adopted dividend policy. Read more at https://www.collector.se/en/about-collector/investors/financial-information/A telephone conference will be held in Swedish today, 12 February, at. 10.00 a.m. CET, at which CEO Martin Nossman and acting CFO Magnus Erkander will present the report. The presentation will be followed by an opportunity to ask questions.To participate in the telephone conference, please dial in on +46 8 505 583 54 or +44 333 300 9269. The switchboard opens at 9.55 a.m. CET. You can follow the presentation and listen in live via https://tv.streamfabriken.com/collector-q4-2018Prior to the presentation, the presentation materials will be available at www.collector.se where a recorded version of the presentation will also be available afterwards.For further information:Magnus Erkander, acting CFO and IR manager, on telephone +46 70 493 08 00 / e-mail magnus.erkander@collectorbank.se This information is such information that Collector AB is obliged to publish under the EU Market Abuse Regulation and the Securities Market Act. The information was issued for publication by the above contact persons on 12 February 2018 at. 8.15 a.m. CET. Stock exchange: Ticker symbol COLL

Year-end report 2018

October – December 2018 · Total operating income increased 19 per cent to SEK 766 million (643). · Items affecting comparability before tax totalled SEK –24 million and are attributable to restructurings and costs related to a business acquisition in Italy. · Profit before tax increased 69 per cent to SEK 186 million (110). · Profit before tax excluding items affecting comparability totalled SEK 210 million, a year-on-year increase of 24 per cent. · Diluted earnings per share amounted to SEK 1.59 (0.92). · Return on equity excluding items affecting comparability was 18 per cent. · Return on equity was 16 per cent (11). · Carrying value of acquired loan portfolios totalled SEK 20,605 million (14,766). · The total capital ratio was 14.14 per cent (17.71) and the CET1 capital ratio was 9.66 per cent (11.70). Figures in brackets refer to the fourth quarter of 2017 for profit comparisons and to 31 December 2017 closing balance for balance sheet items. Events during the quarter · Hoist Finance is evaluating alternatives in response to the FSA’s new interpretation of the capital adequacy regulation for risk weights for non-performing loans, and is adopting measures for continued growth. · Strong volume growth with portfolio acquisitions of SEK 2,246 million, with the first Greek portfolio of non-performing consumer loans and SME loans followed by continued growth focused on Italy and Great Britain. · Increased digitalization and improved operational efficiency. · Hoist Finance signed an agreement to lease and subsequently acquire operations in Italian credit management companies Maran S.p.A and R&S S.r.I (the ”Maran Group”) in a multi-stage process under compulsory administrative proceedings in accordance with Italian insolvency law. Subsequent events · The European Parliament and the Council of the European Union has comprised, as published 3 January 2019, that non-performing loans will likely start to be affected by NPL regulation from 2021. Hoist Finance has identified mitigating actions with ongoing implementation. · Revised financial targets. · Hoist Finance has entered into an agreement to acquire assets held by Polish debt management and collection company GetBack. Strengthened business and navigating through regulatory changes Hoist Finance has delivered a solid financial performance in 2018. We have achieved strong growth in portfolio acquisitions and are broadening our product and geographic spread. We have implemented a new operating model and are making progress towards becoming more effective and efficient. Our market has become materially more attractive over the year as yields are rising and new regulation is encouraging supply. As a bank operating in the secondary market, this same regulation has presented us with some challenges in the short term. We are committed to implementing mitigating actions in the coming year to reduce the impact of these challenges. Beneficial market dynamics intact Following the financial crisis more than 10 years ago, the level of Non-Performing Loans (NPLs) in banks is still very high. The regulators have taken various initiatives and introduced new regulations to push banks to divest their NPLs to make their balance sheets healthier. These regulations are stricter than before and aim to ensure real risk transfer. Driven by the regulatory and accounting changes, as well as the commercial benefits of selling NPLs, the secondary market for acquiring NPLs is developing in a very positive way. The regulators also recognize the need for a well-functioning secondary market as an important and relevant part of the financial value chain. While regulation itself has been an important factor explaining the growth of the Credit Management Services (CMS) industry, recent years’ supply of cost-efficient funding through the high yield bond market has increased demand, competition and margin pressure. In 2018 the CMS industry experienced increased cost of funding and lower access to new financing to finance growth. With no signs of any material improvement in the funding market, the industry is now focusing on reducing leverage, finding alternative sources of funding (e.g. co-investment or asset management structures), and improving operational efficiency. Strengthening our business The winners in the industry will be those companies that have the best operations and the lowest cost of capital. In 2018, Hoist Finance took numerous steps to improve performance and operations. We implemented a new operating model across all markets, which is more agile, with fewer management layers. The model is completely standardised, harmonised across markets and it allows for rapid knowledge transfer. We are implementing new company-wide digital solutions that make performance management, analytics and customer interaction easier and more cost efficient. Through site consolidation and the use of centers of expertise and shared service centers we are committed to bringing down our costs and improving our performance. Our growth in 2018 has been the highest ever, more than the portfolio investments in 2017 and 2016 combined. Broadly speaking, the NPL markets consists of unsecured and secured assets for retail, small and medium sized companies and larger corporates. While the NPLs within the unsecured consumer segment are only around 11 per cent of the total NPL market, this has traditionally been Hoist Finance’s core business. To address a larger portion of the NPL market, and even acquire performing loans, has been a very important strategic priority for Hoist Finance. Our ambition is still to grow within the historic core, and also to expand further into the secured consumer segment which is more than twice the size of the unsecured segments. Last year, 59 per cent of portfolio investments were in unsecured consumer NPLs, 27 per cent in secured NPLs and 14 per cent in performing loans. Regulatory changes Hoist Finance has been regulated as a bank since 1996 and this has served us well. The access to low cost funding through bank deposits represents a clear cost advantage, and our regulated status has also proved its value in many commercial situations. Over the years, many regulatory changes have been implemented for European banks, and Hoist Finance has always, and will at all times, fully comply with regulations. Regulatory changes have recently been put in place to reduce the risks on European banks’ balance sheets. For the CMS market as a whole, this is positive. But it also entails unintended negative consequences for Hoist Finance, as we operate in the secondary market with a banking license. The revised interpretations of required risk weights for purchased unsecured NPLs of 150 per cent do not reflect any change in risk of the underlying assets. However, we have fully implemented these new risk weightings and, we continue to have a CET1 ratio above regulatory requirements and within our stated Board risk appetite for a buffer over regulatory requirements as at 31 December 2018. Unrelated to this change in risk weights, the European Parliament and the Council of the European Union is expected to publish a new legislation by early Q2 2019, which will impact the timeline over which banks are required to provide for new formation of NPLs (NPL Backstop). The NPL Backstop will regulate how the book value for future unsecured NPLs should be treated in capital adequacy calculations. For unsecured debt that is originated after implementation of this regulation and then defaults, the NPL Backstop will require these NPLs to be provided for in a bank’s capital adequacy after the end of year three following default. This regulation only applies to future unsecured NPLs and does not have an impact on Hoist Finance’s existing portfolios at the time of entry into force. The unsecured debt that we acquire from banks, has typically been in default for three to five years before being sold. Whilst this period may shorten following the new rules, this regulation will not have an adverse effect on Hoist Finance’s capital ratios for the next two to three years. Longer term, and without mitigating actions, the NPL Backstop will become more challenging for Hoist Finance as the requirement to write-down the value of unsecured NPLs to zero for capital adequacy by end of year three after default will materially impact the required capital for future unsecured NPL purchases. The effect of the NPL Backstop is counterintuitive and has unintended negative consequences for companies operating in the secondary unsecured NPL market with a banking license. In response to these regulatory changes we are now reviewing various market-standard mechanisms, processes and products such as: introducing more sophisticated risk models (IRB), securitisation, and various alternative investment fund structures leveraging third-party capital. By introducing more sophisticated risk modelling, Hoist Finance will seek to move from the standardised method of calculating Risk Weighted Assets (RWA) to an Internal Rating-Based model (IRB). With IRB, validated and approved, our own internal risk modelling methodology would apply, effectively reducing our applied risk weights from the standardised 150 per cent. To get an IRB model approved typically takes at least two to three years. By securitising NPLs through market standard processes, Hoist Finance may be able to achieve significant risk transfer, enabling a reduction in RWAs, reduced effect of NPL Backstop and thereby strengthen the CET1 ratio. Securitisation is a well proven concept for performing loans, and in recent years, also for NPLs, for example in the Italian market. We are now exploring our options for NPL securitisation and will update the market on our progress. In order to keep optionality with the overall aim of optimising our capital efficiency and maximising return on capital for our shareholders, we also continue to consider other risk mitigation measures, such as establishing fund structures, in order to leverage third party capital. Working with regulators is a core competence for Hoist Finance, and the business model has been pressure-tested over time and through multiple changes to regulation. While adjusting to these changes comes at a cost, our firm belief is that by adjusting to the new requirements Hoist Finance will preserve the competitive strengths we have. Updated Financial targets As a consequence of the new regulatory requirements, our financial targets have been revised. These revised financial targets represent our ‘base case’, assuming no positive effects from mitigating actions. However, through our mitigating actions we are targeting reduced risk weights, improved capital ratios, increased capacity for further growth and consequently improved operational leverage. As a result of the changes to our RWAs which we announced in December, our CET1 ratio is 9.66 per cent for 31 December 2018. Without implementing mitigating actions, this constrains our near term capital flexibility and our expected purchasing volume for 2019. We now expect portfolio investments totalling approximately SEK 5 billion in 2019, broadly in line with the average purchasing volume for Hoist Finance over the last 3 years. We expect purchasing volumes to grow thereafter. In the ‘base case’, our CET1 ratio target and dividend policy remain unchanged per our announcement in December. CET1 ratio target is 1.75– 3.75 per cent over regulatory requirement and, as stated, dividends will not be paid for 2018 and 2019. Longer term dividend policy is 25–30 per cent of net profits per annum. Our commitment to operational improvement, gives us confidence that despite slower top line growth, we will still achieve our cost/income ratio target of 65 per cent by 2021. Our new 15 per cent RoE target is a reduction but still well in excess of our cost of capital. We believe our new 10 per cent EPS CAGR target remains attractive. In summary, Hoist Finance operates in a growing and profitable market, and our operating model is becoming much more efficient. While the new regulations are challenging, we are encouraged by the fact that there are several different countermeasures available to ensure a continued profitable development for Hoist Finance. Klaus-Anders Nysteen CEO Hoist Finance AB (publ) Hoist Finance AB (publ) (the “Company” or the “Parent”) is the parent company of the Hoist Finance group of companies (“Hoist Finance”). The company is a regulated credit market company. Hence, Hoist Finance produces financial statements in accordance with the Swedish Annual Accounts Act for Credit Institutions and Securities Companies. The information in this interim report has been published by Hoist Finance AB (publ) pursuant to the EU Market Abuse Regulation. This information was submitted by Julia Ehrhardt for publication on 12 February 2019 at 8:30 AM CET.

New Australian patent approval for Episurf Medical

The Australian patent office IP Australia has issued a Notice of acceptance for another patent for Episurf Medical (NASDAQ: EPIS B) in Australia. The patent, entitled “System and method for creating a decision support material indicating damage to an anatomical joint” covers Episurf Medical’s 3D-based damage marking technology which constitutes a central part of the Episealer® implant system. "This patent is in the area of damage marking and 3D visualisation of joint damages, which is an area where Episurf is strengthening its IP step by step and where we distinguish ourselves from our competitors.”, comments Katarina Flodström, CRO & Head of IP, Episurf Medical. For more  information, please contact: Pål Ryfors, CEO, Episurf MedicalTel:+46 (0) 709 62 36 69Email: pal.ryfors@episurf.com About Episurf Medical Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com. This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 12 February 2019.

Clinical results for Episealer® to be presented at German clinical congress

Episurf Medical (NASDAQ: EPIS B) today announces that the scientific abstract “Erfolgreiche klinische Ergebnisse mit einer patienten-spezifischen Endoprothese zur Behandlung von fokalen, vollschichtigen Knorpelschäden des Kniegelenks” (Eng: Successful clinical results of an individualised endoprosthesis for treatment of focal full-thickness cartilage lesions in the knee) by Dr. med. Johannes Holz et al. will be presented at the German annual congress of EKB2019 (Endoprothetikkongress Berlin). The congress will take place in Berlin, Germany on February 14-16, 2019. The abstract focuses on interim results from a European multicenter study with the Episealer® knee implant. Dr. med. Holz from OrthoCentrum Hamburg, Germany summarises the results saying “The study shows very good clinical outcomes in the treatment of fourth-degree chondral and osteochondral symptomatic damage of the femoral condyles and trochlea with a new patient-specific mini-prosthesis using patient-individualised instruments”.  “We appreciate the interest in the clinical results from follow-up of patients who received Episealer® implants. The results show high patient reported scores and low revision rate. Our customers continue to report positive results and confirm the treatment gap” says Pål Ryfors, CEO Episurf Medical. For more  information, please contact: Pål Ryfors, CEO, Episurf MedicalTel:+46 (0) 709 62 36 69Email: pal.ryfors@episurf.com About Episurf Medical Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

Calliditas Therapeutics granted orphan drug designation by the FDA for Primary biliary cholangitis

PBC, previously known as primary biliary cirrhosis, is an autoimmune disease of the liver, where common symptoms are tiredness, itching and, in more advanced cases, jaundice. PBC is a rare disease, affecting approximately 4.3 people in 10,000 in US. It is much more common in women, with a ratio of at least 9:1 female to male. The company plans to discuss the regulatory pathway for this indication in consultation with the FDAand investigate the most appropriate way forward for this patient population. “We are very pleased to receive ODD in the US for the treatment of PBC. This confirms the high unmet medical need and further encourages us to continue to explore orphan indications in which we could leverage our existing expertise. This is a disease with few medical alternatives today, but with a lot of exciting research taking place”. , commented Renée Aguiar-Lucander, CEO of Calliditas Therapeutics. Earlier in February 2019, the company was granted ODD by the FDA for AIH. The company plans to agree the regulatory pathway for this indication in consultation with the FDA later this year.  Also, the company is currently running a global, pivotal Phase 3 with study for the treatment of the rare disease IgA nephropathy (IgAN), and which has already obtained ODD by the FDA and the European Medicines Agency (EMA). Top line data for IgAN is expected in H2 2020. The information in the press release is such that Calliditas Therapeutics AB (publ) is required to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 11:15 CET on February 12, 2019. For further information, please contact: Mikael Widell, Head of Communications Email: mikael.widell@calliditas.com Telephone +46 703 11 99 60 About Calliditas Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the company can partially or completely participate in the commercialization efforts. The company is focused on the development and commercialization of the product candidate Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas Therapeutics is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the US. The company is listed on Nasdaq Stockholm (tícker: CALTX). Visit www.calliditas.com for further information. About Primary biliary cholangitis (PBC) PBC, previously known as primary biliary cirrhosis, is an autoimmune disease of the liver. It results from a slow, progressive destruction of the small bile ducts of the liver, causing bile and other toxins to build up in the liver, a condition called cholestasis. Further slow damage to the liver tissue can lead to scarring, fibrosis, and eventually cirrhosis. Common symptoms are tiredness, itching and, in more advanced cases, jaundice. In early cases, there may only be changes in blood tests. PBC is a rare disease, affecting approximately 4.3 people in 10,000, in US. It is much more common in women, with a sex ratio of at least 9:1 female to male. About Orphan Drug Designation (ODD)  The FDA Orphan Drug Act (ODA) provides for granting special status to a drug or biological product to treat a rare disease that affect fewer than 200,000 people in the US. Orphan drug designation qualifies the sponsor of the drug for various development incentives of the ODA, including tax credits, protocol assistance and up to seven years of US marketing exclusivity from time of approval of a Biologics License Application (BLA).

Alligator Bioscience to Host Conference Call to Provide Year-end Report 2018 Business Update

Alligator Bioscience (Nasdaq Stockholm: ATORX) - On 14 February 2019, at 08:00 a.m. CET, Alligator Bioscience will publish its report for the year ended 31 December 2018. All interested parties are invited to participate in a telephone conference, which will include a presentation of the Year-end Report, on the same day at 09:00 a.m. CET. The event will be hosted by CEO Per Norlén and the presentation will be held in English.  When: 09:00 a.m. CET Thursday 14 February 2019 Listen to the presentation: https://financialhearings.com/event/11461 To participate in the telephone conference, please use the dial in details shown below:SE: +46856642692UK: +443333009266US: +18338230590 The conference call will be made available on the company’s website after the call: http://www.alligatorbioscience.com . For further information, please contact:Cecilia Hofvander, Director Investor Relations & CommunicationsPhone +46 46 540 82 06E-mail: cecilia.hofvander@alligatorbioscience.com  About Alligator BioscienceAlligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes five lead clinical and preclinical drug candidates: ADC-1013, ATOR-1015, ATOR-1017, ALG.APV-527 and ATOR-1144. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has 50+ employees. For more information, please visit www.alligatorbioscience.com. ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc. for global development and commercialization.

Nolato year-end report: Strong financial position and proposed increase in dividend

Fourth quarter of 2018: · Sales totalled SEK 1,781 million (1,926) · Operating profit (EBITA) was SEK 214 million (230) · EBITA margin of 12.0% (11.9) · Profit after tax was SEK 158 million (180) · Basic earnings per share were SEK 6.01 (6.84) · Cash flow after investment was SEK 122 million (157) Medical Solutions sales for the fourth quarter increased to SEK 580 million (511). Adjusted for currency, sales increased by a strong 8%. Operating profit (EBITA) rose to SEK 77 million (68). The EBITA margin was 13.3% (13.3). “Sales increased in both Medical Devices and Pharma Packaging,” said Nolato President and CEO Christer Wahlquist. “Activity remains high in Nolato’s market, with project activity primarily in autoinjectors for biological medication, insulin products and incontinence products.” Integrated Solutions sales for the fourth quarter decreased to SEK 703 million (900); adjusted for currency, the decrease was 27%. Operating profit (EBITA) decreased to SEK 99 million (116). The EBITA margin grew to a very strong 14.1% (12.9). The margin was boosted by 2.0 percentage points from the receipt of compensation from Chinese authorities. “As announced, inventory adjustments in Heating Devices had a negative impact on sales in the quarter,” noted Christer Wahlquist. “We assess that volumes will be at a markedly lower level for the first six months of 2019, compared with the rate in the fourth quarter of 2018, pending the launch of new models. Nolato has received orders for the new models and retains a strong position with the customer.” Industrial Solutions sales decreased to SEK 505 million (518); adjusted for currency and Group structure, the decrease was 4%. Operating profit (EBITA) decreased to SEK 39 million (52) and the EBITA margin to 7.7% (10.0). “Production volumes were at a similar level as the previous year taken over the entire quarter, while invoicing of development work and production equipment was slightly lower,” said Christer Wahlquist. “The weak margin was due to continued unsatisfactory efficiency in automotive and low volumes prior to the Christmas break.” Today’s year-end report for 2018 shows the best ever year in Nolato’s history. Full year 2018: · Sales rose by 21% to SEK 8,102 million (6,720) · Operating profit (EBITA) increased sharply to SEK 949 million (763) · Basic earnings per share increased to SEK 27.44 (21.74) · The equity/assets ratio was 50% (45) and net financial assets were SEK 159 million (−153) · The Board of Directors proposes an increased dividend with 12% of SEK 14.00 (12.50) per share Adjusted for currency and Group structure, sales rose by an exceptionally strong 17%. Medical Solutions sales rose to SEK 2,270 million (1,955), which, adjusted for currency, is a strong increase of 12%. Operating profit (EBITA) increased to SEK 295 million (257) and the EBITA margin to 13.0% (13.1). Integrated Solutions sales rose to SEK 3,720 million (2,810). Adjusted for currency, this was an exceptionally strong increase of 28%. Operating profit (EBITA) rose sharply to SEK 473 million (332) and the EBITA margin was a strong 12.7% (11.8). Industrial Solutions sales totalled SEK 2,119 million (1,968). Adjusted for currency and Group structure, growth was a healthy 6%. Operating profit (EBITA) was SEK 186 million (195), with an EBITA margin of 8.8% (9.9). Nolato retains a healthy financial position, with an equity/assets ratio of 50% (45) and net financial assets of SEK 159 million (net financial liabilities of SEK –153 million). The Board proposes an increase in the dividend to SEK 14.00 (12.50). The Annual General Meeting will be held on 8 May 2019 at 4 p.m. CET in Grevie, Sweden. ---------For further information, please contact:Christer Wahlquist, President and CEO, +46 (0)705 804848Per-Ola Holmström, CFO, +46 (0)705 763340 Nolato is a Swedish group with operations in Europe, Asia and North America. We develop and manufacture products in polymer materials such as plastic, silicone and TPE for leading customers within medical technology, pharmaceuticals, telecom, automotive, hygiene and other selected industrial sectors. Nolato’s shares are listed on Nasdaq Stockholm in the Large Cap segment, where they are included in the Industrials sector. This information is information that Nolato AB is obliged to publish pursuant to the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was issued for publication by the above contact person on 12 February at 2.30 p.m. CET. www.nolato.com

Proposals on Board of Directors to 2019 Annual General Meeting

The Nomination Committee proposes that the Board of Directors of Nobia comprise seven members. George Adams, Hans Eckerström, Morten Falkenberg, Nora Førisdal Larssen, Jill Little and Stefan Jacobsson are proposed for re-election. Marlene Forsell is proposed as a new member of the Board. Nobia’s Nomination Committee proposes that the Board of Directors, whose members are elected by the Annual General Meeting, be comprised of seven members with no deputies, a reduction by two Board members. The Nomination Committee proposes re-election of George Adams, Hans Eckerström, Morten Falkenberg, Nora Førisdal Larssen, Jill Little and Stefan Jacobsson. The Nomination Committee also proposes re-election of Hans Eckerström as the Chairman of the Board.Lilian Fossum Biner, Christina Ståhl and Ricard Wennerklint have declined re-election.The Nomination Committee proposes that Marlene Forsell be elected a new Board member.Marlene Forsell holds an MSc in Business Administration and Economics from Stockholm School of Economics. She was CFO in Swedish Match between 2013 and 2018, and before that she held several senior finance positions in the same company. Marlene Forsell is currently Board member of Kambi Group and Lime Technologies.The Nomination Committee’s complete proposal will be presented in the notice of the Annual General Meeting, which will be published on 2 April 2019.The Nomination Committee was appointed by the 2018 Annual General Meeting and comprises Tomas Billing representing Nordstjernan AB, Torbjörn Magnusson representing If Skadeförsäkring, Mats Gustafsson representing Lannebo funds and Arne Lööw representing the Fourth Swedish National Pension Fund.For further information: Chairman of the Nomination Committee, Tomas BillingTel: +46 8 788 50 18This information is information that Nobia is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 12 February 2019 at 15.00 CET. Nobia develops and sells kitchen solutions through a number of strong brands in Europe, including Magnet in the UK; HTH, Norema, Sigdal, Invita and Marbodal in Scandinavia; Petra and A la Carte in Finland; ewe, Intuo and FM in Austria as well as Bribus in the Netherlands. Nobia generates profitability by combining economies of scale with attractive kitchen offerings. The Group has approximately 6,100 employees and net sales of about SEK 13 billion. The share is listed on Nasdaq Stockholm under the ticker NOBI. Website: www.nobia.com  

Cherry initiates early redemption of senior secured callable bonds

The redemption will be carried out on 15 March 2019 as a combination of a voluntary partial redemption and a voluntary total redemption. The amounts to be paid for the partial and total redemptions will be paid in aggregate in an amount corresponding to 103.0925 per cent of the outstanding nominal amount of each bond to each person registered as an owner of bonds in the debt registered (Sw. skuldbok) maintained by Euroclear Sweden AB at the end of business on 8 March 2019. In connection with the redemption, the bonds will be delisted from Nasdaq Stockholm. Notwithstanding the redemption set out above, each bondholder has the right to request that all, or only some, of its bonds are repurchased at a price per bond equal to 101 per cent of the nominal amount, together with accrued but unpaid interest, as a consequence of a right to mandatory repurchase due to a change of control event as notified on 5 February 2019. More information is available in the redemption notice, which is published in full on Cherry’s website, www.cherry.se, and on Stamdata, www.stamdata.com. For further information, please contact:  Gunnar Lind, CEO: gunnar.lind@cherry.seChristine Rankin, CFO: +46 765 399 492, christine.rankin@cherry.seAnders Antonsson, IR & Communications: +46 709 994 970, anders.antonsson@cherry.se This information is such that Cherry AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact persons set out above on 12 February 2019, at 4:30 p.m. CET.

THQ Nordic publishes interim report, Q4 2018: OPERATIONAL EBIT INCREASED 84% to SEK 194 MILLION

FOURTH QUARTER 2018 · Net sales increased 441% to SEK 1,380.6 m (255.4). · Owned IP’s represented SEK 396.0 m (208.2), or 72%, of business area Games sales in the quarter. · EBITDA increased 109% to SEK 326.4 m (156.4), corresponding to an EBITDA margin of 24%. · Operational EBIT increased 84% to SEK 194.4 m (105.8). · EBIT increased 49% to SEK 152.1 m (102.0), corresponding to an EBIT margin of 11%. · Cash flow from operating activities amounted to SEK 455.0 m (98.6). · Earnings per share was SEK 1.33 (0.93). · Two owned IP’s and nine publishing titles were released in the fourth quarter.  JANUARY – DECEMEBER 2018 · Net sales increased 713% to SEK 4,123.6 m (507.5). · Owned IP’s represented SEK 906.5 m (391.2), or 50%, of business area Games sales in the period. · EBITDA increased 257% to SEK 974.1 m (272.6), corresponding to an EBITDA margin of 24%. · Operational EBIT increased 139% to SEK 484.0 m (202.3). · EBIT increased 114% to SEK 402.6 m (188.2), corresponding to an EBIT margin of 10%. · Cash flow from operating activities amounted to SEK 579.2 m (179.1). · Earnings per share was SEK 3.50 (1.88). · As of 31 December 2018, cash and cash equivalents were SEK 921.7 m. Available liquidity including credit facilities was SEK 2,216.4 m. The full interim report is available via link below and on www.thqnordic-investors.com For additional information, please contact:Lars Wingefors, Founder and CEOTel: +46 708 471 978E-mail: lwingefors@thqnordic.com About THQ NordicTHQ Nordic develops and publishes PC and console games for the global games market. The company has an extensive catalogue of over 100 owned franchises, such as Saints Row, Goat Simulator, Dead Island, Darksiders, Metro (license), Titan Quest, MX vs ATV, Kingdoms of Amalur, Time Splitters, Delta Force, Alone in the Dark, Wreckfest amongst many others. The group has a global presence, with its group head office located in Karlstad, Sweden and with three divisions; Deep Silver/Koch Media, THQ Nordic and Coffee Stain. The group has fifteen internal game development studios based in Germany, UK, Finland, USA and Sweden and engages close to 2,000 people. THQ Nordic's shares are publicly listed on Nasdaq First North Stockholm under the ticker THQN B with FNCA Sweden AB (e-mail: info@fnca.se phone: +46-8-528 00 399) as its Certified Adviser. For more information, please visit: http://www.thqnordic-investors.com. This Interim Report is information that is mandatory for THQ Nordic to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 6:00 a.m. CET on 13 February 2019.

THQ Nordic acquires award-winning Warhorse Studios, the studio behind Kingdom Come: Deliverance

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. ”Warhorse Studios is one of the leading independent studios in Europe and I am proud to welcome them to the THQ Nordic group. Kingdom Come: Deliverance, which has now sold over 2 million copies, has been a great success since the release exactly one year ago. I look forward to continue working with the founders who will continue managing the studio under strong creative freedom for many years to come", says Lars Wingefors, CEO of THQ Nordic AB. The transaction in brief ·  THQ Nordic AB ("THQ Nordic" or "The Company") acquires 100 percent of the shares in Warhorse Studios s.r.o. ("Warhorse") through its indirectly wholly owned subsidiary Koch Media GmbH ("Koch Media"). Warhorse is a leading game developer of RPG games for PC and Console. The studio is based in Prague, making it THQ Nordic's first owned development studio in the Czech Republic.   ·  All intellectual property rights for Kingdom Come: Deliverance are included in the acquisition. ·  The preliminary purchase price amounts to 42.8 MEUR, corresponding to 33.2 MEUR on a cash and debt free basis. The purchase price is allocated to 40.4 MEUR in liquid funds through the Company's existing cash and corresponding to 2.4 MEUR with newly issued B shares in THQ-Nordic. The price of the shares is based on a volume-weighted average price of 173.87 SEK per share and is associated with so-called lock-up commitments. ·  For the period January-December 2018, Warhorse generated Net Revenues1 of approximately 42 MEUR and an adjusted EBIT1 of approximately 28 MEUR. “Becoming part of THQ Nordic family is an important milestone for our studio. We began as a small start-up with a handful of employees who were enthusiastic enough to join this challenging project. The skills of our team members, trust and support of our main investor and passion of our fans, who supported development of Kingdom Come: Deliverance through a Kickstarter campaign, helped us grow to an international level. We believe that backing by THQ Nordic will give us an extra push in our mission to bring exciting games to our customers and extend the frontiers of the gaming industry,” says Martin Frývalský, CEO Warhorse Studios. Background and rationale On February 13, 2019, Koch Media entered into an agreement with the sellers to acquire 100 percent of the shares in Warhorse. Warhorse is the leading game development studio behind the global success KC:D, which was released in February 2018 and has already sold over 2 million copies. The studio was founded in 2011 by industry veterans Daniel Vávra and Martin Klíma, who together with their team have an impressive track record of dozens of developed award-winning games. In total, their past titles have sold over 11 million copies, with many are considered to belong to the “classics” within their respective genres. KC:D started as a project crowdfunded by a Kickstarter campaign, where over 35 000 fans partially funded the game and have been able to follow the game under development along the way. KC:D is a story-driven RPG set in an open world that takes place during the Middle Ages in the 15th century. Koch Media has a robust existing relationship with Warhorse and has acted as publisher for KC:D since 2016. Warhorse will continue to act as an independent studio under Koch Media. Warhorse Studios is owned by the founders Daniel Vávra and Martin Klíma and an external financial investor. Both founders will remain in their current roles. CEO Martin Frývalský will continue in his role for Warhorse. Warhorse's financials as of the twelve-month period ended December 31, 2018 Shown below is Warhorse's unaudited Income Statement for the full year 2018. The financials shown below have been adjusted in accordance with THQ Nordic's accounting principles. Warhorse (as adjusted)MEUR Jan-Dec 2018Net Revenue 42.0 Other operating income 3.8Total operating income 45.8Other operating expenses -9.2Adjusted EBITDA 36.5Depreciation and amortization -8.7Adjusted EBIT 27.8Financial items 0.5Earnings before tax EBT 28.4 The period above was driven by the successful launch and sale of Kingdom Come: Deliverance. Warhorse owns the IP as well as the publishing rights for Steam and other PC platforms of this game. Additionally, expansions through so-called DLC have contributed to the strong sales. Estimated additional development costs that can be capitalized based on THQ Nordic's accounting principles amount to 0.2MEUR (which has been adjusted above and included in the item Other operating income). An unaudited balance sheet pro forma for Warhorse as of December 31, 2018 is shown below. Warhorse (as adjusted)MEUR Dec 31 2018Intangible assets 7.8Property, plant and equipment 0.1Current receivables 4.4 Cash and bank balance 14.4Total assets 26.6  Equity 20.1 Deferred tax liabilities  0.4Current liabilities 6.2Total liabilities and equity 26.6 Intangible assets above relate primarily to capitalized development costs (adjusted upwards by approximately 2 MEUR to reflect THQ Nordic GAAP; the adjustment is primarily driven by a different phasing of related amortization). Impact on THQ Nordic's consolidation The acquisition will be consolidated in THQ Nordic's financial reports as of today's date. A customary purchase price allocation exercise will be performed later in the quarter, where the surplus value will be allocated to IP rights, goodwill and possibly other categories of intangible assets, all with a 5-year amortization period. The surplus value has been calculated at 22.7 MEUR as of December 31, 2018, based on the above adjusted balance sheet. Approximately 60 percent of the main game has been amortized in the above adjusted balance sheet. Purchase price and lock-up period 42.8 MEUR, equivalent to 33.2 MEUR on a cash and debt free basis, will be paid at completion of the transaction through a cash payment of 40.4 MEUR to the sellers, and 2.4 MEUR in newly issued class B shares in THQ Nordic issued at the time of the transaction ("Consideration shares") at a price per share which is based on the volume-weighted average price for the Company's shares on Nasdaq First North during the twenty (20) trading days preceding the signing date (i.e. February 13, 2019), i.e. 173.87 SEK. Thus, the Consideration Shares will comprise 142 870 class B shares. The Consideration Shares will be subject to lock-up commitments. 50 percent of the Consideration Shares will be covered by a one-year lock-up and 50 percent of the Consideration Shares will be covered by a two-year lock-up. The Consideration Shares are not subject to any transfer restrictions or Claw Back rights. Issue of the consideration shares The Consideration Shares will represent 0.16 percent and 0,08 percent of the total number of shares and votes in THQ Nordic, respectively, on a fully diluted basis. By issuing the Consideration Shares, the number of shares increases by 142,870 to 91,493,617 and the number of votes increases by 142,870 to 172,493,617 (divided among 9,000,000 class A shares and 82,493,617 class B shares). The share capital increases by approximately 1,191 SEK from approximately SEK 721,256 to approximately 726,447 SEK. Resolution to issue the Consideration Shares will be made by THQ Nordic's Board of Directors in connection with completion with the support of the Annual General Meeting's authorization on 16 May 2018. Advisers Ernst & Young AB is providing transaction support and Baker McKenzie is acting as legal counsel to THQ Nordic in connection with the transaction. For additional information, please contact: Lars Wingefors, Group CEO Tel: +46 708 47 19 78 E-mail: lwingefors@thqnordic.com About THQ Nordic THQ Nordic acquires, develops and publishes PC and console games for the global games market. The company has an extensive catalogue of over 100 owned franchises, such as Saints Row, Goat Simulator, Dead Island, Darksiders, Metro (exclusive license), Titan Quest, MX vs ATV, Kingdoms of Amalur, Time Splitters, Delta Force, Alone in the Dark, Wreckfest amongst others. THQ Nordic has a global presence, with its group head office located in Karlstad, Sweden and with three divisions; Deep Silver/Koch Media, THQ Nordic and Coffee Stain. The group has fifteen internal game development studios based in Germany, Finland, UK, USA and Sweden and engages about 2,000 people. THQ Nordic's shares are publicly listed on Nasdaq First North Stockholm under the ticker THQN B with FNCA Sweden AB as its Certified Adviser, reachable via info@fnca.se or phone: 08-528 00 399. For more information, please visit: http://www.thqnordic-investors.com. This information is information that THQ Nordic is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 6.30 a.m. CET on 13 February 2019. Forward-looking statementsThis press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release. [1]  Warhorse Studios' unaudited Management Accounts for 2018 adjusted in accordance with THQ Nordic GAAP.Note: FX rates used: Warhorse P&L: EUR/CZK 25.642 (2018 average). Balance Sheet: EUR/CZK 25.725 (Dec-2018).Purchase price calculations: EUR/CZK 25.871 (12-Feb-2019)

Restated reported revenue without effect on earnings or cash flow

Tele2’s consolidated income statement has been adjusted retroactively for revenue of joint operations and related expenses to the owners, which previously had not been fully eliminated. The effects of the adjustments for the full year 2017 was a decrease in revenue and expenses of SEK 599 million respectively, representing approximately 2.7 percent of the revenue that Tele2 has previously reported for 2017. The effects of the adjustments for the period January 1, 2018 to September 30, 2018, was a decrease in revenue and expenses of SEK 441 million respectively, representing approximately 2.6 percent of the revenue that Tele2 has previously reported that period. The restatement is published in Tele2’s Interim Report Fourth Quarter 2018, note 10, which is available at www.tele2.com as of today. For more information, please contact:Joel Ibson, Head of Corporate Communications, Tele2 AB, Phone: +46 766 26 44 00Erik Strandin Pers, Head of Investor Relations, Tele2 AB, Phone: +46 733 41 41 88This information is information that Tele2 AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 07:00 CET on February 13, 2019. _________________________________________________________________________ TELE2’S MISSION IS TO FEARLESSLY LIBERATE PEOPLE TO LIVE A MORE CONNECTED LIFE. We constantly strive to be the truly integrated challenger – providing speed, data and video content, no matter where or when. Ever since Tele2 was founded in 1993, we have continued to challenge prevailing norms and dusty monopolies. Today, our award winning networks enable mobile and fixed connectivity, telephony, data network services, TV, streaming and global IoT solutions for millions of customers. We drive growth through customer satisfaction and smart combined offerings. Tele2 has been listed on Nasdaq Stockholm since 1996. In 2018, Tele2 generated revenue of SEK 30 billion and reported an adjusted EBITDA of SEK 9 billion. For latest news and definitions of measures, please see our homepage www.tele2.com

Full Year and Fourth Quarter 2018 Report

CEO comment by Anders Nilsson“In Q4 the transformation of the Group which was initiated in the beginning of 2018 was concluded through the approval of the Dutch merger, conclusion of the merger with Com Hem and the exercise of the put option in Kazakhstan. All this paving the way for the next step in Tele2’s evolution and immediately following the merger with Com Hem we took the first step towards becoming an integrated operator through the launch of FMC offers in Sweden. The restructuring process has started with a 100 percent upgrade to the cost reduction target, to be realized faster than originally expected. Both Tele2 and Com Hem delivered on full-year guidance and we now announce guidance for 2019 and the mid-term for the combined company.” Highlights · Revenue of SEK 7.1 billion representing organic growth of 3 percent including 1 percent organic growth in end-user service revenue · Organic growth of adjusted EBITDA of 11 percent, or 4 percent adjusting for non-underlying items in Sweden and Croatia · Tele2 and Com Hem delivered on their respective full-year guidance for 2018 · Synergy estimate from the Com Hem merger raised from SEK 900 million to SEK 1,350 million annually, of which cost synergies SEK 900 million to be achieved in three years, up from SEK 450 million in five years · First FMC offers launched to consumers in Sweden · New financial guidance including mid-term ambition of low-single digit end-user service revenue growth and mid-single digit adjusted EBITDA growth · Earnings per share, after dilution, was negative SEK 0.84 · Proposed dividend of SEK 4.40 per share, paid in two equal tranches, with additional shareholder remuneration after the closing of the divestments of the operations in Kazakhstan and the Netherlands Teleconference and webcastTele2 will host a teleconference with presentation at 10:00 CET (09:00 GMT, 04:00 EST) on Wednesday, February 13, 2019. The presentation will be held in English and will also be available as a webcast at Tele2’s website: www.tele2.com Dial-in information:To make sure you are connected in time for the teleconference, please dial in a few minutes in advance and register your attendance. Ask for “Tele2 Q4”. Dial-in numbers:SE: +46 (0)8 5065 3942UK: +44 (0)330 336 9411US: +1 929-477-0448 For more information, please contact:Joel Ibson, Head of Corporate Communications, Tele2 AB, Phone: +46 766 26 44 00Erik Strandin Pers, Head of Investor Relations, Tele2 AB, Phone: +46 733 41 41 88This information is information that Tele2 AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 07:00 CET on February 13, 2019. _________________________________________________________________________ TELE2’S MISSION IS TO FEARLESSLY LIBERATE PEOPLE TO LIVE A MORE CONNECTED LIFE. We constantly strive to be the truly integrated challenger – providing speed, data and video content, no matter where or when. Ever since Tele2 was founded in 1993, we have continued to challenge prevailing norms and dusty monopolies. Today, our award winning networks enable mobile and fixed connectivity, telephony, data network services, TV, streaming and global IoT solutions for millions of customers. We drive growth through customer satisfaction and smart combined offerings. Tele2 has been listed on Nasdaq Stockholm since 1996. In 2018, Tele2 generated revenue of SEK 30 billion and reported an adjusted EBITDA of SEK 9 billion. For latest news and definitions of measures, please see our homepage www.tele2.com

THQ Nordic acquires leading Australian publishing partner, 18POINT2

”THQ Nordic and Koch Media will through the acquisition access an established platform on an exciting and growing market. We see great opportunities to establish us on a new market and through local engagement being able to offer the use of THQ Nordic’s global channels to Australian game developers. We look forward to working with Roger Clarke and his team” says Lars Wingefors, Group CEO THQ Nordic.  18POINT2 is considered as one of the most experienced and reputable teams on the local market. The Company acts as partner to leading international brands. Roger Clarke, who has previously held executive positions within Warner Bros. Home Entertainment Group, founded 18POINT2 during 2016 which today has 8 employees. The company is owned by Roger Clarke and Cahn Hewitt, both of whom will continue leading the Company. ”We look forward to, together with THQ Nordic and Koch Media, strengthen our position on the Australian and New Zealand markets. We believe that THQ Nordic’s and Koch Media’s experience will contribute to continued profitable growth for 18POINT2 in the future”, says Roger Clarke, CEO 18POINT2. Background and rationale THQ Nordic has a clear growth strategy and a long and successful history of acquiring game franchises, development studios, publishing, and partner publishing companies. The acquisition of 18POINT2 means that THQ Nordic and Koch Media expands their global network and establishes a local platform for continued development in Australia and New Zealand. This is in line with the long-term global growth strategy. Through the acquisition, THQ Nordic expands its network of local publishing partners to new exciting markets with great potential outside of Europe and USA. The acquisition also provides an opportunity to launch current portfolios of gaming products to new markets and gives Koch Media’s partners within development, publishing and distribution, a chance to further develop a collaboration with local publishing expertise. The acquisition also creates an opportunity for Australian game developers to work with a local publishing office, Purchase price, Issue of Consideration Shares, earn-out and lock-up period MEUR 2.41, equivalent to MEUR 1.91 on a cash and debt free basis will be paid at the time of completion through a cash payment of approximately MEUR 1.21 to the sellers, and the equivalent of approximately MEUR 1.21 of newly issued class B shares in THQ Nordic issued at closing of the transaction (the "Consideration Shares") at a price per share which is based on the volume-weighted average price of THQ Nordic's shares on Nasdaq First North during the twenty (20) trade days preceding 12 February (i.e. 11 February 2019), i.e. SEK 172.51. Thus, the Consideration Shares will comprise 74,357 class B shares. Through the issue of the Consideration Shares the number of shares increase by 74,357 and the number of votes by 74,357. The Consideration Shares will represent 0.08 percent and 0,04 percent of the total number of shares and votes in THQ Nordic, respectively, on a fully diluted basis. The share capital increases with approximately SEK 620. Following the issue of Consideration Shares and the issue of shares in connection with the acquisition of Warhorse Studios s.r.o. that was announced earlier today, the number of shares increase in total by 217,227 to 91,567,974 and the number of votes increase with 217,227 to 172,567,974 (divided between 9,000,000 A shares and 82,642,331 B shares). The share capital increases with in total approximately SEK 1,810 from approximately SEK 721,256 to approximately SEK 763,066. Both share issues will represent 0.24 percent and 0.13 percent of the total number of shares and votes in THQ Nordic, respectively, on a fully diluted basis The Consideration Shares will be subject to lock-up and subject to other customary transfer restrictions that will gradually release one third of the Consideration Shares per year if Roger Clarke and Cahn Hewitt, respectively, remain within the THQ Nordic Group for a period of three years. THQ Nordic has the right to redeem or require the sellers to transfer to THQ Nordic, at no consideration, the Consideration Shares, if the sellers does not remain with the THQ Nordic Group, whereby the sellers are entitled to keep one third of the Consideration Shares per year.The sellers will be entitled to keep the Consideration Shares and THQ Nordic has the right to redeem or repurchase the Consideration Shares depending on if certain milestones are met. In addition to the purchase price, the sellers are entitled to an earn-out payment of no more than approximately MEUR 0.41, subject to fulfilment of specific commercial milestones. Advisers Ernst & Young AB is providing transaction support and Baker McKenzie is acting as legal counsel to THQ Nordic in the transaction. For additional information, please contact: Lars Wingefors, Group-CEO Tel: +46 708 47 19 78 E-mail: lwingefors@thqnordic.com About THQ Nordic THQ Nordic acquires, develops and publishes PC and console games for the global games market. The company has an extensive catalogue of over 100 owned franchises, such as Saints Row, Goat Simulator, Dead Island, Darksiders, Metro (exclusive license), Titan Quest, MX vs ATV, Kingdoms of Amalur, Time Splitters, Delta Force, Alone in the Dark, Wreckfest amongst others. THQ Nordic has a global presence, with its group head office located in Karlstad, Sweden and with three divisions; Deep Silver/Koch Media, THQ Nordic and Coffee Stain. The group has fifteen internal game development studios based in Germany, Finland, UK, USA and Sweden and engages about 2,000 people. THQ Nordic's shares are publicly listed on Nasdaq First North Stockholm under the ticker THQN B with FNCA Sweden AB (e-mail: info@fnca.se phone: +46-8-528 00 399) as its Certified Adviser. For more information, please visit: http://www.thqnordic-investors.com. Forward-looking statementsThis press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release. [1]  FX rates used: 18POINT2’s P&L: AUD/EUR 0.6332 (2018 average). Purchase price calculations: AUD/EUR 0.6279 (12-Feb-2019)

Year-end report 2018

FOURTH QUARTER • Consolidated revenue increased by 49 percent to MSEK 904 (608), with organic revenue growth amounting to 41 percentage points. Corporate acquisitions contributed 0.5 percentage point and currency 7.5 percentage points.• Profitability improved and EBITDA increased by 40 percent to MSEK 198 (141) and the EBITDA margin was 22 percent (23).• Profit for the period amounted to MSEK 120 (18).• Earnings per share before and after dilution amounted to SEK 1.14 (0.05) and SEK 1.14 (0.05) respectively.• European Entertainment Intressenter BidCo AB (“EE Intressenter”), a company jointly controlled by a consortium of Bridgepoint and major shareholders in Cherry AB, announced a takeover bid for SEK 87 in cash per Class A and B share in Cherry AB. The independent bid committee for Cherry recommended that shareholders accept the public offer.• Companies in the Online Gaming business area secured a total of eight Swedish gaming licenses in December.• An Extraordinary General Meeting in November elected Rolf Åkerlind as a new member of the Board and approved the decision to acquire the remaining five percent of the shares in Game Lounge Sweden AB. FULL-YEAR • Consolidated revenue increased by 44 percent to MSEK 3,236 (2,252), of which organic growth amounted to 3 percent. Corporate acquisitions contributed 1 percentage point and currency 8 percentage points.• Profitability improved and EBITDA increased by 89 percent to MSEK 813 (429) and the EBITDA margin was 25 percent (19).• Profit for the period amounted to MSEK 487 (110). Profit was affected positively by an item affecting comparability of MSEK 50 regarding the reassessment of the value of Highlight Games.• Earnings per share before and after dilution amounted to SEK 4.45 (0.53) and SEK 4.44 (0.53) respectively.• As for the 2017 financial year, Cherry AB’s Board of Directors proposes to the Annual General Meeting that no dividend be paid for the 2018 financial year. EVENTS AFTER THE END OF THE PERIOD • On 12 February, EE intressenter announced that it controls approximately 98.2 percent of the total number of shares in Cherry AB (publ) after the expiry of the final acceptance period, and that EE Intressenter intends to initiate a compulsory acquisition procedure and to promote a delisting of the shares of series B in Cherry AB from Nasdaq Stockholm.• On 12 February, Cherry announced the initiation of early redemption of senior secured callable bonds. In connection with the redemption, the bonds will be delisted from Nasdaq Stockholm. Comments by the CEO An excellent year for all companies in the Cherry Group Cherry’s development in 2018 can be summarized with one word: excellent. On almost all measurements, our operations delivered in line with our expectations. Financially, we have performed well with total growth of 44 percent, and full-year revenue amounting to MSEK 3,236 (2,252) with an EBITDA margin of 25 percent (19). For a significant part of the year, we worked to prepare for the re-regulation of the Swedish gaming market. We were involved right from the inquiry phase prior to the legislation being drafted and have participated in issues on which we have specialist knowledge on an ongoing basis. We are satisfied with the framework, which should contribute to a high level of channelization, which is important for the long-term perspective that our market needs to be able to develop in a way that assures all stakeholders the security they need. It is reasonable that gaming companies be taxed and, to some extent, controlled when it comes to marketing, but the legislators must be aware that this is an industry in which customers are aware of their options and can therefore quickly shift their preferences. This can result in tax revenue and preventive actions from game addiction being lost. The more laws there are and the more detailed the regulations, the greater the risk that companies position themselves outside the licensing system, with the effect that everyone loses. We now have only a few weeks’ experience of the Swedish regulations and it is too early yet to have a clear idea of how development is progressing for Cherry and the rest of the industry. Our experience of similar changes in other countries is that the companies and brands that cope best are those with a clear digital strategy, that are at the forefront in technology and their customer relationships, and are led by entrepreneurs. This is the core of Cherry’s business model and the companies within our Group hold strong positions, are strongly focused on what they do and are quick to grasp opportunities. Marketing investments are often in focus among investors. During the quarter, business area Online Gaming accounted for the largest share, MSEK 253, and we can see that these investments continued to yield good returns. The business area’s revenue for the fourth quarter rose by 48 percent, to MSEK 722 (485) and the EBITDA result amounted to MSEK 141 (92). During the quarter, expenses affecting the comparison between periods were incurred, relating to doubtful receivables and gaming tax of MSEK 45.2, and impacting earnings. Underlying EBITDA amounted to MSEK 186.7 and the underlying EBITDA margin was 25.9 percent. A few days ago, the ICE trade fair closed. This is one of the industry’s foremost meeting places, and Yggdrasil once again held a prominent position there as the leading game developer. Its attendance at ICE is the company’s largest initiative in presenting itself and its new games. For the third consecutive year, Yggdrasil received the industry’s “Innovator of the year” award. The other company in business area Game Development, Highlight Games, has now launched its virtual football game in Italy together with some of the country’s largest gaming operators, Eurobet and Sisal. We believe that this game can quickly capture market share in one of Europe’s foremost football nations. On 18 December 2018, European Entertainment Intressenter BidCo AB (“EE Intressenter”), announced a public cash offer of SEK 87 per share to Cherry AB shareholders. EE Intressenter is a company jointly controlled by a consortium consisting of Bridgepoint Advisers Limited, acting as manager for and on behalf of, Bridgepoint Europe VI Fund, major shareholders in Cherry AB and others. The Board of Directors’ independent bid committee recommended that Cherry’s shareholders accept the bid from EE Intressenter. In its assessment, the recommendation took into account factors including the thorough analysis performed by the company’s financial advisers Carnegie. Key components of the bid committee’s assessment were the consideration of the bid premium over an extended time frame, the major shareholders’ decision to participate and changed market environments for listed gaming companies in Sweden. On 25 January 2019, EE Intressenter announced that the offering was accepted by shareholders holding 45,425,416 shares, corresponding to approximately 43.0 percent of the shares in Cherry. The shares submitted in the offering, together with the shares controlled by the Consortium, totalled 4,988,000 Class A shares and 90,537,784 Class B shares in Cherry, corresponding to approximately 90.4 percent of the total number of shares and 93.3 percent of the total number of votes in Cherry AB. EE Intressenter extended the acceptance deadline to 8 February and announced on 12 February that it had secured approximately 98.2 percent of the total number of shares in Cherry. EE Intressenter intends to initiate a compulsory acquisition procedure regarding the shares in Cherry that were not tendered in the offer and to promote a delisting of the shares of series B in Cherry from Nasdaq Stockholm, the operations will continue in a private setting. In a way, Cherry can be said to be Sweden’s oldest gaming company. The Group’s roots date back to 1963, when Bill Lindwall and Rolf Lundström initiated gaming operations under the name Restaurang AB Rouletter. In 1968, cooperation was initiated with AB Roulett konsult & Spelautomater, which had been founded Per Hamberg and Lars Kling. In 1972, the name of the company was changed to Cherry, and the cherry symbol began to be used as a trademark. The period as a listed company began in 1997, with the company’s listing on the SBI list, and after the current planned delisting of the company’s series B shares from Nasdaq Stockholm, Mid Cap list, to continue the business in a private setting. The foundation of Cherry’s development has been, and remains, to have a clear focus on entrepreneurial spirit and innovation, as well as offering the best workplace and development opportunities for all of our employees. We will now work with partly new owners to implement the existing strategy, while, at the same time, being able to implement efficient investments to safeguard Cherry’s market position. I would like to thank all of the shareholders, employees, partners and other stakeholders who have participated in Cherry’s journey thus far. I am convinced that Cherry and its Group companies will remain significant players in the gaming and entertainment industry for many years to come and I look forward to following developments. Gunnar LindActing CEO MARKET OUTLOOKThe gaming market is currently growing strongly and Cherry estimates that demand in the Group’s largest geographic markets will continue to develop favourably. The Group continuously studies conditions for new business in related business areas and geographic markets within Europe and beyond. The Group focuses on generating value for shareholders by participating actively in the development of new and existing companies in the gaming, media and entertainment sector. The objective is for the companies to become market leaders in their respective areas by building on their core values of entrepreneurship, responsibility and commitment. These are important prerequisites for the Group to be able to achieve its financial targets and to continue its successful profitable growth, through both organic growth and acquisitions, in existing and new verticals and geographic markets. For further information, please contact: Christine Rankin, CFO, Telephone: +46 76 539 94 92, christine.rankin@cherry.se  Anders Antonsson,  IR & Communications, Telephone: +46 709 994 970, anders.antonsson@cherry.se (carolina.stromlid@cherry.se)  The complete Year-end report is attached and is also available on www.cherry.se This information is such that Cherry AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on 13 February 2019, at 7.30 a.m. CET.

Storebrand ASA: Q4 Interim Result 2018 - Strong full-year result, strengthened solidity and increased dividend

- 2018 was a solid year for Storebrand with strong underlying growth and cost control. The 4th quarter result is negatively impacted by weak financial markets and non-recurring items. Storebrand strengthened its solidity further in the 4th quarter. It is pleasing to see that Storebrand reaffirms its position as the market leader for pension savings throughout the year, says CEO Odd Arild Grefstad. Continued growth, despite weak financial markets in the fourth quarter The operating profit for the 4th quarter is NOK 551m and NOK 2 516m for the full year 2018. The operating profit has increased by 4% compared to 2017 and by 14% when adjusting for SKAGEN and currency effects. Income grew by 5% in 2018 compared to the previous year. Weak financial markets have a negative impact on the 4th quarter result and reduce total AUM to NOK 707bn. After the resurgence in the financial markets since New Year, much of this decline has already been regained.Strengthened solidity  The Solvency II margin is calculated to 173% at the end of the 4th quarter, including transitional rules. Without transitional rules, the solvency margin is 172%, up from 155% at the end of 2017. Risk management, as well as volatility reducing factors in the solvency regulation, compensate for the negative market impact on the solvency margin. Transitional effects from new tax legislation increase the solvency margin by approximately 6 percentage points. Dividend of NOK 3.0 per share The Board of Directors proposes a dividend of NOK 3.0 per share for 2018. This amounts to an increase of the ordinary dividend of 43% compared to 2017 and a pay-out ratio of 68%, adjusted for the transitional effects from new tax legislation. Strategic transactions strengthen the business During the 4th quarter Storebrand announced the sale of Nordben, which has been delivering international pension schemes to the Nordic industry. The company has been closed for new business in recent years and has a closed portfolio of NOK 6 bn. Earlier this week, Storebrand announced the acquisition of Cubera Private Equity. The group is building a strong Nordic private equity provider with the largest team of investment professionals in the region. The transaction strengthens Storebrand's offering to institutional asset management clients and makes Storebrand a natural partner for international clients seeking investments in the Nordics. Storebrand is today the only provider in Norway to include private equity and real estate in its defined contribution portfolios. This has provided customers within defined contribution pensions the best investment return in the market. The acquisition is in line with the strategy Storebrand communicated at its capital markets day – to look for bolt-on acquisitions that complement our current business and create growth, as well as turning the business towards non-guaranteed savings products. The investor and analyst presentation Wednesday 13 February 2019 at 10:00 CET will be webcasted at Storebrand.com/ir. Questions addressed to ir@storebrand.no will be answered during the Q&A session if time permits. An analyst conference call will be arranged at 14:00 CET. To attend the conference call we kindly ask participants to dial in 10 minutes in advance by calling +44 (0) 20 3003 2666 for international participants or 21 56 33 18 from Norway. Passcode is Storebrand. Contact persons/media inquiries: Group CFO, Lars Aa Løddesøl: lars.aa.loddesol@storebrand.no or (+47) 934 80 151 SVP Communications, Vibeke Hansen: vibeke.hansen@storebrand.no or (+47) 990 13 349 Storebrand's ambition is to be the best provider of saving for pensions. Storebrand will deliver sustainable solutions adapted to the customer's individual situation, so that each person receives a better pension in a more sustainable world. Storebrand has about 40.000 corporate customers and 2 million individual customers, and has its headquarter at Lysaker outside of Oslo, Norway. Storebrand manages more than NOK 700bn and is Norway's largest private asset manager. We work hard to fulfil our vision: Recommended by our customers. Storebrand (STB) is listed on Oslo Stock Exchange. Visit us at www.storebrand.no and follow us on twitter: @Storebrand_no This announcement is subject to information pursuant to the Securities Trading Act § 5-12

Kindred Group plc - Year end report January – December 2018 (unaudited)

“Strong levels of activity and all-time high in active customers resulted in all-time high for Gross winnings revenue” “In the fourth quarter of 2018 we have seen strong levels of activity, together with an all-time high in active customers. This has resulted in record Gross winnings revenue, proving that our long-term strategy, to maintain a sustainable business by increasing the number of active customers rather than the ARPU, is paying off. Despite the exceptional sportsbook margin in the fourth quarter of 2017 making the comparatives for this quarter very tough, we have still managed to grow the business by 5 per cent.”  ”During the fourth quarter, Gross winnings revenue from mobile grew by 11 per cent compared to the fourth quarter last year and amounted to 74 per cent of our total Gross winnings revenue. Of the Group’s Gross winnings revenue, 45 per cent came from locally regulated markets. For the full year 2018, betting duties increased by 40 per cent with an EBITDA margin of 22 per cent which shows the Group’s ability to absorb betting duties through its focus on scalability and cost control.” “On 1 January, we successfully went live under the new local license in Sweden with five of our brands and we have also continued to lay the foundation for the USA early this year with the agreement in Pennsylvania. Always planning ahead, the Group prepared for the opening of the Swedish market and enlarged the customer base through bonus offers and marketing investments already from the start of the World Cup last summer. During the first six weeks of 2019, we awarded our Swedish customers with one additional bonus under the terms of the new licensing system, which resulted in new depositing customers up by 166 per cent and active customers up by 97 per cent over the last 90 days. As expected, we can now see the bonus expenditure tail off.” “For the period 1 January to 10 February 2019, the daily average Gross winnings revenue in GBP was 17 per cent higher (18 per cent in constant currency) than for the full first quarter last year.” says Henrik Tjärnström, CEO of Kindred Group. Today, Wednesday 13 February 2019, Kindred Group’s CEO Henrik Tjärnström will host a presentation in English at FinancialHearings, Tändstickspalatset, Västra Trädgårdsgatan 15, in Stockholm at 9.00 CET. The presentation is also webcast live on www.kindredgroup.com/Q42018. For those who would like to participate in the telephone conference in connection with the presentation, the telephone numbers are UK: +44 3333 009 269 or USA: +1 646 722 4956.   The Kindred Group companies hold local gambling licences in UK, France, Belgium, Denmark, Sweden, Germany (Schleswig-Holstein), Italy, Australia, Ireland, Romania and Estonia. The Kindred Group also holds international gambling licences in Malta and Gibraltar. The Kindred Group pays betting duties in all markets in accordance with applicable local laws. The information in this report is such that Kindred Group plc is required to disclose under the EU Directive of Market Abuse Regulation.

Interim report and Year-end report 2018

"Record earnings despite challenges" “Trelleborg reported an operating profit that was its highest to date for a fourth quarter, despite challenges in some units. Although areas of improvement remain, we can conclude that we had a decent end to a largely satisfactory year. For the full year we once again achieved a record result, although parts of our project business fought an uphill battle. Full-year sales increased by 8 percent, with organic sales contributing 3 percent. EBIT, operating profit excluding items affecting comparability, increased 15 percent year-on-year. Both EBIT and the EBIT margin were the highest to date for the Group for a full year. Quarterly sales increased by 8 percent, of which organic sales amounted to 2 percent, while structural growth contributed 2 percent. EBIT, excluding items affecting comparability rose by 5 percent compared with 2017. During the quarter, we continued to grow in large parts of the world and it was essentially only in parts of Eastern Europe that our sales declined. This, in turn, is largely a consequence of bottlenecks in the Czech production units. The bottlenecks are due to difficulties in recruiting qualified operators as a result of the very low rate of unemployment in the country. The resulting situation is addressed through various measures, but during the quarter created significant inefficiency and affected both sales and earnings in parts of Trelleborg Industrial Solutions. The quarter remained difficult for our project-related operations in Trelleborg Offshore & Construction. During the period, the operation was also charged with impairments related to certain project transactions. Improvement measures in the business area were implemented over the past 12 months and have created a more market-adapted and efficient operation. While there was certainly an upturn in the level of activity at the end of 2018, we expect that a distinct earnings improvement will only occur in the second half of 2019, when the higher activity level rolls over into increased sales. Our largest business area, Trelleborg Sealing Solutions, performed well in all regions and its deliveries to both general industry and the aerospace industry were on the rise. However, sales to the automotive industry declined somewhat, which was attributable to the North American market. There was a mixed trend in our tire business during the quarter. Sales of agricultural tires were slightly negative, but at the same time we noted that this was mainly attributable to the comparative period in 2017 being very strong as a result of new emission regulations that drove the new registration of tractors before year-end. Deliveries of material handling vehicles and construction machinery grew satisfactorily. The Group’s rate of investment remained high during the fourth quarter. We are investing in new sites and new technology, at the same time as we are increasing our capacity at several existing sites. The purpose is to always build a stronger Trelleborg with a long-term plan in focus, and it is part of the Group’s strategy to strengthen its positions in attractive market segments. Another example of this strategy is that we have formed a joint venture in India to promote our continued expansion in that part of the world. The company will manufacture tires for two-wheeled motor vehicles. After the close of the period, we finalized the acquisition of Sil-Pro, which expands our capacities within cleanroom manufacturing, primarily to healthcare & medical. At the time of writing, the global economy is marked by great uncertainty, impacted by the Brexit negotiations and trade policy restrictions. As a global player in our industry, with manufacturing units located in nearly all parts of the world, Trelleborg stands well prepared to manage fluctuating market conditions. Our assessment is that demand in the first quarter of 2019 will be on a par with, or somewhat lower than, the fourth quarter of 2018”, says Peter Nilsson, President and CEO. Fourth quarter 2018 Net sales for the fourth quarter of 2018 rose 8 percent to SEK 8,342 M (7,708). Organic sales increased 2 percent. Excluding project deliveries, the corresponding increase was 3 percent. EBIT, excluding items affecting comparability, rose 5 percent to SEK 997 M (928), which was equivalent to an EBIT margin of 11.7 percent (12.0). EBIT was the highest ever for the Group in a fourth quarter. Items affecting comparability for the quarter were a negative SEK 98 M (neg: 314) and pertain to restructuring costs. For 2017, the amount comprised a negative SEK 781 M in restructuring costs and SEK 467 M as an earnings effect from a receivable related to the divestment of Vibracoustic. Earnings per share for continuing operations excluding items affecting comparability totaled SEK 2.55 (2.31); for the Group in its entirety, earnings per share amounted to SEK 2.22 (1.01). Operating cash flow amounted to SEK 1,166 M (1,208). The cash conversion ratio for the most recent 12-month period declined to 74 percent (90), impacted primarily by a higher level of capital expenditure. Full-year 2018 Net sales for the full-year 2018 increased 8 percent to SEK 34,005 M (31,581). Organic sales rose 3 percent. Excluding project deliveries, the corresponding increase was 4 percent. EBIT, excluding items affecting comparability, rose 15 percent to SEK 4,694 M (4,091), corresponding to an EBIT margin of 13.8 percent (13.0). Both EBIT and the EBIT margin were the highest to date for the Group for a full year. Items affecting comparability were a negative net amount of SEK 176 M (neg: 69). For 2017, the amount included restructuring expenses in the negative amount of SEK 1,008 M, a positive SEK 467 M as an earnings effect from the receivable related to the divestment of Vibracoustic and the capital gain of SEK 472 M from the divestment of the compounding operation in Lesina in the Czech Republic. Earnings per share for continuing operations, excluding items affecting comparability, totaled SEK 12.34 (10.82). For the Group in its entirety, earnings per share amounted to SEK 11.77 (10.60). Net profit for the Group totaled SEK 3,190 M (2,874). The tax expense for 2018 was impacted by expenses of SEK 51 M related to the tax reform in the U.S.; the corresponding negative effect for 2017 was SEK 129 M. Operating cash flow for continuing operations amounted to SEK 3,488 M (3,688), down 5 percent. The cash conversion ratio for the most recent 12-month period declined to 74 percent (90), impacted primarily by a higher level of capital expenditure.  Market outlook for the first quarter 2019Demand is expected to be on a par with, or somewhat lower than, the fourth quarter of 2018, adjusted for seasonal variations.  Market outlook from the interim report published on October 30, 2018, relating to the fourth quarter of 2018Demand is expected to be on a par with the third quarter of 2018, adjusted for seasonal variations. Dividend 2018The Board of Directors proposes a cash dividend of SEK 4.75 per share (4.50). For further information, please contact:Media: Vice President Media Relations Karin Larsson, +46 (0)410 67015, +46 (0)733 747015, karin.larsson@trelleborg.comInvestors/analysts: Vice President IR Christofer Sjögren, +46 (0)410 67068, +46 (0)708 665140, christofer.sjogren@trelleborg.com    This information is information that Trelleborg AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 7:45 a.m. CET on February 13, 2019. This is a translation of the company’s Interim Report in Swedish. 

NATTOPHARMA ENHANCES OFFERING WITH TECHNOLOGY PARTNERSHIP

Oslo, Norway (13 FEB 2019) — NattoPharma has reached an accord with Inventia Healthcare Ltd. and Laila Nutraceuticals that provides NattoPharma with the exclusive rights in core markets to add Inventia and Laila’s proprietary ingredient, in the mood and energy segments, supported by unique composition of actives and proprietary novel technology, to its clinically validated portfolio.   Not only does the agreement bring an exciting innovation to a dynamic ingredient category, but it is also the first ingredient NattoPharma will introduce separate from the Vitamin K2 as menaquinones segment.  “NattoPharma has been incubating a number of new concepts based on our high standard of clinical validation confirming true health benefits,” says NattoPharma CEO Kjetil Ramsøy. “Laila’s long, rich history in developing superior actives and Inventia’s entry into Nutraceuticals with its pharmaceutical background equates to tighter product specifications, stringent quality standards, and an insistence upon delivering products based on science, which is perfectly in line with NattoPharma’s principles.” “We are delighted to partner with Inventia and NattoPharma to bring Nutraceutical Ingredients to the market that address consumer needs and are backed by robust science and quality,” says Kiran Bhupathiraju, CEO Laila Nutraceuticals. “We are excited to sign this agreement with NattoPharma, as it combines the market reach of NattoPharma, superior active from Laila, along with the technology advantage of Inventia Healthcare to provide customers with more benefits,” says Vishal Shah, Whole Time Director at Inventia. “Our three companies are likeminded in holding ourselves to the highest standards, ensuring the ingredients we put in the marketplace are supported by substantial evidence confirming efficacy and safety. This partnership further validates the application of our diverse delivery platforms and its applications in the Nutritional space for the betterment of human health.” Inventia Healthcare Ltd. is a 33-year-old innovative drug delivery company that specializes in novel, science-based, oral delivery technologies for Pharmaceutical applications. With a state-of-the-art research and development center approved by the Ministry of Science and Technology, Government of India, Inventia is well equipped to undertake formulation and development projects on Novel Drug Delivery Systems in the Nutraceuticals segment. Laila Nutraceuticals is a world leader in developing innovative botanical ingredients that have become top sellers across various countries over the last several decades. With a rich heritage of 44 years, Laila Nutraceuticals has state of the art GLP laboratories with 150 scientists dedicated to research and innovation of botanical actives coupled with cGMP compliant, NSF GMP certified manufacturing facilities that have been approved by US FDA and other regulatory agencies. Ramsøy adds, “Inventia’s delivery technology and Laila’s superior ingredient composition is a perfect complement to our existing ingredient family in that it has a long history of safe use, along with the requisite clinical evidence that our customers demand and expect. We continue in the substantiation process, including human clinical studies validating superior health benefits, which signify real process for our project. Given the sales cycle and timing, we would expect to begin realizing commercial sales in Q1 2020.” XXX About NattoPharma and MenaQ7® NattoPharma ASA, based in Norway, is the supplement industry world leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK-7) with guaranteed actives and stability, clinical substantiation, and international patents granted and pending; and now the new MenaQ7® Full Spectrum, which delivers menaquinones 6, 7, and 9. The company has a multi-year research and development program to substantiate and discover the health benefits of Vitamin K2 for applications in the marketplace for functional food and dietary supplements, in addition to exclusive access to the research efforts of its pharmaceutical arm, Kaydence Pharma AS (est. 2017), outside of the pharmaceutical domain. With a global presence, the company established its North American subsidiary, NattoPharma USA, Inc., in Edison, NJ, and NattoPharma R&D Ltd. in Cyprus. For more information, visit www.nattopharma.com or www.menaq7.com. For more information, please contact: Kate Quackenbush, NattoPharma Director of Communications Phone: 609-643-0749 x 220; E-mail: kate.quackenbush@nattopharma.com

NATTO: STRONG GROWTH AND POSITIVE RESULT

Oslo, Norway (13 February 2019) - NattoPharma increased revenues by 52% in the second half of the year and delivered a positive net result in the half year and for the full year 2018. This is coupled with a strong financial position with no interest-bearing debt and an equity ratio of 74,5% as at December 31st, 2018. “We are very pleased to deliver a strong second half fueled by a record fourth quarter with Product Revenues of approximately NOK 31 million and an EBITDA of 10%. This is the first full year where the Group has a positive net result, demonstrating our ambition of profitable growth. We are especially pleased that we have achieved this already in the first year following the spin-off of the pharma business into Kaydence Pharma AS. We are also increasing our focus on growing shareholder value. In December we signed an agreement for 2019 with Nordea Markets for Commissioned Research and anticipate the first report to be available in early March. At the same time, we are returning to a quarterly reporting cycle.” Kjetil Ramsøy, CEO NattoPharma. Financial highlights: +----------------+------+-------+------------+------+------+------------+|(mnok) |H2’18 | H2’17 | Change | 2018 | 2017 | Change |+----------------+------+-------+------------+------+------+------------+|Product Revenue | 54,5 | 36,0 |18,6 (+52%) |101,7 | 66,4 |35,3 (+53%) |+----------------+------+-------+------------+------+------+------------+|Gross Margin  |44,3% |48,8 % | -4,5%| 43,1%|47,4% | -4,3% |+----------------+------+-------+------------+------+------+------------+|Adj. EBITDA  | 4,2 | 3,8 | 0,3 | 6,7 | 5,3 | 1,4 |+----------------+------+-------+------------+------+------+------------+|Net profit  | 3,2 | -0,9 | 4,1 | 1,8 | -4,1 | 5,8 |+----------------+------+-------+------------+------+------+------------+ Please find attached the Nattopharma Group 2018 Second Half and Preliminary Full Year Earnings Release. A presentation will be held via webcast at 10 am CET, Wednesday 13thFebruary 2019, followed by a Q&A session. Please follow the below link to join the webcast; http://webtv.hegnar.no/presentation.php?webcastId=97603094 For more information, please contact: Kjetil Ramsøy CEO, NattoPharma E-mail: kjetil.ramsoy@nattopharma.com This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. 

Year-end report 2018

OCTOBER – DECEMBER · Order intake amounted to 40.0 SEK million (12.6) · Net sales increased to 37.8 SEK million (11.1) · Operating profit/loss amounted to -32.7 SEK million (-20.1) · Earnings per share amounted to -0.7 SEK (-0.5) · Climeon increased the capacity with a new test center for development and testing of Heat Power modules in Kista · Climeon won the Japanese innovation prize “Top 10 Innovation” at Innovation for Cool Earth Forum (ICEF) inTokyo, hosted by the Japanese Government · In December, Climeon received an order from Iwana Power GK within geothermal in Japan worth SEK 40.0 million. Iwana Power GK is part owned by Baseload Power Japan and local entrepreneurs JANUARY – DECEMBER · Order intake amounted to 478.5 SEK million (330.1) · Order backlog amounted to 818.6 SEK million (353.7) · Net sales increased to 58.9 SEK million (11.9) · Operating profit/loss amounted to -101.9 SEK million (-56.7) · Earnings per share amounted to -2.3 SEK (-1.5) · Cash and cash equivalents amounted to 90.0 SEK million (204.0) IMPORTANT POST-CLOSING EVENTS · Christoffer Andersson, former COO of Climeon, was appointed CFO and deputy CEO. Olle Tholander was appointed Head of Sales and Marketing · Due to external factors Borealis GeoPower has experienced major delays, which is why Climeon has decided to remove their order, worth SEK 10 million, from the order backlog as of the first quarter 2019 · As of January 1, 2019, Climeon applies IFRS9 for valuation of financial assets which implies that Baseload Capital will be valued at fair value, SEK 37.7 million, an increase of SEK 0.40 per share CEO COMMENT RECORD NUMBER OF MODULES DELIVERED The fourth quarter 2018 was intensive with a record number of modules delivered. Net sales increased significantly for the quarter as well as the full year and amounted to SEK 37.8 million (11.1) in the fourth quarter. Net sales for the full year amounted to SEK 58.9 million (11.9). Within the geothermal segment, Japan and Iceland continue to be in focus. The Japanese customers have completed the first drillings and two local Japanese Heat Power Operators are now ready: Hayabusa Power and Iwana Power GK. In Fludir in Iceland, where there one year ago was nothing but a single heat source, there is now a power plant that has begun to produce clean and renewable electricity. Now, final testing of the power plant is under way, including the surrounding components and the heat source, which will supply over 1 100 homes with green electricity. We are entering 2019 with a large order backlog to be delivered and an on-going global expansion. This has increased the need for operational focus in both management and organization, which is why we have altered the management team and organization somewhat. The new composition gives us the best possible conditions for the rapid growth we have ahead of us, with power plants to be delivered and commissioned in several different parts of the world at the same time. The new development and testing site in Kista, which we inaugurated in October 2018, is now fully operational. After only a few months in Kista we can see how much more efficient the testing process has become and how the time from production start to delivery could be shortened. The operational costs have been kept low despite rapid growth. At the same time, we have been preparing the company for continued expansion through our investments in the Kista test site, SEK 8.5 million, where the main part of the costs has been in the fourth quarter. The large number of deliveries within the maritime segment during the fourth quarter, with payments in the first quarter of 2019, also had a certain negative effect on cash flow. This has affected our cash balance which by the end of the year amounted to SEK 90.0 million, in line with the business plan that was communicated in connection to the listing on Nasdaq First North Premier in October 2017. The sentiment that I share with my colleagues right now is incredible. Our idea of changing societies by providing them with fossil-free electricity 24 hours a day, 7 days a week, regardless of sunshine and wind, has begun to be realized. Thomas Öström, CEO Climeon For full report, please see attached file. For further information, please contact:Thomas Öström, CEO, +46 708 94 96 05, thomas.ostrom@climeon.com Christoffer Andersson, CFO & Deputy CEO, +46 762 00 72 99, christoffer.andersson@climeon.com This press release contains such information that Climeon AB (publ) is required to publish in accordance with the EU Market Abuse Regulation. The information was published for public disclosure on February 13th, 2019 at 08:00 CET through the agency of the contact persons set out above.  About ClimeonClimeon is a Swedish product company within energy technology. The company's unique technology for heat power - Heat Power - provides sustainable electricity around the clock all year round, in abundance and cheaper than the alternatives, and thus outperforms other types of energy. Climeon aims to become a global leader and the world's number one climate solver. The B share is listed on Nasdaq Stockholm First North Premier. Certified Adviser is FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se. 

Q4 2018: Growth in fourth quarter closes the year

Significant events in the fourth quarter• Fourth-quarter net sales rose to MSEK 163, up 36%, or MSEK 43 compared with the year-on-year period, due to continued recovery from a customer-specific destocking programme• First commercial order after the introduction of Probi’s product to improve bone health in postmenopausal women – Probi® Osteo• Promising initial results from clinical trials to evaluate the effects of Probi’s strains on physical performance and acute stress• Tom Rönnlund appointed new CEO as of January 1, 2019 and Henrik Lundkvist new CFO as of January 7, 2019• Board of Directors propose that the 2019 Annual General Meeting resolves that no dividends will be paid for the 2018 financial year Financial overview MSEK   Full-year 2018   Full-year 2017   Net sales   604.1   612.2Net sales growth, constant   -2.2%   38.2%currency, %Gross margin, %   46.0%   45.4%EBITDA   154.9   157.3EBITDA margin, %   25.6%   25.7%Operating profit (EBIT)   101.1   104.1Net income   76.3   69.1Earnings per share before and   6.69   6.06after dilution, SEKShare price on closing day, SEK   360.00   340.00Market cap on closing day   4,101.9   3,874.0See note 5 for definitions of        ratios not defined according toIFRS  Invitation to teleconferenceDate: 13 February 2019Time: 10:00 a.m.Phone: +46 8 56 64 27 07Participants from Probi:Tom Rönnlund, CEO:Henrik Lundkvist, CFO The presentation is available at www.probi.se and www.financialhearings.com ContactTom Rönnlund, CEO: Phone: +46 (0)46 286 89 40, E-mail: trd@probi.comHenrik Lundkvist, CFO: Phone: +46 (0)46 286 89 41, E-mail: henrik.lundkvist@probi.com This information is information that Probi AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 13 February 2019 at 8:00 a.m. CET. This a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails. About ProbiProbi AB is a Swedish publicly traded bioengineering company. Probi’s vision is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research.Founded by scientists in Sweden in 1991, Probi is a multinational company, active in more than 40 markets around the world and holding over 400 patents worldwide. In 2018, Probi had net sales of MSEK 604. The Probi share is listed on Nasdaq Stockholm, Mid Cap. Probi had about 4,000 shareholders on December 31, 2018.probi.com

Quimper declares the offer for Ahlsell unconditional and will acquire all tendered shares

On 11 December 2018, Quimper AB (a company that has been or will be indirectly invested in by CVC Funds) (“Quimper”)[1], announced a public cash offer to the shareholders in Ahlsell AB (publ) (“Ahlsell” or the “Company”) to tender all their shares in Ahlsell to Quimper (the “Offer”). The offer document regarding the Offer was made public on 19 December 2018. The shares tendered in the Offer at the end of the initial acceptance period on 11 February 2019, together with the shares already held or otherwise controlled by Quimper, and closely related parties, amount to in aggregate 403,296,725 shares in Ahlsell, corresponding to approximately 93.9 percent[2] of the share capital and the voting rights in Ahlsell. Quimper hereby announces that all conditions for completion of the Offer have been fulfilled. Accordingly, the Offer is declared unconditional in all respects and Quimper will complete the acquisition of the shares tendered in the Offer. Settlement for shares tendered in the Offer during the initial acceptance period will take place in accordance with previously communicated plan, i.e. around 19 February 2019. To provide the remaining shareholders of Ahlsell who have not tendered their shares time to accept the Offer, the acceptance period will be open beyond the end of the initial acceptance period, until 27 February 2019 at 15.00 (CET). Settlement for shares tendered in the Offer during the additional acceptance period is expected to start around 7 March 2019. Quimper reserves the right to further extend the acceptance period for the Offer. Prior to announcement of the Offer, Quimper, and closely related parties, held in aggregate 109,578,323 shares in Ahlsell, corresponding to approximately 25.1 percent[3] of the share capital and the voting rights in Ahlsell. At the end of the initial acceptance period on 11 February 2019, the Offer had been accepted by shareholders representing in total 293,718,402 shares in Ahlsell, corresponding to approximately 68.4 percent[4] of the share capital and the voting rights in Ahlsell. Quimper does not hold any financial instruments that give financial exposure to Ahlsell shares and has not acquired any such shares or financial instruments outside the Offer. Quimper will initiate compulsory acquisition of the remaining shares in Ahlsell as well as promote a delisting of Ahlsell's shares from Nasdaq Stockholm. Quimper  For more information about the Offer, please see: www.quimperbidco.com Information about CVC CVC is a leading private equity and investment advisory firm. Founded in 1981, CVC today has a network of 24 offices and approximately 450 employees throughout Europe, Asia and the US. To date, CVC has secured commitments of over US$ 116 billion from some of the world's leading institutional investors across its private equity and credit strategies. CVC Funds have been investing in the Nordic region for more than 20 years and currently invest in a wide range of portfolio companies in the region, including Synsam, ÅR Packaging, eTraveli and Mehiläinen. In total, CVC currently manages approximately US$69 billion of assets. Today, CVC Funds are invested in 72 companies worldwide, employing c.200,000 people in numerous countries. Together, these companies have combined annual sales of over US$150 billion. For further information about CVC please visit: www.cvc.com.  This information was submitted for publication on 13 February 2019 at 08:00 (CET). Information about the Offer: www.quimperbidco.com  Important notice   The Offer is not being made, directly or indirectly, in or into Australia, Canada, Hong Kong, Japan, New Zealand or South Africa by use of mail or any other means or instrumentality (including, without limitation, facsimile transmission, electronic mail, telex, telephone and the Internet) of interstate or foreign commerce, or of any facility of national security exchange, of Australia, Canada, Hong Kong, Japan, New Zealand or South Africa, and the Offer cannot be accepted by any such use, means, instrumentality or facility of, or from within, Australia, Canada, Hong Kong, Japan, New Zealand or South Africa. Accordingly, this press release and any documentation relating to the Offer are not being and should not be sent, mailed or otherwise distributed or forwarded in or into Australia, Canada, Hong Kong, Japan, New Zealand or South Africa. This press release is not being, and must not be, sent to shareholders with registered addresses in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa. Banks, brokers, dealers and other nominees holding shares for persons in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa must not forward this press release or any other document received in connection with the Offer to such persons. Statements in this press release relating to future status or circumstances, including statements regarding future performance, growth and other trend projections and the other benefits of the Offer, are forward-looking statements. These statements may generally, but not always, be identified by the use of words such as “anticipates”, “intends”, “expects”, “believes”, or similar expressions. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There can be no assurance that actual results will not differ materially from those expressed or implied by these forward-looking statements due to many factors, many of which are outside the control of Quimper. Any such forward-looking statements speak only as of the date on which they are made and Quimper has no obligation (and undertakes no such obligation) to update or revise any of them, whether as a result of new information, future events or otherwise, except for in accordance with applicable laws and regulations. Special notice to shareholders in the United States  The Offer is being made for shares of Ahlsell AB (publ), a company incorporated under Swedish law, and is subject to Swedish disclosure and procedural requirements, which are different from those of the United States. The Company’s financial statements, and all financial information that is included in any offer document, or any other documents relating to the Offer, have been or will be prepared in accordance with IFRS and may not be comparable to financial statements of companies in the United States or other companies whose financial statements are prepared in accordance with US generally accepted accounting principles. The Offer is being made in the United States pursuant to Section 14(e) and Regulation 14E under the US Exchange Act as a “Tier II” tender offer, and otherwise in accordance with the requirements of Swedish law. Accordingly, the Offer will be subject to disclosure and other procedural requirements, including with respect to withdrawal rights, offer timetable, settlement procedures and timing of payments that are different from those applicable under U.S. domestic tender offer procedures and law. It may be difficult for U.S. shareholders to enforce their rights and any claims they may have arising under the U.S. federal securities laws in connection with the Offer, since the Company and Quimper are located in countries other than the United States, and some or all of their officers and directors may be residents of countries other than the United States. U.S. shareholders may not be able to sue the Company or Quimper or their respective officers or directors in a non-U.S. court for violations of U.S. securities laws. Further, it may be difficult to compel the Company or Quimper and their respective affiliates to subject themselves to the jurisdiction or judgment of a U.S. court. To the extent permissible under applicable law or regulations, Quimper and its affiliates or brokers (acting as agents for Quimper or its affiliates, as applicable) may from time to time after the date hereof directly or indirectly purchase or arrange to purchase shares of the Company outside the United States other than pursuant to the Offer, before or during the period in which the Offer remains open for acceptance, or any securities that are convertible into, exchangeable for or exercisable for such shares. These purchases may occur either in the open market at prevailing prices or in private transactions at negotiated prices. Any information about such purchases will be announced through relevant electronic media if, and to the extent, such announcement is required under applicable Swedish law, rules or regulations. In addition, the financial advisors to Quimper may also engage in ordinary course trading activities in securities of the Company, which may include purchases or arrangements to purchase such securities. The receipt of cash pursuant to the Offer by a U.S. shareholder may be a taxable transaction for US federal income tax purposes and under applicable U.S. state and local, as well as foreign and other, tax laws. Each shareholder is urged to consult his or her independent professional adviser immediately regarding the tax consequences of accepting the Offer. NEITHER THE SEC NOR ANY U.S. STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED THE OFFER, OR PASSED ANY COMMENT UPON THE ADEQUACY OR COMPLETENESS OF THIS ANNOUNCEMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENCE IN THE UNITED STATES. ---------------------------------------------------------------------- [1] Quimper is a newly formed entity that has been or will be indirectly invested in by funds or vehicles ("CVC Funds") advised by CVC Advisers Company (Luxembourg) S.à r.l. and/or its affiliates. "CVC" means CVC Advisers Company (Luxembourg) S.à r.l. and its affiliates, together with CVC Capital Partners SICAV-FIS S.A. and each of its subsidiaries.  [2] Based on all 436,302,187 outstanding shares in Ahlsell, excluding the 7,000,000 shares which are held by Ahlsell in treasury. [3] Based on all 436,302,187 outstanding shares in Ahlsell, including the 7,000,000 shares which are held by Ahlsell in treasury.  [4] Based on all 436,302,187 outstanding shares in Ahlsell, excluding the 7,000,000 shares which are held by Ahlsell in treasury.

National Museum of Science and Technology and Stora Enso build Stockholm’s smartest wooden building

With Stora Enso as the principal partner and donations of SEK 85 million, Tekniska Museet – Sweden’s National Museum of Science and Technology – is mustering forces to create a digital, interactive learning and test environment for scientific communication: Wisdome. This is one of the single most important initiatives at the National Museum of Science and Technology since it was founded almost 100 years ago. An innovative, sustainable new wood building is to be erected for the purpose. Using state-of-the-art Swedish visualisation technology, Wisdome will surround visitors with projections and take them on a journey farther away, closer in and deeper down than anyone has ever been before – experiences that will help the visitor to see and understand connections that are otherwise hard to perceive. “We need new ways of understanding how the world works, and we must inspire and provoke curiosity if we are to deal with the global challenges of the future. We want to create a place that brings research and innovative ideas from the academic and business worlds together with the general public, and gets children and young people involved in building their own future,” says Peter Skogh, Museum Director at The Swedish National Museum of Science and Technology. Sweden is a world leader in the visualisation of large amounts of data. Wisdome will involve talent and technology found in only a few places worldwide. This includes sophisticated laser projectors, audio systems and sufficient processor power to transform the latest research data into interactive journeys – journeys where visitors themselves can be involved in steering their own path through galaxies and dizzying special effects, and down to the tiniest molecular level. Stockholm’s smartest building – a signature building made of massive woodWisdome is expected to be finished in late 2021 or early 2022, and will be in a brand-new building next to the Museum of Science and Technology in the National City Park, in Djurgården, Stockholm. To inspire innovation and promote a sustainable future, the entire construction will be made of massive wood. The Museum is therefore initiating a new collaboration with forest industry company Stora Enso, who will contribute expertise and sustainable wood products. “Wood is a building material that’s all about innovation and the future, but also one that tells the story of our past. We are delighted to be involved in the Museum of Science and Technology’s efforts to inspire children and young people, and to be providing the most sustainable building material around for a signature building in Stockholm. We aim to create a finished structure that pushes the boundaries and shows what can be achieved with the building material of the future. We want our wood products to be used sustainably, innovatively and cost effectively, so this will be the smartest building in Stockholm,” says Per Lyrvall, Country Manager Sweden at Stora Enso. SEK 85 million for world-class scientific communicationThe donation of SEK 85 million (EUR 8 million) which has made the Wisdome project possible has been made by the Knut and Alice Wallenberg Foundation, the Erling-Persson Family Foundation and the Marianne and Marcus Wallenberg Foundation, as well as the Stora Fund and forest industry company Stora Enso, which are museum affiliates. The Wisdome project Wisdome will be a digital, interactive learning and test environment for scientific communication. Wisdome is a collaboration between Sweden’s five leading science centres: Science Center Malmö Museer, Universeum in Gothenburg, Umevatoriet in Umeå, the National Museum of Science and Technology in Stockholm, and the main coordinating centre Norrköping Visualization Center-C. Also, connected to the project are ten or so universities and scientific environments with expertise in research, technology, application and didactics. The Wisdome project was created through a jubilee donation from the Knut and Alice Wallenberg Foundation in 2017  The National Museum of Science and TechnologyThe Swedish National Museum of Science and Technology aims to enhance the public’s and particularly young people’s interest in science and technology in a joyful, inspiring way. The Museum also has a national charter to preserve Sweden’s technological and industrial cultural heritage. The National Museum of Science and Technology is Sweden’s biggest technical museum, welcoming 323 399 visitors in 2018.Link to a video: https://youtu.be/5ItbtaDEbOMFor further information, please contact:Sara KvarfordhCommunications Manager SwedenStora EnsoTel. +46 70 234 45 90sara.kvarfordh@storaenso.com Calle Ros-Pehrson,Press OfficerThe Swedish National Museum of Science and Technology,tel: +46 8 450 57 10calle.ros-pehrson@tekniskamuseet.se Part of the bioeconomy, Stora Enso is a leading global provider of renewable solutions in packaging, biomaterials, wooden constructions and paper. We believe that everything that is made from fossil-based materials today can be made from a tree tomorrow. Stora Enso has some 26 000 employees in over 30 countries. Our sales in 2018 were EUR 10.5 billion. Stora Enso shares are listed on Nasdaq Helsinki (STEAV, STERV) and Nasdaq Stockholm (STE A, STE R). In addition, the shares are traded in the USA as ADRs (SEOAY). storaenso.com   STORA ENSO OYJ 

BioArctic’s product candidate SC0806 for treatment of patients with complete spinal cord injury is now in Phase 2

Stockholm, Sweden, February 13, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient in the second panel of the Phase 1/2 study now has been treated with SC0806. This means that the study with the product candidate SC0806 for complete spinal cord injury has progressed into Phase 2. BioArctic develops a new innovative treatment for patients with complete spinal cord injury. The product candidate SC0806 is a combination of a biodegradable medical device and a drug substance (FGF1). SC0806 is designed to support nerve regeneration across the injured area in the spinal cord. Due to the novelty of the treatment, patients have been included sequentially, in order to monitor the effect and safety. A safety evaluation of all the patients in the first panel has been performed and provided support to start the next panel. The first patient in the second panel has now received treatment with SC0806 and hereby the Phase 2 part of the study has been initiated. The inclusion of patients to the second of the three panels in the study is on-going. Each panel consists of six patients receiving SC0806 and three control patients. The treatment with SC0806 includes a surgical procedure. The surgery is followed by 18 months of intensive training in a robotic system to support nerve regeneration and muscle rebuilding in the part of the body affected by the paralysis. Patients receiving SC0806 are also given the option to participate in a 12 months extension study. An interim analysis of safety and efficacy of SC0806 in the first panel at 18 months is planned Q4 2019/Q1 2020.   ”Today there is no effective treatment for patients with complete spinal cord injury. The initiation of the second panel was depending on a positive safety evaluation of the patients in the first panel. I am pleased that the study with SC0806 now has progressed into Phase 2 and we are looking forward to the important activities ahead of us within this therapeutic area,” said Gunilla Osswald, CEO of BioArctic. For more information, please contactGunilla Osswald, PhD, CEO, BioArctic ABE-mail: gunilla.osswald@bioarctic.seTelephone: + 46 8 695 69 30 Christina Astrén, Director IR & Communications, BioArctic ABE-mail: christina.astren@bioarctic.seTelephone: + 46 70 835 43 36  This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, at 08.00 a.m. CET on February 13, 2019. About SC0806SC0806 is a novel product under development for the treatment for patients with complete spinal cord injury. The product candidate is currently in an ongoing Phase 1/2 clinical trial. The first patient was treated in 2016. BioArctic has obtained approvals from the regulatory authorities and ethics committees to recruit patients in Sweden, Estonia, Finland and Norway to the study. The product candidate is a combination of a biodegradable medical device and a drug substance (FGF1) designed to support nerve regeneration across the injured area in the spinal cord. The product obtained orphan drug designation in 2010 in EU and in 2011 in the US, which may give the company 10 and 7 years of market exclusivity in Europe and the US, respectively. BioArctic has received funding from the European Union’s Horizon 2020 Research and Innovation Program under Grant Agreement No. 643853 to perform a clinical study with SC0806. About Spinal Cord InjurySpinal Cord Injuries (SCI) occur when trauma or disease damages the spinal cord and results in partial or complete paralysis. A complete spinal cord injury is defined as an injury where the patient cannot provide any voluntary movement or has any sensory feedback below the injury. A spinal cord injury causes degeneration of the nerve fibers below the site of the injury, as nerve cells do not regenerate. The incidence ranges between 12.7 and 44.3 per million inhabitants depending on country.1 Some 40% of these patients are estimated to have chronic complete spinal cord injury.2 Patients with complete spinal cord injury require life-long therapy and care, which means high costs for the healthcare system. The victims are usually young people. The injury has little effect on life expectancy, but leads to major challenges to maintain an acceptable quality of life. Following complete injury, the patient faces a permanent loss of function below the site of injury, with devastating consequences for the patient’s quality of life. Today there is no effective treatment available for the patients. 1) Datamonitor, Stakeholder Opinions: Spinal Cord Injury, 2010.2) NSCISC Annual Statistics report 2010. About BioArcticBioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential.BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B).For more information about BioArctic, please visit us at www.bioarctic.com.

Notice to the holders of bonds issued by Ahlsell under the MTN programme

Notice to the holders of bonds issued by Ahlsell AB (publ) (”Ahlsell”) under Ahlsell’s MTN programme in relation the public tender offer to the shareholders of Ahlsell. Following the public tender offer to the shareholders of Ahlsell as of 11 December 2018 Quimper AB has on 13 February 2019 announced that Quimper AB completes the offer and thereby becomes owner of shares representing 93.9 per cent of the total number of shares and votes in Ahlsell. Quimper AB’s acquisition of the shares in Ahlsell constitutes a change of control event pursuant to the terms and conditions of Ahlsell AB’s Medium Term Note (MTN) programme. As a result of the change of control event, each bondholder may exercise its right to request that all or part of its bonds (ISIN: SE0010599266) be repurchased pursuant to condition 9 of the terms and conditions, at a price per bond equal to 100 per cent of the nominal amount plus accrued and unpaid interest up until the Repurchase Date (pursuant to the definition below). Bondholders who wish to exercise their right to request repurchase of all or part of their bonds must sign and send an application form to the following e-mail address: DNB Bank ASA, filial SverigeSecurities ServicesGroup number: +46 8 473 45 50E-mail: emissioner@dnb.se The application form is provided to bondholders by Ahlsell via Euroclear Sweden’s messaging service and can also be obtained from DNB. Please note that a complete application form must have been received by DNB no later than 22 March in order to be valid. A submitted application form may be withdrawn by the bondholder until such date. The repurchase date applicable to those bondholders who have sent an application form in respect of all or part of their bonds as a result of the change of control event in due time will be 5 April “Repurchase Date”). For further information, please contact:Karin Larsson, Head of IR and external communications+46 8 685 59 24, karin.larsson@ahlsell.se Ahlsell is the Nordic region’s leading distributor of installation products, tools and supplies for installers, construction companies, facility managers, industrial and power companies and the public sector. The unique customer offer covers more than one million individual products and solutions. The Group has a turnover of just over BSEK 31 and is listed on Nasdaq Stockholm. About 97% of revenue is generated in the three main markets of Sweden, Norway and Finland. With about 5,700 employees, more than 230 branches and three central warehouses, we constantly fulfil our customer promise: Ahlsell makes it easier to be professional! Press release, February 13, 2019  

Notice of Extraordinary General Meeting in Moberg Pharma AB (publ)

Attendance at the Extraordinary General Meeting Shareholders who wish to participate in the Extraordinary General Meeting must: -         be recorded in the share register maintained by Euroclear Sweden AB (“Euroclear”), on Saturday, March 9, 2019 (since the record date is a Saturday, shareholders must make sure to be entered in the share register on Friday, March 8, 2019), and -         give notice of attendance to the Company under address: Moberg Pharma AB (publ), Gustavslundsvägen 42, 5 tr, 167 51 Bromma, Sweden att. Malin Nilsson or by e-mail to malin.nilsson@mobergpharma.se, at the latest on Monday, March 11, 2019, preferably before 4:00 p.m. (CET). When giving notice of attendance, shareholders must state their name, civil registration number or corporate registration number, address, telephone number and, where applicable, number of accompanying assistants (no more than two). Shareholders can participate and vote at the Extraordinary General Meeting personally or by proxy. Shareholders whose shares are registered in the name of a nominee must, in order to be entitled to participate in the Extraordinary General Meeting, with the help of the nominee, re-register their shares in their own names in the share register maintained by Euroclear, so that they are registered on Saturday, March 9, 2019 (since the record date is a Saturday, shareholders who wish to make such re-registration should inform their nominee well in advance of Friday, March 8, 2019). Shareholders represented by proxy should submit a power of attorney in original, along with other authorization documents, when giving notice of attendance to the Extraordinary General Meeting. A power of attorney may be valid for up to five years from issuance. The Company provides forms of power of attorney on the Company’s website www.mobergpharma.se. Representatives of legal persons must present a copy of the legal person’s certificate of registration or other equivalent document demonstrating the right to act on behalf of the legal person. Number of shares and votes As per the date of this notice, there are a total of 17,703,762 shares and votes in the Company. The Company holds 263,000 ordinary shares. Proposed agenda 1.Opening of the Meeting 2.Election of Chairman of the Meeting 3.Preparation and approval of the voting list 4.Election of one or two persons to verify the minutes 5.Determination whether the Meeting has been duly convened 6.Approval of the agenda 7.Resolutions in connection to a proposed divestment of the Company’s OTC-business:a) Proposal for resolution on approval of the proposed Transactionb) Proposal for resolution on conversion of the Company’s financial year and thereto related amendments of the articles of associationc) Proposal for resolution to instate a new share class, redeemable and convertible series B shares, and thereto related amendments of the articles of associationd) Proposal for resolution regarding authorization for the Board of Directors to issue redeemable and convertible series B shares, with deviation from the shareholders’ pre-emptive rightse) Proposal for resolution regarding authorization for the Board of Directors to issue warrants, with deviation from the shareholders’ pre-emptive rightsf)  Proposal for the appointment of Andrew B. Hochman, the Purchaser’s nominee to the Board of Directors of the Company, conditional upon, and with effect from, closing of the Transaction 8. Closing of the Meeting Proposals for resolution Election of Chairman of the Meeting (Item 2) The Board of Directors proposes to elect the Chairman of the Board of Directors in the Company, Thomas Eklund, as Chairman of the Extraordinary General Meeting. Resolutions in connection to a proposed divestment of the Company’s OTC-business (Item 7) The proposals pursuant to item 7 are conditional upon the Extraordinary General Meeting resolving to approve all proposals under this item. a)       Proposal for resolution on approval of the proposed Transaction (Item 7 a) Background and summary of the Transaction On 12 February 2019, the Company announced that it entered into an agreement (the “SPA”) with a holding company owned by RoundTable Healthcare Partners and Signet Healthcare Partners (the “Purchaser”), relating to the sale and purchase of the entire share capital in the Company’s subsidiary, MPJ OTC AB, and all of the units in Moberg Pharma North America, LLC, pursuant to which the Purchaser shall acquire (the “Acquisition”), subject to the terms and the conditions of the SPA (see below), the Company’s entire global consumer health business comprising both direct and distributor sales under the over-the-counter brands Kerasal®, Kerasal Nail®, New Skin®, Dermoplast®, Domeboro®, Emtrix® and Zanmira®, including all assets and liabilities related to such business (the “OTC-business”) for cash consideration of USD 155 million (subject to working capital adjustments) (the “Purchase Price”). The Company intends to use the net proceeds from the Purchase Price to redeem its outstanding bonds and make a payment to its shareholders. In connection with the Acquisition, the Company will, shortly before the closing of the Acquisition, enter into an asset transfer agreement with MPJ OTC AB, pursuant to which the Company will to transfer certain assets and liabilities (the “Asset Transfer”) which it holds in the OTC-business to MPJ OTC AB. In connection with the Acquisition and the Asset Transfer, the Company will also enter into a transitional services agreement, pursuant to which the Company will provide certain services to MPJ OTC AB with respect to the OTC-business. In addition to the Acquisition, the Purchaser and the Company have entered into: (i) an investment and subscription agreement pursuant to which the Purchaser has agreed to subscribe for, and the Company has agreed to issue and allot newly issued series B shares in the capital of the Company at a subscription price of SEK 35.16 per share, for an aggregate subscription price of USD 2.5 million; (ii) an investment and warrant instrument agreement pursuant to which the Purchaser has agreed to: (A) subscribe for, and the Company has agreed to issue and allot, 659,421 warrants, each of which entitles the holder to subscribe for one new ordinary share in the capital of the Company at a subscription price of SEK 35.16 per share, equalling a total of SEK 23,185,242 upon such warrants being fully exercised; and (B) grant a loan to the Company for an aggregate principal amount of USD 2.5 million, to be advanced to the Company in connection with closing of the Acquisition. In connection with the Acquisition, the Purchaser has obtained the benefit of representations and warranties insurance as the Purchaser’s sole recourse under the SPA in respect of the business warranties given by the Company under the SPA. In the absence of any fraud on the part of the Company, the liability of the Company in respect of such business warranties is limited to USD 1. The transaction as described in this item 7 (the “Transaction”) will enable the Company to further focus resources on the development and commercialization of the Company’s MOB-015 pipeline program and to distribute significant value to its shareholders. Voting Undertakings All of the members of the Board of Directors holding shares in the capital of the Company and certain other shareholders who hold shares in the capital of the Company have given irrevocable undertakings to the Purchaser to vote in favour of the Transaction. The undertakings together are in respect of, in aggregate, 6,836,225 of shares representing approximately 38.6% of the share capital of the Company. Recommendation The Transaction is, inter alia, conditional upon shareholder approval at a general meeting in the Company. Against the background provided in this notice, the Board of Directors of the Company consider the terms of the Transaction to be fair and reasonable and in the best interests of the Company and its shareholders. Accordingly, the Board of Directors unanimously recommend that the Extraordinary General Meeting approves by voting in favour of the Transaction on the main terms set out in this item 7 a), including the consequential proposals to be approved in connection with the Transaction as set out in items 7 b) to f) below. The recommendation by the Board of Directors is supported by a diligent auction process conducted by the Company’s financial advisor Sawaya Partners LLC aimed at providing the Company and the shareholders with the best possible transaction outcome in terms of value and deal certainty, where multiple third party transaction proposals and offers were evaluated, and where this Transaction was compared with similar transactions, of which this Transaction was determined by the Board of Directors to offer the shareholders the best value and highest level of deal certainty. The Board of Directors, accordingly, based on this process, found the current Transaction to be fair and reasonable and in the best interests of the Company and its shareholders. Information in connection to the Board of Director’s proposal At least one week prior to the Extraordinary General Meeting, the Board of Directors will publish an information document containing detailed information on the Transaction and on the Company’s business going forward. Transaction rationale The rationale for the Transaction is mainly to: ·to realize the value the Company has created in developing its OTC-business over the last five years; · provide continued funding to support on-going development of MOB-015; and · allow for the Company and management to be focused on value creating development and commercialization of MOB-015. Conditions for closing of the Transaction The Transaction is conditional on, inter alia: ·the passing at a general meeting in Moberg Pharma of a resolution to approve the contemplated Transaction and any other steps related thereto, passed with the relevant required majority; ·the waiting period (and any extension thereof) applicable to the SPA and the Transaction under the HSR Act (Hart-Scott-Rodino Antitrust Improvements Act) shall have been terminated or shall have expired; ·certain fundamental warranties under the SPA being true, accurate and not misleading on closing of the Transaction; and ·the Purchaser having received debt financing on certain specified terms. Termination Fee If all other conditions are satisfied, but the Purchaser fails to secure debt financing to fund the Transaction and the Company is otherwise able to close on the Transaction, the Purchaser will be liable to pay the Company a termination fee of USD 6 million. Reimbursement of expenses If the Board of Directors of the Company change its recommendation to the shareholders set out in this notice or the shareholders vote against the proposals put forward by the Board of Directors in connection with the Transaction, the Purchaser will be entitled to terminate the SPA and the Company will be obliged to reimburse the Purchaser of any direct external expenses incurred in connection with the Transaction. Purchase price The purchase price for the OTC-business consists of a cash consideration of USD 155 million (subject to working capital adjustment). The purchase price will be paid by the Purchaser on closing. The Company intends to use the remaining part of the Purchase Price net of the Company’s transaction expenses and cash retained for the MOB-015 development program to redeem the Company’s outstanding bonds with a total nominal amount of SEK 600 million at a call premium of 104 % and to make a payment to its shareholders (the “OTC-dividend”). It is the Company’s current estimate that the OTC-dividend is expected to amount to approximately SEK 43–45 per ordinary share in the Company. The definitive OTC-dividend will be announced by the Company through a press release well in advance of the payment to the shareholders of the Company. Investment and subscription undertakings The Purchaser has undertaken to invest in the Company’s remaining business on the closing date or as soon as possible thereafter, through: (i)            subscribing for in an aggregate subscription amount of USD 2.5 million newly issued series B shares at a subscription price of SEK 35.16 per share; (ii)           subscribing for 659,421 warrants without consideration, each of which will give the holder a right to subscribe for one newly issued ordinary share at a subscription price of SEK 35.16 per share; and (iii)             providing a loan with a total nominal amount of maximum USD 2.5 million (the “Loan”). Closing Subject to satisfaction or waiver (as applicable) of the conditions (noted above), closing of the Transaction is planned to take place on 29 March 2019. The SPA may be terminated by either party if closing has not occurred by 10 April 2019. Miscellaneous The Company contemplates to pay the OTC-dividend to its shareholders through a share split and redemption of shares, although the payout procedure is still subject to final decision. The new shares to be subscribed for by the Purchaser on closing, or later though exercising the warrants, will not entitle the holder to the OTC-dividend. In order to pay the OTC-dividend during 2019, it is proposed that the Company’s financial year is converted from calendar year to broken financial year, whereby the last day of the current financial year will be 30 June 2019 (see item 7 b) below). At the Annual General Meeting for the current financial year, 1 January–30 June 2019, the Board of Directors will propose that the Annual General Meeting resolves to make a share split and a redemption of shares and to convert the Company’s financial year from a broken financial year, back to a calendar year. Below is an indicative high-level timetable for the Transaction and payment of the OTC-dividend to the shareholders of the Company. Date: Event:12 Announcement of TransactionFebruary201915 Announcement of notice of Extraordinary General Meeting in theFebruary Swedish Official Gazette201915 March Extraordinary General Meeting2019End of Closing, including that the Purchaser (i) pays the Purchase Price,March 2019 (ii) extends the Loan and (iii) subscribes for the new series B shares and the warrantsNotice of redemption of the Company’s bondsEnd of Redemption of the Company’s bondsApril 201930 June Last day of shortened financial year2019End of Annual general meeting for shortened financial year resolving onSeptember among other things payment of the OTC-dividend to shareholders2019End of Payment of OTC-dividend to shareholdersOctober2019 b)       Proposal for resolution on conversion of the Company’s financial year and thereto related amendments of the articles of association (Item 7 b) The Board of Directors proposes that the Extraordinary General Meeting resolves to convert the Company’s financial year from calendar year to broken financial year, 1 July–30 June. In connection therewith, the Board of Directors proposes that the current financial year is shortened to only cover a period of six months. If the Extraordinary General Meeting resolves in accordance with the Board of Director’s proposal, the last day of the current financial year will be 30 June 2019. In view of the above, the Board of Directors also proposes that the Extraordinary General Meeting resolves to amend the current § 11 of the articles of association, whereby this will receive the following wording: “§13. Financial year The financial year of the company shall be 1/7–30/6.” The articles of association with the proposed new wording are attached in their entirety as Appendix 1 to the Board of Director’s full proposal. c)       Proposal for resolution to instate a new share class, redeemable and convertible series B shares, and thereto related amendments of the articles of association (Item 7 c) The Board of Directors proposes that the Extraordinary General Meeting resolves to introduce a new share class; series B shares. The series B shares shall, under certain conditions as stated in the articles of association, be redeemable at the quota value and convertible into ordinary shares, but shall otherwise have the same rights as the Company’s ordinary shares. In view of the above, the Board of Directors also proposes that the Extraordinary General Meeting resolves to amend the current § 5 of the articles of association and to introduce two new provisions, § 6 and § 7, in the articles of association as follows: “§ 5. Number of shares The number of shares shall amount to no less than 17,000,000 and no more than 68,000,000. Shares may be issued in three series, common shares, shares of series B and shares of series C. Common shares and series B shares may be issued in a maximum number corresponding to not more than 100 % of the total number of shares in the company and series C shares may be issued in a maximum number corresponding to no more than 2 % of the total number of shares in the company. Each common share and series B share entitles the holder to one vote and each series C share entitles the holder to one- tenth of a vote. Series C shares do not entitle to dividends. Series B shares do not entitle to the OTC-dividend (as defined below). Upon the company’s liquidation, series C shares carry an equal right to the company’s assets as common shares, however not to an amount exceeding the share’s quotient value. If the Company decides to issue new common shares, series B shares and series C shares through a cash issue or an issue against payment trough set-off claims, each owner of common shares, series B shares and series C shares shall have a pre-emptive right to subscribe for new shares of the same series in proportion to their existing shareholdings (primary pre-emptive rights). Shares not subscribed trough primary pre-emptive rights shall be offered to all shareholders for subscription (subsidiary pre-emptive rights). Should the number of shares offered not be enough for subscription through subsidiary pre-emptive rights, the said shares shall be apportioned among the subscribers in proportion to their existing shareholdings and, to the extent that this cannot be done, by lottery. If the Company decides through a cash issue or a set-off issue to only offer common shares, series B shares or series C shares, shall all shareholders, regardless of whether their shares are common shares, series B shares or series C shares, have right to subscribe for new shares in proportion to their existing shareholdings. The above shall not constitute any restriction on the possibility to decide on a cash issue or a set-off issue, deviating from the pre-emptive rights of the shareholders. What is stated above about the shareholders’ pre-emptive rights shall apply mutatis mutandis for new issues of warrants and convertibles not made against contribution in kind. If the share capital is increased through a bonus issue, new shares in each series shall be issued in proportion to the existing number of shares in each series. Old shares in a specific series shall thus carry entitlement to new shares in the same series. The aforesaid shall not constitute any restriction on the possibility to issue new shares of a new series through a bonus issue, following the requisite amendments to the Articles of Association. § 6 Redemption provision In case of a share split, whereby each share in the company is split into two (2:1) in order to carry out the OTC-dividend (as defined below), the Board of Directors may resolve on a reduction of the share capital by redemption of half of all series B shares existing after the split, in which case in relation to the shareholders, redemption shall be made in proportion to the number of series B shares held (each redeemed share, a “redemption share”). In case of a resolution on redemption, holders of series B shares shall be obliged to have all their redemption shares redeemed against an amount corresponding to the quota value. Payment of the redemption amount shall be made as soon as possible. The “OTC-dividend” means the dividend that exceeds the previous year's dividend with more than 30 per cent. to be made by the company, corresponding to part of the cash consideration to be paid by the purchaser to the company in connection with the divestment announced by the company on 12 February 2019, and which may include a formal dividend distribution, share split and redemption of split shares, reduction of the share capital or similar events. The Board of Directors may resolve on reduction of the share capital by redemption of all series C shares. In case of a resolution on redemption, holders of series C shares shall be obliged to redeem all series C shares against a redemption amount corresponding to the share’s quotient value. Payment of the redemption amount shall be made as soon as possible. § 7 Conversion provision After share split and redemption of redemption shares referred to in § 6, first paragraph, or after the payment of the OTC-dividend or no later than 30 June 2020, series B shares shall automatically be converted (reclassified) into common shares. The Board of Directors shall without delay report the reclassification to the Swedish Companies Registration Office for registration. The reclassification will enter into effect as soon as the registration is completed and it has been noted in the securities depository register. Series C shares held by the company itself may, upon request by the Board of Directors, be converted (reclassified) into common shares. Immediately thereafter, the Board of Directors shall report the reclassification to the Swedish Companies Registration Office (Sw. Bolagsverket) for registration. The reclassification is effected when it has been registered in the Swedish Register of Companies and the reclassification been noted in the Swedish Central Securities Depository Register.” The articles of association with the proposed new wording are attached in their entirety as Appendix 1 to the Board of Director’s full proposal. d)       Proposal for resolution regarding authorization for the Board of Directors to issue redeemable and convertible series B shares, with deviation from the shareholders’ pre-emptive rights (Item 7 d) In order to secure delivery of newly issued series B shares to the Purchaser in accordance with the executed transaction agreements, the Board of Directors proposes that the Extraordinary General Meeting resolves to authorize the Board of Directors to, on one or several occasions during the period until the next Annual General Meeting, resolve to issue new redeemable and convertible series B shares, with deviation from the shareholders’ pre-emptive rights. The issue shall be effected on the following terms. ·The subscription price to be paid for each new share shall be SEK 35.16. The subscription price is deemed to correspond to the market value of the share. The total subscription price shall be the amount in SEK corresponding to USD 2.5 million, by applying the exchange rate reported by Bloomberg one business day prior to issuance of the new shares (the “Total Subscription Price”). ·The number of series B shares that may be issued may amount to no more than the number obtained through dividing the Total Subscription Price by a subscription price per share of SEK 35.16. ·An increase of the Company’s share capital with no more than an amount corresponding to the maximum number of new series B shares calculated in accordance with the above, multiplied by the quota value of the shares. ·The new shares shall - with deviation from the shareholders’ pre-emptive rights - be subscribed for only by an external party who has been informed in advance.The reason for deviating from the shareholders' pre-emptive rights is to promote the Company’s long-term interests by offering the Purchaser the opportunity to become a shareholder in the Company and thereby secure financing of the Company’s continuing operations. ·The new shares shall be subscribed for at the latest on 10 April 2019, with a right for the Board of Directors to extend the subscription period. Oversubscription is not permitted. ·Payment for shares subscribed for shall be effected at subscription of the shares. · The new shares shall be entitled to dividends for the first time on the record date occurring after the registration of the new shares with the Swedish Companies Registration Office and entry into the shareholder register kept by Euroclear.[1] · The new series B shares will be subject to restrictions as set forth in Chapter 4, Section 6 (conversion provision) and Chapter 20, Section 31 (redemption provision) of the Swedish Companies Act (SFS 2005:551). The Board of Directors, Chief Executive Officer or such person as the Board of Directors authorize, shall be authorized to carry out amendments and clarifications of the Extraordinary General Meeting’s decisions that are required in connection with the filing with the Companies Registration Office and Euroclear. e)       Proposal for resolution regarding authorization for the Board of Directors to issue warrants, with deviation from the shareholders’ pre-emptive rights (Item 7 e) In order to secure delivery of warrants to the Purchaser in accordance with the executed transaction agreements, the Board of Directors proposes that the Extraordinary General Meeting resolves to authorize the Board of Directors to, on one or several occasions during the period until the next Annual General Meeting, resolve to issue warrants, with deviation from the shareholders’ pre-emptive rights. The issue shall be effected on the following terms. ·The number of warrants that may be issued may amount to no more than 659,421 warrants. ·The warrants shall not be issued against payment. ·Each warrant shall entitle to subscription for one ordinary share in the Company, against a price of SEK 35.16 per share. Payment for the shares shall be made in cash or by way of set-off. ·The warrants shall - with deviation from the shareholders’ pre-emptive rights - be subscribed for only by an external party who has been informed in advance.The reason for deviating from the shareholders' pre-emptive rights is to promote the Company’s long-term interests by offering the Purchaser the opportunity to become a shareholder in the Company and thereby secure financing of the Company’s continuing operations. ·In case all of the warrants are exercised, the Company’s share capital will increase by SEK 65,942.10. ·The warrants shall be subscribed for at the latest on 10 April 2019, with a right for the Board of Directors to extend the subscription period. Oversubscription is not permitted. ·Subscription for shares by exercising the warrants may be made during the period from and including the date when the warrants have been registered with the Companies Registration Office, the Purchaser has advanced the Loan to the Company and the OTC-dividend has been paid up to and including 31 March 2023. ·The new shares subscribed for by exercising the warrants shall be entitled to dividends for the first time on the record date occurring after the registration of the new shares with the Swedish Companies Registration Office and entry into the shareholder register kept by Euroclear. ·Customary recalculation provisions shall apply to the warrants. The Board of Directors, Chief Executive Officer or such person as the Board of Directors authorize, shall be authorized to carry out amendments and clarifications of the Extraordinary General Meeting’s decisions that are required in connection with the filing with the Companies Registration Office and Euroclear. f)        Proposal for the appointment of Andrew B. Hochman, the Purchaser’s nominee to the Board of Directors of the Company, conditional upon, and with effect from, closing of the Transaction (Item 7 f) The Board of Directors proposes that the Board of Directors shall have six (6) members. The Board of Directors proposes that the Purchaser’s nominee, Andrew B. Hochman, is appointed as new member of the Board of Directors for a period from and including the day when closing of the Transaction has occurred, until the end of the next Annual General Meeting. Born 31 March 1979, Andrew B. Hochman has more than 16 years of experience in pharmaceutical and consumer healthcare investments and is currently a partner at RoundTable Healthcare Partners, where he is involved in all aspects of the transaction process, including deal sourcing, transaction structuring, valuation, due diligence, negotiations, financing, and execution. He joined RoundTable in 2007 from Graceway Pharmaceuticals, where he served as Vice President of Business Development, and prior to that was an associate at GTCR Golder Rauner and an analyst at William Blair & Company. He earned Bachelor degrees in Economics from the Wharton School and in Psychology from the University of Pennsylvania. He serves as a board member of Santa Cruz Nutritionals, Revision Skincare/Goodier Cosmetics, and Deerland Probiotics & Enzymes, and previously served as a board member of Aqua Pharmaceuticals. Majority requirements A valid resolution in accordance with the Board of Director’s proposals under items 7 a), and 7 f) above requires a simple majority among the votes cast. A valid resolution in accordance with the Board of Director’s proposals under items 7 b), 7 c), 7 d) and 7 e) above requires that shareholders representing not less than two-thirds of the votes cast as well as of the shares represented at the meeting approve the resolution. Shares held by the Company may not be represented in the Extraordinary General Meeting. Information at the Extraordinary General Meeting Shareholders may request that the Board of Directors and the Chief Executive Officer provide information regarding circumstances that may affect the assessment of an item on the agenda for the Extraordinary General Meeting, and circumstances that can affect the assessment of the Company’s financial position. The Board of Directors and the Chief Executive Officer shall provide such information at the Extraordinary General Meeting if they believe that it can be done without material harm to the Company. Shareholders wishing to submit questions in advance may send them to Moberg Pharma AB (publ), att. Malin Nilsson, Gustavslundsvägen 42, 5 tr, 167 51 Bromma, Sweden, or by e- mail to malin.nilsson@mobergpharma.se. Documents Forms of power of attorney will be available for shareholders at the Company and on the Company’s website www.mobergpharma.se, at the latest on Friday, February 15, 2019. Documents according to the Companies Act will be available for shareholders at the Company and on the Company’s website as above, no later than three weeks before the Extraordinary General Meeting. All of these documents will also, without charge, be sent to shareholders who so request and state their address. The documents will also be available at the Extraordinary General Meeting. Processing of personal data For information on how your personal data is processed, see the integrity policy that is available at Euroclear’s webpage, www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf. __________________________________________________ Stockholm in February 2019Moberg Pharma AB (publ)The Board of Directors The information was submitted for publication at 9.45 a.m. (CET) on 13 February 2019. ---------------------------------------------------------------------- [1] The new shares will, however, not entitle to the OTC-dividend.

Nustay receives approval for listing and publishes prospectus

Press release, Nustay A/S: About the upcoming new share issue and listing at Spotlight Stock Market: During 2019 and forward, Nustay’s revenue is expected to increase significantly as more budget is allocated towards online performance marketing activities. Furthermore, Nustay aims to launch a new customer loyalty program, a mobile app, and to launch additional hotels and holiday homes on its platform. Nustay’s platform is already globally scalable and highly customizable with localized content using cutting-edge frontend- and backend technologies. An increasing handled revenue continuously strengthens the company’s own cash reserves, as the company will have the customers’ advance payments in hand until the suppliers are paid. This reduces the need for additional external funding and provides more financial resources for additional marketing. When the net revenue exceeds the company’s marketing spend, which is possible through a large-enough handled revenue, Nustay will reach positive marketing contribution. The Board assesses that this will occur during 2020. In order to add capital, Nustay has decided to raise approximately DKK 21.3 million before issue costs, prior to a planned listing on Spotlight Stock Market. The capital that Nustay is provided with through the new issue is primarily intended to finance marketing of the company’s hotel booking platform to facilitate Nustay’s continued growth. The new share issue is also intended to finance other operating expenses and provide a spread in ownership to build a wide base of ambassadors and potential new customers. Nustay has been approved for listing at Spotlight Stock Market. The approval is given under the condition that the company raises the minimum limit of approximately DKK 13.9 million and that the company obtains a sufficient number of shareholders in accordance with Spotlight Stock Market’s listing agreement. The first day of trading on Spotlight is planned to be the 22nd of March 2019. Investor meetings In connection with the IPO, Nustay will present the business and future plans at a number of investor events. See schedule below for details. Participation at the investor events is free of charge. Date and Event Place RegistrationtimeFebruary Investor Nordnet Registration is made at19, meeting in BankHavneholmen www.sedermera.se February Investor Scandic Registration is made at21, meeting in Klara,Slöjdgatan www.sedermera.se February Webinar in The webinar will No registration25, Helsinki be broadcast beforehand is necessary201917:00 together with online– Nordnet at Sedermera’s and18.00 Nordnet’s websites  February Investor Nordnet Registration is made at26, breakfast in BankAkersgata www.sedermera.se February Webinar in The webinar will No registration27, Copenhagen be broadcast beforehand is necessary201916:00 together with online– Nordnet at Sedermera’s and16.45 Nordnet’s websites Offering in summary · Subscription period: February 14th – March 5th, 2019. · Subscription price: DKK 7,20 per share. · Subscription post: The minimum subscription is 500 shares, corresponding to 3 600 DKK. · Issue volume and minimum limit for implementation: The offer comprises a maximum of 2 962 777 shares, equivalent to approx. DKK 21,3 million. The minimum limit for the new share issue’s implementation is approx. DKK 13,9 million, approx. 65% of the total issue volume. · Number of shares before new share issue: 15 257 888 shares. · Valuation (pre-money): Approximately DKK 110 million, corresponding to approximately SEK 151 million. · Subscription commitments: The Company has received subscription commitments of approximately DKK 12 million, a total of approximately 56 percent of the issue volume. · Listing on Spotlight Stock Market: The share in Nustay is planned to be listed on Spotlight. The trading is planned to commence on March 22nd, 2019. Financial advisor, legal advisor and Selling Agent Sedermera Fondkommission is acting as financial advisor and issuing agency to Nustay in connection with the IPO and the planned listing at Spotlight Stock Market. Legal advisor is Markets & Corporate Law. Nordnet Bank AB will act as nordic Selling Agent in the IPO. For further information about the IPO and the listing, please contact: Sedermera Fondkommission Telephone: +46 (0) 40-615 14 10 E-mail: info@sedermera.se Website: www.sedermera.se For further information about Nustay, please contact:         Mathias Lundoe Nielsen, Founder and CEO, Nustay A/S Telephone: +45 22 91 94 99 E-mail: mln@nustay.com Website: www.nustay.com About Nustay Nustay is a Danish company within the hotel booking market that offers its customers a new booking concept. Nustay has a vision of becoming the best and most disruptively innovative hotel booking platform in the world. The company’s innovative and advanced hotel booking platform has been under development since 2014 and is today online, active and has proven its ability to handle customers all over the globe. Nustay is an Online Travel Agency that delivers personalised hotel deals for each registered user depending on the preferences of the user and the type of stay. Nustay differs itself from its competitors – current OTA market actors such as Booking.com and Hotels.com – by combining the best and most important aspects of existing online booking – a large hotel inventory, a great booking experience and lower prices than its competitors. Click HERE  for direct link to prospectus. - Nustay A/S, 13/02/19

Financial Report October - December 2018

Financial Summary - Q4'18• Consolidated Net Sales $535 million• Net Sales growth (10)%, Organic Sales* growth (9)%• Active Safety Sales growth 1%, Organic Sales* growth 3%• Operating Margin (14)% 2019 Outlook  • Light vehicle production slightly down as compared to 2018• Organic Sales* are expected to be flat to decline slightly versus 2018• Currency translation impact on sales ~(2)% versus 2018• Operating margin weaker during H1'19, with improvement in H2'19 Business Highlights • FY'18 record order intake for Veoneer was more than $1.2 billion average annual sales, estimated lifetime order value ~$5.9 billion• FY'18 record order intake for Active Safety close to $900 million average annual sales, estimated lifetime order value ~$3.8 billion• Awarded a significant LiDAR contract with a major global OEM for an autonomous vehicle application• Hired ~350 engineers in RD&E during the fourth quarter and ~1,100 during FY'18 to prepare for future organic sales* growth• Organization refinement in combination with our market adjustment initiatives is expected to deliver efficiencies, agility and stronger customer engagement Key FiguresFor Key Figures summary table, please refer to attached file below.    Comments from Jan Carlson, Chairman, President and CEO The environment around us is rapidly changing and we currently see a shift across the automotive and autotech industries. New technologies, creating new levels of interaction and driver support are starting to revolutionize driving, but we also see the driver being actively involved for years to come. We call this Collaborative Driving; the industry also calls it “Level 2+” driver support. At the same time there is also a growing realization that the introduction of truly self-driving cars will likely take longer and be more expensive than previously anticipated. This fundamental insight opens up new opportunities for companies, including Veoneer, but it also requires a reprioritization of resources. In the near term there is also an increased uncertainty regarding the development of global light vehicle production (LVP). During the fourth quarter of 2018 we saw a sharp decline in the LVP in China and Western Europe and we anticipate that these markets will continue to show weakness in the first half of this year. We expect the situation to improve in the second half, but we currently expect a slight decline in the global LVP for the full year 2019. In response to the larger role in the market for Collaborative Driving, the expected delay of self-driving, and the weaker LVP trend, we are actively reviewing our investment priorities and the focus of our product portfolio. Our purpose is to identify the most effective way to allocate talent and capital to meet these new market realities. In December we refined our organization to create a more agile and focused company, and during 2019 we expect our renewed organization, combined with other initiatives, to gradually start delivering efficiency gains and stronger customer engagement. We expect the combined effects of a stronger LVP and new program launches in the second half of the year combined with our own efficiency and prioritization initiatives to start to lead to improved cash-flow in the latter part of the year. Assuming successful execution of these initiatives, we expect our net cash to cover our funding requirements until the Company reaches positive cash flow. However, additional funding may be required if order intake increases beyond our expectations, if the underlying near-term business conditions deteriorate further, or if we make acquisitions. We build our 2019 plan on a strong base. In 2018, our order intake grew strongly to a record lifetime order value of close to $6 billion. Active Safety orders almost doubled, and we expanded our Active Safety customer base from 9 to 12 car manufacturers. From a product perspective, I am particularly pleased with the strong market and customer reception of our vision products based on Veoneer’s internally developed software algorithms and the fact that we won our first major commercial LiDAR order with a global OEM. We move forward in 2019 with a strong focus on capturing the opportunities in a new industry situation. By balancing growth, cost, and effective capital allocation we are building a focused, industry leading product portfolio, all with the objective to make Veoneer the leading company in our chosen business segments. An earnings conference call will be held today, February 13, 2019 at 14:00 CET. To follow the webcast or to obtain the phone number/pin code, please see www.veoneer.com. The slide deck will be available on our website prior to the earnings conference call. See also the Non-U.S. GAAP Financial Measures section on page 10 of this earnings release for further disclosures.  *For these non-U.S. GAAP financial measures, and any others marked with an “*” throughout this earnings release, see the reconciliation tables in this earnings release, including the Non-U.S. GAAP Financial Measures section on page 10. See the Non-U.S. GAAP Financial Measures section for further discussion of the forward-looking organic sales non-U.S. GAAP financial measure. Contacts:Thomas Jonsson - EVP Communications & IR, +46 8 527 762 27 or Thomas.jonsson@veoneer.com and Ray Pekar - VP Investor Relations,+1 248 794 4537 or ray.pekar@veoneer.com. This report is information that Veoneer, Inc. is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the EVP Communications and IR set out above, at 12:00 CET on Wednesday February 13, 2019. Inquiries - Corporate website www.veoneer.com.

Stora Enso issues its first Green Bonds

THIS ANNOUNCEMENT IS NOT BEING MADE IN, AND COPIES OF IT MAY NOT BE DISTRIBUTED OR SENT INTO, THE UNITED STATES, THE UNITED KINGDOM OR JAPAN. Stora Enso has today successfully issued its first Green Bonds. The bonds are issued under its EMTN (Euro Medium Term Note) programme. The total aggregated principal amount of the transaction is SEK 6 000 million. The bonds are issued under Stora Enso’s Green Bond framework  published in May 2018. The bonds have three tranches as follows: 1)  SEK 3 000 million matures in August 2021 and pays a floating coupon of STIBOR +0.85%. 2)  SEK 1 250 million matures in February 2024 and pays a floating coupon of STIBOR +1.45%. 3)  SEK 1 750 million matures in February 2024 and pays a fixed coupon of 1.875%. The issue price is 100, and is equal to SEK-swap +145 basis points. There are no financial covenants for the bonds. The bonds will be listed on the Luxembourg Stock Exchange. The bookrunners for the transactions were DnB, Nordea, and SEB. “Stora Enso has the long-term aim to secure funding partners that have sustainability as a fundamental part of their agenda. We are very pleased to successfully issue our first Green Bonds. The proceeds are intended entirely to finance our ongoing acquisition of forest assets in Bergvik Skog. This is fully in line with our Green Bond Framework, as Bergvik Skog’s forest lands are 100% certified to sustainable forestry,” says SVP Group Treasurer Pasi Kyckling. “This successful Green Bond is further evidence that our Sustainability Agenda underpins core business processes, such as the raising of new finance to grow our share of the bioeconomy,” says Noel Morrin, EVP Sustainability. More information about our Green Bonds is available at storaenso.com/greenbonds . For further information, please contact: Pasi KycklingSVP, Group Treasurertel. +358 40 820 6902 Investor enquiries: Ulla PaajanenSVP, Investor Relationstel. +358 40 763 8767 Part of the bioeconomy, Stora Enso is a leading global provider of renewable solutions in packaging, biomaterials, wooden constructions and paper. We believe that everything that is made from fossil-based materials today can be made from a tree tomorrow. Stora Enso has some 26 000 employees in over 30 countries. Our sales in 2018 were EUR 10.5 billion. Stora Enso shares are listed on Nasdaq Helsinki (STEAV, STERV) and Nasdaq Stockholm (STE A, STE R). In addition, the shares are traded in the USA as ADRs (SEOAY). storaenso.com   STORA ENSO OYJ IMPORTANT NOTICE This announcement is not being made in and copies of it may not be distributed or sent into the United States, the United Kingdom or Japan. The information contained herein does not constitute an offer to sell or the solicitation of an offer to buy the securities referred to herein. There shall be no offer, solicitation or sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Stora Enso Oyj does not intend to register any of the securities in the United States or to conduct a public offering of the securities in the United States. This communication does not constitute an offer of the securities to the public in the United Kingdom. No prospectus has been or will be approved in the United Kingdom in respect of the securities. This communication is being distributed to and is directed only at (i) persons who are outside the United Kingdom or (ii) persons who are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “Relevant Persons”). Any investment activity to which this communication relates will only be available to and will only be engaged with, Relevant Persons. Any person who is not a Relevant Person should not act or rely on this document or any of its contents. MiFID II professionals/ECPs-only – Manufacturer target market (MIFID II product governance) is eligible counterparties and professional clients only (all distribution channels).

Fazer in 2018: strong focus on implementing the new strategy

Financial year 2018 in brief · Net sales were 1,618.2 million euros (1,641.6) · Operating profit was 84.2 million euros (92.1) · Cash flow from operating activities was 114.6 million euros (149.6) and gross investments amounted to 50.5 million euros (108.0) · The first year of implementing Fazer’s new strategy · The Fazer brand was renewed to support the ongoing transformation to a modern sustainable food company Outlook for 2019 Fazer will continue its transformation, with strong focus on execution. Development of Fazer’s business and product portfolios will remain key cornerstones in implementing the strategy, along with the renewed Fazer brand and several growth initiatives. In addition to organic growth, active M&A work will continue to further strengthen growth and internationalisation. Fazer will also continue to work on strengthening its competitiveness through its value creation programmes and the continuous development of its organisational and structural efficiency. In 2019, the net sales and the operating profit are expected to increase compared to previous year. Christoph Vitzthum, President & CEO of Fazer Group summarises:  “In 2018, we began implementing our new strategy to become a modern sustainable food company. We are heading towards our joint strategic goal backed by a strengthened consumer focus and a renewed Fazer brand positioning. We emphasize value creation through portfolio choices, continued operational excellence and structural improvements. With our renewed purpose driven Fazer brand, we will ensure that Fazer will be meaningfully different in the eyes of the consumer also in the future. Northern Magic. Made Real. is unique and forward-looking; it is an ambitious promise that builds on our heritage and reaches out into the future, enabling Fazer’s ambition of strong expansion in Northern Europe and beyond. How we grow, produce and consume food has a significant impact on the environment, on society and on our well-being. To take a stronger stand and to deliver concrete actions, we defined a new sustainability approach. It is aligned with Fazer’s mission, strategy and the renewed Fazer brand. The new sustainability approach consists of four core goals: 1) 50% less emissions, 2) 50% less food waste, 3) 100% sustainably sourced, and 4) more plant-based. Financially, our operating result fell behind previous year even if the net sales were at 2017 levels. All of Fazer’s main foreign currencies weakened against the euro, which affected Fazer’s financial performance negatively. Unfortunately, consumers’ weakening purchasing power had a negative effect on the business performance of Fazer Bakery in Russia. Fazer Bakery Sweden did not perform according to plan, but some improvement was seen towards the end of the year.   People’s criteria for making choices have changed. We as a company are expected to understand what people want before they’ve even asked for it. At Fazer, we aim high and dare to think big. We have grown stronger as a company and the market sees us in a new light – as being more progressive and forward-looking. We continue to concentrate on delivering our strategy, with an emphasis of future proofing for a digitalised world, high performance and our safety culture. Fazer is well equipped to strengthen its positions on its home markets and to grow in Northern Europe and beyond.” For further information please contact: Jouni Grönroos, CFO & Deputy CEO, Fazer Group, jouni.gronroos@fazer.com, tel. +358 40 504 5125 Ulrika Romantschuk, Executive Vice President, Communications & Branding, Fazer Group, ulrika.romantschuk@fazer.com, tel. +358 40 566 4246 Fazer’s media phone line is open Mon–Fri from 8:00 to 16:00, tel. +358 40 668 2998 Fazer Group In 1891, the young Karl Fazer opened his first café with a mission to make food with a purpose – and a passion to create moments of joy for all the people around him. It became Northern Magic. Made Real. Today, Fazer is an international family-owned company offering quality bakery, confectionery, biscuit and grain products, plant-based meals, non-dairy products, on-the-go food & drinks as well as food and café services. The Group operates in eight countries and exports to around 40 countries. The success of Fazer has been built on Karl Fazer’s vision, values and fearless creativity: the best product and service quality, beloved brands, the passion of skilful people and responsible ways of working. In 2018, Fazer Group had net sales of 1.6 billion euros and more than 15,000 employees. Fazer’s operations comply with ethical principles that are based on the Group’s values and the UN Global Compact. Northern Magic. Made Real.   Full year report 2018 In 2018, Fazer commenced the implementation of its new strategy to transform into a modern sustainable food company with a joint direction. While the economies in Fazer’s key markets continued to develop favourably, the competitive landscape became tougher for all the businesses. Also, the extraordinarily hot summer affected Fazer’s businesses. In addition, the weak performance in Fazer Bakery Russia and Sweden and the weakening of all Fazer’s main foreign currencies had a negative impact on the 2018 financials. As a result, Fazer Group’s net sales and operating profit decreased from the previous year. In 2018, Fazer’s brand positioning was redefined to amplify the consumer-centric approach. At the start of 2018, Fazer Retail was established as a separate business unit to strengthen the direct-to-consumer business. Also, the organisational setup for Fazer Lifestyle Foods was further developed. Focus on efficiency improvements continued with initiatives in several fields. Occupational safety and developing Fazer’s safety culture remained an important theme with positive results. Markets, business environment and sales In 2018, the economies in Fazer’s key markets continued to develop favourably. On the other hand, all of Fazer’s main foreign currencies weakened against the euro, and affected Fazer´s financial performance negatively. The largest foreign currency impact on Fazer came from the Swedish krona, which weakened by 6% against the euro. Year 2018 was a challenging year for Fazer Bakery Russia and Sweden. At the same time, the performance in Finland reached record levels and business in the Baltics developed positively: in these markets Fazer’s market share also increased. Artisanal bread maintained its popularity, especially in Finland and Sweden. Bread consumption in Russia shifted towards lower-priced segments. The extraordinarily hot summer affected bread consumption in all markets. Fazer Bakery’s net sales decreased to 552.3 M€ (2017: 583.2 excluding net sales of Bakery Shops transferred to Fazer Retail and net sales of Alku porridges transferred to Fazer Lifestyle Foods). Programmes are in place to turn the development and to increase operational efficiency in all Fazer Bakery operations. Fazer Confectionery’s net sales for 2018 reached 333.1 M€ (2017: 331.2). The market share in chocolate tablets increased and biscuit sales grew in Finland. In Sweden, Fazer kept its confectionary market share. Fazer Candy Store was opened to serve consumers online. Currently, the web store ships to EU countries only but the geographical expansion is being planned. Cooperation was started with JD.com to explore opportunities in the Chinese market. Fazer Food Services with more than 1 000 restaurants in Finland, Sweden, Norway and Denmark reached net sales of 593.2 M€ (607.7). With comparable currency rates the net sales were at previous year level. Retention of existing contracts was on a good level while some unprofitable contracts were exited. Actions to improve performance were initiated and they will continue further into 2019 to strengthen the competitiveness of the business. Fazer’s Culinary Teams from Sweden and Finland took a double victory at the culinary World Championships in Luxembourg in November.  The competition tightened in the smoothie and non-dairy markets, with both branded and large private label competitors vying for market share. Fazer Lifestyle Foods’ net sales increased 21% and amounted 121.8 M€ (100.4). Several new products were launched during the year. The Froosh smoothie range was complemented with functional smoothies. Cereals and organic porridges were launched under the Fazer Alku breakfast food brand. The Fazer Yosa oat product family was expanded with eight products and the brand was refreshed with, for example, a new packaging design. Oat-based products have sparked global interest and Nordic oats are highly regarded around the world. Significant investments were made in Fazer Lifestyle Foods’ organisational development and marketing activities to ensure future growth. Fazer Retail was established as a separate business unit at the start of 2018 to strengthen Fazer’s direct-to-consumer business. The business unit combines the Gateau bakery shops in Finland and Sweden with Fazer Cafés in Finland. The new business unit combines artisanal bakery products and high-quality delicacies with a first-class experience. In 2018, the focus was on building an organisation and operating platform for future growth and for expanding its retail expertise. The net sales of the new business unit reached 46.4 M€ during its first year of operation. The Fazer Experience Visitor Centre was visited by more than 200,000 people in 2018, which is a new record. Financial results Fazer’s reported net sales decreased by 1% from previous year and reached 1,618.2 M€ (1,641.6). The weakened foreign exchange rates reduced the net sales by 48.6 M€.  The businesses acquired in 2017 increased 2018 net sales by 18.8 M€ compared to previous year. The Group’s operating profit decreased to 84.2 M€ (92.1). Operating profit included 4.2 M€ (3.5) one-time restructuring costs and write-offs (net). Profit for the financial period amounted to 63.9 M€ (72.1). Fazer Confectionery was the only business area that improved its profitability. Cash flow and financial position The Group’s financial position remained strong. Interest-bearing net debt totalled 95.0 M€ (79.0). The Group’s equity ratio was 56.8% (55.1%). Cash flow from operating activities was 114.6 M€ (149.6) and gross investments amounted to 50.5 M€ (108.0). The majority of the investments were done in new production equipment and upgrades to the existing machinery in the bakery and confectionery operations. Key figures                                       2018                        2017                           2016 Net sales, M€                                1,618.2                    1,641.6                        1,603.1 Operating profit, M€                           84.2                        92.1                              90.1 − share of net sales, %                        5.2                          5.6                                5.6 Return on equity, %                            11.6                        13.3                              14.1 Equity ratio, %                                    56.8                        55.1                              54.2 Gearing, %                                         17.5                        14.2                              10.8 Personnel At year-end, Fazer had 15,696 employees (15,993). Out of these, 91 (68) were employed by the parent company. Personnel                                             2018                      2017                     2016 Number of employees, 31.12.             15,696                   15,993                  16,048 Number of employees, avg. FTE        13,242                    13,198                 13,287 Wages and salaries, M€                       423.7                      433.3                   422.2 Strategy implementation In 2018, Fazer began to implement its new strategy, with the aim to become a leading modern, sustainable food company in Northern Europe and beyond. With this strategic goal in mind, Fazer strengthened its focus on the consumer and updated the Fazer brand positioning. Fazer targets growth and value creation through portfolio choices, continued operational excellence and structural improvements. Despite 2018 having been a challenging year, Fazer is committed to improve its performance in all its businesses and geographies. Implementation of Fazer’s new strategy included in 2018 a large number of value creation initiatives in different businesses and Group functions, building the organisation and capabilities for growth in the new Fazer Lifestyle Foods business area, creating the new Fazer Retail business unit, establishing a distribution company for Fazer Confectionary in the USA as well as planning and developing other means for profitability, growth and geographical expansion.   Quality, environment, occupational health & safety and food safety In 2018, the focus in quality, environment, health and safety (QEHS) was on the development and digitalisation of the related management system, ensuring compliance with regulations, improving competences, strengthening risk management and promoting safety leadership. New ways of communication and leadership activities continued to improve occupational health and safety. Management safety walks, safety reviews, safety commitments and other safety practises are part of the daily operations. Accident frequency fell by 17% from 2017. All businesses have safety plans in place. Fazer continued to improve its quality and food safety management in many ways. In addition to the new digital QEHS system taken into use, the programme to certify all production sites against a global food safety system was continued, and allergen management was developed. Fazer has certified all its production sites against the Global Food Safety System (FSSC 22000). In addition to this, also other QEHS management systems have been certified depending on the demands of the markets and customers. Fazer Food Services’ HACCP (preventative food safety) process was digitalised and harmonised across the Nordics. In 2018, there were no product recalls. Fazer’s environmental management continued to improve through internal programmes and 3rd party certifications. Fazer continued to engage in energy efficiency activities, conducting energy efficiency mappings and self-assessments. Waste reduction actions across the Group were carried out, focusing on preventing food waste and recycling side streams. Fazer was the first food industry company to make a Finnish water stewardship commitment. Sustainability In 2018, Fazer revised and updated its sustainability approach to support the transformation into a leading, modern and sustainable food company with a joint direction. Fazer’s ambitious direction towards 2030 consists of four core goals that support reaching the UN sustainable development goals through food. The core goals are: 1) 50% less emissions, 2) 50% less food waste, 3) 100% sustainably sourced and 4) more plant based. The highlights of Fazer’s sustainability work for 2018 include systematic work to improve energy efficiency to reduce climate emissions and continuing to focus on food waste reduction. Fazer continued its commitments concerning the sustainable sourcing of cocoa, grain, soy, palm oil and fish, and increase of its offering of plant-based foods. Fazer’s reputation remained on a good level in its main markets. Risk management Fazer regularly evaluates and analyses the Group's strategic, operative and financial risks within the framework of its risk management policy and takes action to mitigate these risks. In 2018, no major risks were realised. Research and development Fazer continued to execute the Fazer Brainhow programme, which focuses on the connection between food and cognitive performance. Two clinical trials were successfully finalised in 2018. The BRAVE study, a cooperative project with Nokia and Nightingale Health investigating the effects of brain-friendly food on cognitive functions, physiology and blood biomarkers, showed very promising results that will be published in 2019. Fazer Lifestyle Foods’ technology and new product development work resulted in the launch of the new non-dairy oat products under the Fazer Yosa brand. The Fazer LOFO improver, which is a result of long-term R&D work, was presented at the international bakery exhibition (IBA) in Munich. This patented improver is the world’s first enzyme-based solution to reducing the amount of FODMAP compounds in bread making the bread more belly-friendly. Fazer’s cooperation with universities and researchers continued and resulted in the publication of one doctoral dissertation and multiple master thesis works. Research and development costs amounted to 9.8 M€ (9.9). Changes in Group legal structure Fazer continued its work to simplify its legal structure and several legal entities were merged in 2018. Board of Directors and auditors At the Shareholders’ Meeting on 10 April 2018, the following Board members were re-elected: Berndt Brunow (Chairman), Anders Dreijer (Vice Chairman), Klaus Cawén, Ketil Eriksen, Jan Fazer, Leif Hagelstam, Johan Linder, Cecilia Marlow and Juhani Mäkinen. Chartered Accountants PricewaterhouseCoopers were chosen as auditors, with Chartered Accountant Martin Grandell as auditor-in-charge. Outlook for 2019 GDP growth in most of Fazer’s main markets is expected to continue, but to slow down in 2019. The competitive environment is expected to remain tough for all Fazer’s businesses. Fazer will continue its transformation, with strong focus on execution. Development of Fazer’s business and product portfolios will remain key cornerstones in implementing the strategy, along with the renewed Fazer brand and several growth initiatives. In addition to organic growth, active M&A work will continue to further strengthen growth and internationalisation. Fazer will also continue to work on strengthening its competitiveness through its value creation programmes and the continuous development of its organisational and structural efficiency. In 2019, the net sales and the operating profit are expected to increase compared to previous year.

Q-FREE - FOURTH QUARTER AND PRELIMINARY FULL YEAR RESULTS 2018

Performance in the fourth quarter of 2018 adjusted for one-off expenses related to the close-down of Jakarta was solid. The company delivered an EBITDA margin before non-recurring items of 9 percent, high order intake, and positive cash flow from operations. Highlights for Q4-18 include: * 241 MNOK in revenues, down 9% YoY as strong growth (32%) in non-tolling segments partly compensated for lower project revenues in tolling * 22 MNOK in adjusted EBITDA (9% margin) compared to 40 MNOK in Q4 2017. 9 MNOK in reported EBITDA due to 13 MNOK in one-off expenses related to close down of Jakarta operation * 262 MNOK in order intake, up 97% from 133 MNOK in Q4 2017 * 22 MNOK in operating cash flow incl. net investments and free cash flow of 18 MNOK Highlights for FY 2018 include: * 889 MNOK in revenues, down 9% from 2017 * 89 MNOK in EBITDA before non-recurring items (10% margin), down from 110 MNOK in 2017.71 MNOK in reported EBITDA due to 18 MNOK in one-off expenses related to close down of Serbia, Malta and Jakarta * 971 MNOK in order intake, up 58% from 2017. In addition, Q-Free signed frame agreements worth >100 MNOK in 2018 * 1 128 MNOK in order backlog (not including >200 MNOK in frame agreements), up from 1 049 MNOK at the end of Q4-17 * 117 MNOK in operating cash flow incl. net investments - We are satisfied with the fourth quarter of 2018. It represents the ninth consecutive quarter with positive EBITDA margin. It is also very encouraging to see the continued strong growth in our order intake, which almost doubled compared to the fourth quarter of 2017. Given a healthy backlog for 2019 and good momentum in the business, we target double-digit revenue growth in 2019 and margin expansion driven by operational leverage and a shift towards higher-margin products and services, comments CEO in Q-Free, Håkon Volldal. The live broadcast, starting at 9 AM CET, can be followed on https://www.q-free.com/investor_relations/web-cast/ A recorded version will be available after the webcast has been concluded. Enclosures: Q4-18 report, Q4-18 presentation For further information, please contact: President & CEO, Håkon Volldal: +47 977 19 973 CFO, Tor Eirik Knutsen: +47 950 50 062 About Q-Free Q-Free is a leading global supplier of ITS (Intelligent Transportation Systems) products and solutions. The company has approximately 385 employees, offices in 16 countries, and a presence on all continents. Headquartered in Trondheim, Norway, Q-Free is listed on the Oslo Stock Exchange under the ticker QFR. www.q-free.com Twitter:@Q-FreeASA

Haldex has initiated a concept phase with brake solutions for autonomous vehicles with world-leading truck manufacturer

Haldex presented its future projects on connected, autonomous and electrified vehicles, "Scalable Brake System", in the spring of 2018. Subsequently, a number of customer dialogues have been initiated where one of them has now resulted in Haldex being selected for a concept phase, with the goal of signing a development contract at end of the year. A development contract means that the manufacturer and Haldex in close collaboration will develop a solution that is expected to go into production 4-5 years later. “We have worked closely with the customer during the fall and have conducted a number of tests where our test results have been far better than the other solutions presented. We therefore, with confidence, look forward to prove this under the concept phase that is now initiated,”, says Åke Bengtsson, President and CEO of Haldex. “We are very happy for the breakthrough this cooperation entails. It is proof that our technology is innovative and that our solutions are world-leading.” "Scalable brake systems" stand out against other solutions in the market by: · advanced vehicle dynamics where Haldex uses sensors and algorithms to get the tractor and trailer to brake and follow the desired direction in an optimal way, · open and integrable interface with the vehicle manufacturer's VMM (vehicle motion management), where the vehicle manufacturer maintains control of the VMM and at the same time gets access to all vehicle data, · a system that works with both pneumatic brake systems and electrified brake systems, · and an architecture that is modular and scalable.

Evolution Gaming: Year-end report 2018

Fourth quarter of 2018 (Q4 2017)  · Operating revenues increased by 38% to EUR 70.2 million (50.7) · EBITDA increased by 40% to EUR 31.6 million (22.6), corresponding to a margin of 45.0% (44.6) · Profit for the period amounted to EUR 25.5 million (18.0) · Earnings per share amounted to EUR 0.71 (0.50) Full-year 2018 (2017)  · Operating revenues increased by 38% to EUR 245.4 million (178.4) · EBITDA increased by 34% to EUR 107.7 million (80.6), corresponding to a margin of 43.9% (45.2) · Profit for the period amounted to EUR 83.5 million (62.1) · Earnings per share amounted to EUR 2.32 (1.73) · The Board proposes a dividend of EUR 1,20 per share (0.90) and intends to propose a buy-back programme to the Annual General Meeting Events during the fourth quarter of 2018 · Launch of scalable Infinite Blackjack · Continued expansion in North America Events after the end of the quarter · Acquisition of Ezugi completed · 10 new game titles launched at ICE 2019 – increasing the gap to competition Comments from CEO Martin Carlesund: I am very pleased to summarise a good end to the year with continued favourable growth and high profitability. Revenues in the fourth quarter amounted to EUR 70.2 million, corresponding to an increase of 38 percent compared with the same period in 2017. EBITDA amounted to EUR 31.6 million with a margin of 45 percent. For the full-year, the margin was 44 percent, which is satisfactory given the high expansion pace. At year-end, we had approximately 550 tables live; significantly more than what we had planned in the beginning of 2018. During 2019, we will invest in a new studio in Malta and continue to expand our existing studios to meet the market demand. At the same time, we optimise the expansion from last year, and we expect a slightly strengthened EBITDA margin in the range of 44-46 percent for the full-year. We continue to grow in North America. During the fourth quarter, we went live with several new customers in the US, and just after year-end we also signed an agreement with a second customer in Canada. To further strengthen our position, we have also carried out Evolution’s first-ever acquisition. With the business of Ezugi, we further extend our footprint especially in the US, while also gaining more studio capacity and resources within product development. Another key activity in North America will be to roll out more games; Live Infinite Blackjack is one example that was successfully launched for our European operators in the past quarter. Among our markets, the Nordics in particular have exhibited favourable growth in the quarter. Rest of Europe also showed positive progress, while the growth in Rest of World was somewhat lower than in previous quarters. As before, the UK market is currently slow as a consequence of the latest regulatory requirements. At year-end, Sweden’s new gaming regulation came into effect, and we can note that several of our customers have been off to a great start. At the publication of this report, this year’s edition of ICE has just taken place, and I am immensely proud of the 10 game titles that Evolution revealed at the show. Our product and development teams have put countless hours into creating games beyond the expected, which lay the foundation for continued long-term growth. The main highlight is MONOPOLY Live, which is an evolved special edition of our successful Dream Catcher. We also launched a live game show based on the popular TV programme Deal or No Deal. Both titles have been developed to take the entire Live Casino category to the next level, expand to new player types and create more commercial value for our operators. Among all the new products, I would also like to highlight our new dice games Lightning Dice and Super Sic Bo. Dice games have a long history and a global attraction, and we confidently look forward to introducing our innovative live versions for our customers. All in all, we can look back at yet another amazing year in the Evolution history with expansion outside Europe and many successes in innovation and created customer value. With a new studio in Malta and all games that will be launched, I am confident that we are in excellent shape to continue increasing our market leadership going forward. In that context, we can also conclude that the first quarter has been off to a good start. Presentation for investors, analysts and media CEO Martin Carlesund and CFO Jacob Kaplan will present the report and answer questions on Thursday, 14 February 2019 at 09:00 a.m. CET via a telephone conference. The presentation will be in English and can also be followed online. Number for participation by telephone: +46 8 566 42 707 / +44 333 300 9035. Follow the presentation at https://tv.streamfabriken.com/evolution-gaming-group-q4-2018.

MIPS - Year end report 2018

CEO’S Comments ANOTHER STRONG QUARTER BEHIND US The strong sales momentum continued during the important fourth quarter and we increased net sales by 53% to SEK 62.2m (40.6). Adjusted for currency effect, the growth was 44% in the quarter. For the full year, sales increased by 53% to SEK 192.5m (125.6), adjusted for currency effect, the growth was 50%. Our major customers continued to be the main contributor of growth by increasing the number of helmet models they offer equipped with the MIPS Brain Protection System (BPS). It is very satisfying to see that all our 15 largest customers have grown their volumes with MIPS during the year and we see good growth in all our product categories. In 2018 we increased our customer base with the addition of 18 new helmet brands. In total 146 new helmet models with MIPS BPS were introduced around the world. MIPS cooperates with 78 helmet brands that offer 448 models equipped with MIPS BPS. We delivered 3.8 million MIPS BPS equipped units during the year and have delivered 9.2 million units since 2011 to the market.Our operating profit for the quarter amounted to SEK 28.7m (14.6), an increase of 96%. With an improved operating margin of 46.1%, the scalability of our business model is again confirmed. In addition, we delivered a strong cash flow from operating activities of SEK 23.8m (0.9). Looking at development for the full year, we see a similar trend with an adjusted operating profit of SEK 73.0m (27.8) and an adjusted operating margin of 37.9% (22.1). The positive development during the year enables the Board of Directors, for the first time in MIPS´ history to propose a dividend to MIPS shareholders of 2.50 SEK. POSITIVE DEVELOPMENT IN OUR MAIN CATEGORIES In November one of the world´s leading bicycle brands, Specialized, communicated that they will strengthen their safety story by launching MIPS BPS in all helmet models. This move provides important evidence that the expanded selection of MIPS BPS solutions can be implemented to increase safety across a wide range of price points. This is an important ingredient in our strategy to continue increasing penetration and growth. INCREASED CONSUMER COMMUNICATION AND MEDIA ATTENTION Throughout the year, we have met with many of the leading international journalists and thus had the opportunity to present the medical and scientific reasons behind the benefits of MIPS BPS rotational motion protection. This has generated several in-depth articles in world-leading publications for cycling, motorcycle, equestrian and skiing audiences. The fact-based articles help consumers understand what MIPS BPS is and how our solutions can help reduce the risk of brain damage.  In the fourth quarter, the American Virginia Tech University published an updated report where they expanded their previous test of 20 bicycle helmets to 50. I am pleased that MIPS equipped helmets are now found in places 1 through 13 on this influential list of the safest products.   2020 TARGETS WITHIN REACH 2018 has been a year when we established ourselves as an important player in the helmet market. Several external institutions have validated our technology; we have successfully defended our patents; our product portfolio has expanded; collaborations with helmet brands have deepened; and the positive media exposure has been more extensive than ever. The consumer awareness of our technology has been improved and are now not just for the well informed but also something that the average consumer demands. At the same time, we have delivered rapid sales growth and greatly improved profitability. Supported by a strong 2018, we are looking forward to delivering according to our financial targets for 2020. JOHAN THIELPresident and CEO

Alligator Bioscience AB Year-end Report 2018

Significant events October-December• The Swedish MPA (Medical Products Agency) approved start of Phase I clinical trial of ATOR-1015.• New preclinical data for ATOR-1017 and ALG.APV-527 presented at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC).• The company expanded its pipeline and initiated preclinical development of the ATOR-1144 drug candidate.• Research funding granted from Vinnova.• Alligator Bioscience recorded a revenue of approximately USD 3 million related to a collaboration with AbClon Inc.Events after the end of the period• Alligator Bioscience launched RUBY™, a novel concept in bispecific antibody formats.• Clinical Phase I data for ADC-1013 published in the International Journal of Cancer.• Since the ADC-1013 Phase I study is not yet fully completed, the next revenue, the first phase II milestone payment, is expected to move into 2020.• ATOR-1015 phase I clinical study commenced enrollment of patients. Financial summaryOctober-December• Net sales, SEK 25.6 million (51.3).• Operating result, SEK -30.1 million (10.7).• Result for the period, SEK -30.6 million (12.5).• Result per share, SEK -0.43 (0.18).• Cash and cash equivalents, incl. interest-bearing securities, SEK 436.4 million (547.0).• Cash flow for the period, SEK -41.8 million (-41.7).January-December• Net sales, SEK 27.0 million (56.9).• Operating result, SEK -153.1 million (-62.3).• Result for the period, SEK -150.0 million (-63.8).• Result per share, SEK -2.10 (-0.89).• Cash flow for the period, SEK -111.8 million (-183.2). Financial summary (Group)   2018 2017 2018 2017  Oct-Dec Oct-Dec Jan-Dec Jan-DecNet sales, TSEK (SEK 25,594 51,299 26,959 56,875thousand)Operating profit/loss -30,060 10,733 -153,080 -62,299Profit/loss for the period, -30,589 12,516 -150,043 -63,758TSEK Cash flow for the period, -41,780 -41,694 -111,770 -183,173TSEKCash, cash equivalents and 436,391 547,041 436,391 547,041bonds, TSEKEquity ratio, % 92% 96% 92% 96%R&D costs as % of operating 78.6% 80.5% 76.8% 73.3%costs excluding impairmentsEarnings per share before -0.43 0.18 -2.10 -0.89dilution, SEKEarnings per share after -0.43 0.18 -2.10 -0.89dilution, SEKAverage number of employees 54 46 51 42 Read the complete report in the pdf below. Conference callAll interested parties are invited to participate in a telephone conference, which will include a presentation of the Year-end Report. The event will be hosted by CEO Per Norlén and the presentation will be held in English.  When: 09:00 a.m. CET Thursday 14 February 2019 Listen to the presentation: https://financialhearings.com/event/11461 To participate in the telephone conference, please use the dial in details shown below:SE: +46856642692 UK: +443333009266 US: +18338230590 The conference call will be made available on the company’s website after the call: http://www.alligatorbioscience.com . For further information, please contact:Per Norlén, CEO, per.norlen@alligatorbioscience.com, +46 46 540 82 00.Per-Olof Schrewelius, CFO, per-olof.schrewelius@alligatorbioscience.com, +46 46 540 82 03.Cecilia Hofvander, Director IR & Communications, cecilia.hofvander@alligatorbioscience.com, +46 46 540 82 06.Alligator Bioscience AB (publ) 556597-8201Medicon Village, Scheelevägen 2, 223 81 Lund, SwedenPhone +46 46 540 82 00. www.alligatorbioscience.com This information is such information as Alligator Bioscience AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 8:00 a.m. CET on February 14, 2019. About Alligator BioscienceAlligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes five lead clinical and preclinical drug candidates: ADC-1013, ATOR-1015, ATOR-1017, ALG.APV-527 and ATOR-1144. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has 50+ employees. For more information, please visit http://www.alligatorbioscience.com. ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc. for global development and commercialization.

Eltel Group: Full-year report January–December 2018

October–December 2018 ·Net sales EUR 330.9 million (374.2). Total growth -11.6% and organic growth* in Power and Communication -5.1% ·Operative EBITA** EUR 2.9 million (2.2) and operative EBITA margin 0.9% (0.6) ·Operating result (EBIT) EUR -0.2 million (1.2) and EBIT margin -0.1% (0.3) ·Net result EUR -3.3 million (-7.7) ·Earnings per share EUR -0.02 (-0.05), basic and diluted ·Cash flow from operating activities EUR 70.0 million (42.3) January–December 2018 · Net sales EUR 1,188.9 million (1,329.9). Total growth -10.6% and organic growth* in Power and Communication 0.3% ·Operative EBITA** EUR -2.2 million (-25.5) and operative EBITA margin -0.2% (-1.9) ·Operating result (EBIT) EUR -9.2 million (-184.6) and EBIT margin -0.8% (-13.9%) ·Net result EUR -22.2 million (-204.6) ·Earnings per share EUR -0.15 (-1.56), basic and diluted ·Cash flow from operating activities EUR 3.2 million (-65.2) Significant events during and after the reporting period ·On 14 December 2018, it was announced that Leif Göransson was appointed Managing Director (MD) of Country Unit Sweden starting 1 January 2019. Leif succeeded Casimir Lindholm who since October was acting MD for Eltel Sweden. ·On 1 January 2019, Elin Otter, Head of Communications and Investor Relations was appointed new member of the Eltel Group Management Team. ·Eltel signed six contracts of significance to a value of about EUR 158 million during October 2018–January 2019. +-------------+-----+-----+-------+-------------+-------+-------+---------+|EUR million | Oct| Oct|Change,|EUR million |Jan-Dec|Jan-Dec|Change, %|| | -Dec| -Dec| %| | 2018| 2017| || | 2018| 2017| | | | | |+-------------+-----+-----+-------+-------------+-------+-------+---------+|Net sales | | | |Net sales | | | |+-------------+-----+-----+-------+-------------+-------+-------+---------+|Power |115.1|130.7| -11.9%|Power | 438.8| 470.4| -6.7%|+-------------+-----+-----+-------+-------------+-------+-------+---------+|Communication|207.1|215.6| -3.9%|Communication| 727.3| 756.8| -3.9%|+-------------+-----+-----+-------+-------------+-------+-------+---------+|Other | 3.6| 27.6| -87.1%|Other | 23.1| 103.8| -77.7%|+-------------+-----+-----+-------+-------------+-------+-------+---------+|Total Group |330.9|374.2| -11.6%|Total Group |1,188.9|1,329.9| -10.6%|+-------------+-----+-----+-------+-------------+-------+-------+---------+|Operative | | | |Operative | | | ||EBITA** | | | |EBITA** | | | |+-------------+-----+-----+-------+-------------+-------+-------+---------+|Power | -1.9| -0.5|-309.2%|Power | -0.5| -0.3| -99.6%|+-------------+-----+-----+-------+-------------+-------+-------+---------+|Communication| 9.7| 12.9| -24.6%|Communication| 24.8| 34.5| -28.1%|+-------------+-----+-----+-------+-------------+-------+-------+---------+|Other | -1.1| -5.8| 81.3%|Other | -11.1| -43.7| 74.5%|+-------------+-----+-----+-------+-------------+-------+-------+---------+|Items not | -3.8| -4.4| 13.5%|Items not | -15.4| -16.1| 4.2%||allocated | | | |allocated | | | |+-------------+-----+-----+-------+-------------+-------+-------+---------+|Total Group | 2.9| 2.2| 34.4%|Total Group | -2.2| -25.5| 91.2%|+-------------+-----+-----+-------+-------------+-------+-------+---------+ *Adjusted for divested operations and currency effects** Please see page 20 for definitions of the key ratios  Comments by the CEO The fourth quarter showed a strong cash flow of EUR 70 million and improved operative EBITA on Group level. At the same time, our net sales decreased according to plan. However, looking at the quarter and year-on-year we are not satisfied with the overall performance of the underlying business. In the Power segment, we can see that the measures taken in High Voltage to improve efficiency, strengthen control and finalise low margin projects have started to show effect. We continue to reduce risk in the overall High Voltage portfolio and we produce a handful projects with very low gross margin. Poor project execution in Finland affected the result negatively while Smart Grids showed strong performance with high net sales and operative EBITA. However, Smart Grids is a cyclical business and we expect lower volumes in 2019. The Communication segment became somewhat a disappointment for the quarter, but even more so for the full year. In the quarter, we experienced good and stable performance in Norway, Finland and Denmark. However, this was offset by Sweden underperforming, primarily due to higher costs than anticipated at project closing. During the autumn, we changed the Swedish management and the new team is taking measures to improve the performance. We will continue to work with operational improvements throughout the organisation. Our operational excellence strategy is all about improving our day-to-day activities and ensuring we are our customers’ first choice. The strategy will help us to simplify things by going back to basics in terms of how we operate and execute our work. This is supported by our country-based organisation where we stay close to our customers. By implementing operational excellence, Eltel has positioned itself for a turn-around. Our long-term goal is to return to an EBITA-margin of 5% with a stable cash flow and a healthy balance sheet. This will require a focus on the customer interface, flawless execution, production planning as well as efficiency in our operations, including strengthening our financial situation and reducing our net debt over time. Casimir Lindholm, President & CEO For further information, please contact:Petter Traaholt, CFOTel. +46 72 59 54 749, petter.traaholt@eltelnetworks.se Elin Otter, Head of Communications and Investor RelationsTel. +46 72 59 54 692, elin.otter@eltelnetworks.se Eltel AB discloses the information provided herein pursuant to the EU’s Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the above contacts, on 14 February 2019 at 08:00 a.m. CET. About EltelEltel is a leading Northern European provider of technical services for critical infrastructure networks – Infranets – in the segments of Power, Communication and Other, with operations throughout the Nordics, Poland and Germany. Eltel provides a broad, integrated range of services from maintenance and upgrade services to project deliveries. Eltel has a diverse contract portfolio and a growing customer base of large network owners. In 2018, Eltel had annual sales of EUR 1.2 billion. The total number of employees currently stands at around 7,400. Eltel AB has been listed on Nasdaq Stockholm since 2015.

Eastnine to acquire S7 in Vilnius

S7 office park located on Saltoniškių 7 and in close vicinity to the city centre in Vilnius, consists of four adjacent office properties developed by M.M.M. projektai. Three of four possible buildings have recently been or will be commissioned during the coming year, and all buildings are expected to receive BREEAM Excellent certification. Building I has already been certified BREEAM Excellent and has received several other awards such as Best office development in the Baltics (2018) and Most Vibrant Workplace in Central and Eastern Europe (2019). ”We are excited about the acquisition of this sizable, landmark asset in Vilnius, consistent with our strategy to acquire the most sustainable A-class office properties in the Baltic capitals and expanding our property portfolio to over 100,000 sqm” says Kestutis Sasnauskas, CEO. Building I was completed in Q4 2017. It is fully leased to Danske Bank Global Services Lithuania, which is a key strategic centre of Danske Bank Group for banking operations, business support functions and front-end product development. Building II was completed in Q1 2019. It is fully leased to Telia Lietuva, which is the leading telecommunications company in Lithuania and part of Telia Company Group. Closing of the acquisition is scheduled for Q2 2019. Building III is scheduled to be completed in Q4 2019. It is fully pre-leased to Danske Bank Global Services Lithuania. Closing of the acquisition is scheduled for Q1 2020. The transactions will be financed by existing cash and new debt. SEB acted as the lead arranger of a syndicated loan, in which the other lender is OP Corporate Bank. Sorainen acted as legal advisor to Eastnine. For further information contact: Kestutis Sasnauskas, CEO, +46 8 505 97 700 Mattias Lundgren, Interim CFO, +46 70 228 88 81 Eastnine AB (publ) is a Swedish investment company with a net asset value of EUR 232.4m as of Q3 2018. The company is currently transitioning into a focused Baltic real estate company, with an aim to generate predictable cash flows by being a long-term provider of sustainable prime office space in the Baltic capitals. Eastnine is listed on Nasdaq Stockholm, Mid Cap, sector Real Estate. This information is information that Eastnine AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08.00 a.m. CET on 14 February 2019.

YEAR-END REPORT 2018

FULL YEAR AND THE FOURTH QUARTER · Net sales amounted to MSEK 1,615.1 (657.6), of which the fourth quarter amounted to MSEK 463.3 (238.7). This corresponds to an increase of 146% for the full year, and 94% for the fourth quarter. A large part of the growth is attributable to products acquired during the period. · Organic growth was + 7.0% (proforma) for the period, and for the fourth quarter + 5.4%. Pharmaceutical drugs accounted for an organic growth of +3.2% for the period, and +5.8% for the fourth quarter. · EBITDA amounted to MSEK 632.2 (169.3), of which the fourth quarter was MSEK 165.4 (41.8), corresponding to a margin of 39.1% (25.7%) for 2018 and 35.7% (17.5%) for the fourth quarter. EBITDA increased by 273% during the period compared with the previous year. (The numbers for 2017 refer to adjusted EBITDA). · The gross margin during the period was 58.1% (52.0%), and 55.8% (48.8%) in the quarter. Excluding milestone payments in the second quarter of 2018 and 2017, the gross margin was 55.8% for the period (50.7%). · Cash flow from operating activities during the period amounted to MSEK 309.5 (33.5), of which the fourth quarter amounted to MSEK 19.6 (-28.8). During the fourth quarter, inventory from Leo was taken over. · Earnings per share were SEK 4.63 (0.17), of which the fourth quarter was SEK 0.17 (-0.42) · Cash and cash equivalents and other short-term investments amounted to MSEK 398.6 (838.6) at the end of the period. · During the period June 18, 2018 until July 27, 2018, the Company repurchased 2,464,990 Karo Pharma shares within the agreed repurchasing program. The repurchasing program is thus implemented and finalized. IMPORTANT EVENTS AFTER PERIOD END  · On October 29, 2018, EQT VIII through its wholly owned subsidiary Karo Intressenter AB submitted a recommended public offer to the shareholders of Karo Pharma to transfer all shares in Karo Pharma to Karo Intressenter for a cash consideration of SEK 36.90 per Karo Pharma share. The acceptance period in the offer initially expired on December 10, 2018 and was extended on December 13, 2018 until January 4, 2019. · On January 2, 2019, Karo Intressenter announced that it raised the consideration in the offer to SEK 38.00 in cash for each share in Karo Pharma, and extended the acceptance period until 17.00 CET January 17, 2019, and that the condition regarding obtaining required regulatory permits, approvals, decisions or similar had been fulfilled. The offer was later extended to February 12. · In light of the changes in ownership that have taken place, notice has been sent to an Extraordinary General Meeting of Karo Pharma AB on February 14, 2019. The Meeting is to resolve on the election of a new Board of Directors, number of Board members and Board renumeration. · On February 11, Karo Intressenter presented its proposal to the meeting on February 14, as regards, among other things, the election of a new Board of Directors. (See separate press release per February 11). AUDIOCAST TODAY AT 11.00 A.M. CETA presentation of the report (in Swedish) will take place today at 11 a.m. The presentation can be attended through the corporate website www.karopharma.se or by telephone +46 8 505 564 74. Questions may be submitted over the internet or by the telephone. LETTER FROM THE CEO We follow our plan and the fourth quarter provided strong growth, increased profits and improved margins. In the report for the third quarter, we forecasted sales and EBITDA for the full year. The outcome was within the indicated intervals. During the year, the business developed positively with almost tripled sales and profit. Sales increased 146% and EBITDA by 273%. The organic growth of 7.0% (proforma) is gratifying for a year with a strong focus on integration. We have worked intensively to first fully integrate Weifa into our business and now we have a very strong organization and profitability development in Norway. On March 1, the acquisition of the LEO portfolio was announced, and the products were taken over on April 4, where ten well-established pharmaceuticals with strong brands were acquired. The products are characterized by stable sales and profitability and have improved the company’s total gross margin by 5.6%. Through the acquisition of the LEO portfolio, we were also able to report a significant tax revenue by recording a value on our previous tax loss carry-forwards in the balance sheet. In 2018, we have succeeded in significantly expanding Karo Pharma’s portfolio of interesting products. Karo Pharma has established distribution in many new markets in Europe and the rest of the world. The acquisition of the LEO portfolio complements our product portfolio and geography well. Our new product Viruseptin® for the treatment of colds and flu-like symptoms was successfully launched during the fourth quarter in Sweden. We have gained market share as well as created growth in the cold category at pharmacy chains. In 2019, Viruseptin® will launch in other Nordic markets. We enter the new year with products that will be launched in the Nordic market. An example of this is Dolerin®, which is a combination of paracetamol and ibuprofen for the treatment of severe pain. The drug is medically approved in all Nordic markets and will be launched in 2019 2018 was also a year of great sorrow. In December, we received the tragic message that the company’s chairman, Anders Lönner, had died. Anders spirit, who has greatly contributed to Karo Pharma’s change and success in the last four years, will continue to "aim higher than you think is possible to reach, work harder, more efficient and without bureaucracy, and success will come". Together with the organization, I will do everything possible to maintain and implement Anders’ winning business ideas. Today, Karo Pharma is an attractive Specialty Pharma company with well-established brands and an interesting pipeline of new products. We see opportunities to continue our business consolidation and reap synergies that improve our profitability and growth, and combining it with making interesting acquisitions in a controlled manner. Lastly, I would like to thank all employees for truly good work efforts. We are looking forward, towards new exciting challenges, our priorities are continued expansion with good profitability. Peter BlomCEO FOR FURTHER INFORMATION, PLEASE CONTACTPeter Blom, CEO +46 70 655 56 98, peter.blom@karopharma.seMats-Olof Wallin, CFO +46 760 026 010, mats-olof.wallin@karopharma.se ABOUT KARO PHARMAKaro Pharma is a specialty pharma company that develops and markets products to pharmacies and directly to healthcare providers. The share is listed on Nasdaq Stockholm in the Mid Cap segment. The information in this report is such that Karo Pharma is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, on February 14, 2019 at 8.30 a.m. CET.  

Year-End Report 2018:

myTaste AB (publ) Year-End Report for 2018 has now been made public and is available at https://mytastegroup.com/investors/financial-reports   CEO Andereas Friis comments: “With a record-breaking quarter behind us, we are one step closer of becoming the global market leader in performance-based marketing”I am pleased to announce that, the fourth quarter of 2018 for Mytaste Group was very strong, which is a confirmation that our strategy for becoming a leader in performance-based marketing works. We have both streamlined and developed present business segments, and partly strengthened the company through acquisitions and thus prepared for an even stronger development ahead. Growth in net sales was strong and amounted to 53 percent, of which organic growth accounted for 50 per cent. Adjusted EBITDA increased by 123 percent to KSEK 3,945 (1,771) and the adjusted EBITDA margin reinforced to 19 percent (13). The Group reports a positive result after tax and generates a positive cash flow for its operating activities. It is with pride I note, that development greatly exceeds our long-term financial objectives, that growth should increase by an average of 25 per cent per year. When we sum up 2018, we have had a growth of 61 percent. During the quarter, we welcomed a new majority shareholder in Optimizer Invest. The deal is the largest investment so far for the investment company and for Mytaste Group, this means a significantly strengthened financial position. Combined with the fact that Optimizer Invest adds solid expertise in M&A and has a proven ability to build successful companies, it is clear that our cooperation has all the prerequisites to be very beneficial. Acquisitions within the financial vertical On January 18, after the end of the fourth quarter, Mytaste Group signed an agreement to acquire Lånakuten, lanakuten.com, which is a popular online-based comparison website for private loans. The acquisition strengthens our position in the market for performance-based marketing in finance. We believe that the market for private loans is growing and that Lånakuten has good opportunities to contribute to increased profitability for the Group. Not least since we already operate a number of services within the financial vertical, which enables significant synergy effects. Mytaste Shopping Strong organic growth in the segment for the fourth quarter is mainly due to Shopello’s success, included in segment Mytaste Shopping which had an 88 percent increase in growth, with a significant increase in EBITDA. We continue to see good opportunities for organic growth in the segment, even though the fourth quarter is the strongest seasonally. Among the new contracts signed during the period, I want to emphasize that the Swedish evening newspaper Expressen has increased its cooperation with Mytaste Group, to now include performance-based marketing in Expressen’s on-line comparison service of odds and gambling, spel.expressen.se. Our objective during 2019, is to similarly help other publishers in Europe to generate significant revenue through our service Affilijet. Mytaste Food & Beverage The segment’s net sales for the period fell slightly, but at the same time, because of increased focus and efficiency enhancements, EBITDA for the period improved by 204 percent. The decrease in sales is mainly due to reduced traffic on the Group’s food sites The work of developing Vinklubben proceeds. We will continue to launch new products in the coming quarter in order to strengthen our offering in performance-based marketing for wines that already are distributed through Systembolaget’s assortment. Outlook Mytaste Group is well positioned and one of the most experienced players in Europe in a young and growing market. Our strategy is to build a portfolio of world-class products in performance-based marketing, through continued strong organic growth combined with geographic expansion and an aggressive acquisition strategy. As a result of our strong growth, the Board will revise Mytaste Group’s long-term financial targets in the coming quarters. The company will also investigate various financing options to support our continued acquisition strategy. As part of the work of developing rapidly into a leading global group in performance-based marketing, we have decided to strengthen the organization with key competence with relevant experience. In the short term, this can increase the cost base of the company. However, we anticipate that it will accelerate the process of building a scalable organization that can manage the increasing growth and additional acquisitions. I look forward to, together with our committed and skilled employees and with the support of the Board and shareholders, continue to create strong growth for our customers and thus also for Mytaste Group! KEY FIGURES FOURTH QUARTER 2018 (2017)• Net sales amounted to 20,752 KSEK (13,600)• Adjusted operating profit (EBITDA) amounted to 3,945 KSEK (1,771)• Adjusted operating profit margin (EBITDA %) amounted to 19 percent (13)• Operating profit (EBITDA) amounted to 3,567 KSEK (283)• Operating profit margin (EBITDA %) amounted to 17 percent (2)• Earnings per share amounted to +0,02 SEK (-0,14)SIGNIFICANT EVENTS THE FOURTH QUARTER 2018• During the fourth quarter, revenues amounted to KSEK 20,752 (13,600), which corresponded to a 53 percent increase. • Adjusted EBITDA profit increased 123 percent and amounted to KSEK 3,945 (1,771), corresponding to an adjusted EBITDA margin of 19 percent (13). EBITDA increased by 1 160 percent and amounted to KSEK 3,567 (283). • Mytaste Shopping increased its sales by 88 percent to KSEK 17,238 (9,162) and EBITDA amounted to KSEK 3,453 (77). • Mytaste Food & Beverage increased its EBITDA by 204 percent and amounted to KSEK 1,912 (629). • On November 7, 2018, it was announced that Mytaste Group is taking in a new principal shareholder - the investment company Optimizer Invest largest investment so far. • The Group has entered into an agreement with Google to become a Comparison Shopping Services (CSS) Partner and market the ad format Google Shopping in Europe. Four new sales persons have been hired to process the markets in Norway, Germany, Switzerland, Austria, Italy, Poland. Mytaste Group is now active in 11 markets with CSS. • In December, we welcomed Ulrika Jones as the new Group CFO. Ulrika has solid experience in both financial management, strategic work and within legal and has held senior roles at including Bambuser and Bisnode. SIGNIFICANT EVENTS AFTER THE END OF THE FOURTH QUARTER 2018• The outcome of the options subscribed in October 2017 where the utilization period ended on December 31, 2018 has added approximately SEK 3.5 million before issue costs to the company, which further increases our opportunities to make more acquisitions. • Optimizer Invest subscribed for 6,862,745 shares and 5,084,746 warrants in a directed issue and MyTaste Group received MSEK 17.5. Upon full exercise of the warrants, this means that Mytaste Group will receive a total capital of approximately MSEK 32.5. • On December 7, the Extraordinary General Meeting decided to elect André Lavold from Optimizer Invest as new ordinary Board member for the period until the end of the next Annual General Meeting. • Mytaste Group acquired Lånakuten, (lanakuten.com), a popular online-based comparison service for personal loans. The total purchase price was MSEK 16, of which MSEK 10 was paid in cash and the rest in shares, 573,583 shares corresponding to MSEK 6 and to a share price of SEK 10.46. Lånakuten generated a profit of approximately MSEK 1.1, during Q4, 2018. • Mytaste Group signed a new exclusive agreement with newspaper magazine Expressen for odds / games. This means that Mytaste Group now manages Expressen’s services in private economy, discount offers and odds / games. • As a result of our even stronger growth, the Board will revise Mytaste Group’s long-term financial targets in the coming quarters. • The Board of Directors has decided to investigate possible future financing alternatives to support Mytaste Group’s continued acquisition plans. DIVIDEND The Board of Directors proposes that no dividend will be paid for the financial year 2018. The reason is the acquisitions and investments made by MyTaste Group in 2018 and early 2019, in line with the company's strategy. The Board intends to continue to apply a growth-oriented strategy, including both organic growth and aggressive acquisition strategy. CHANGE OF THE DATE FOR THE ANNUAL GENERAL MEETING The board has decided to change the date of the annual general meeting to 13 May 2019. Mytaste Group’s financial calendar in its entirety available in the year-end report and at https://mytastegroup.com/investors/calendar.This information is such information that myTaste AB (publ) is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the agency of the contact person below, for publication on 14 February, 2019 at. 8:30 a.m. CET.

Stora Enso’s Annual Report 2018 published

Stora Enso’s Annual Report 2018 has been published at storaenso.com/annualreport2018 . The Annual Report 2018 consists of four sections: Strategy, Sustainability, Financials and Governance. Strategy explains how our transformation is progressing and how we create value as a renewable materials company, highlighting key events from all divisions. Sustainability covers Stora Enso’s social, environmental, and economic sustainability performance. Financials consists of the report of the Board of Directors and the financial statements, Stora Enso in capital markets, and our tax footprint. The non-financial reporting according to the Finnish Accounting Act is included in the report of the Board of Directors. The official audited financial statements in Finnish and a Swedish translation can be downloaded at storaenso.com/annualreport2018 . Governance covers Stora Enso’s governance policy, practices, and actions as well as remuneration in 2018. An English translation of the Parent Company Financial Statements for 2018 can be downloaded at the group’s website at storaenso.com/en/download-centre . For further information, please contact:Ulrika Lilja, EVP, Communications, tel. +46 72 221 9228 Investor enquiries:Ulla Paajanen, SVP, Investor Relations, tel. +358 40 763 8767  Part of the bioeconomy, Stora Enso is a leading global provider of renewable solutions in packaging, biomaterials, wooden constructions and paper. We believe that everything that is made from fossil-based materials today can be made from a tree tomorrow. Stora Enso has some 26 000 employees in over 30 countries. Our sales in 2018 were EUR 10.5 billion. Stora Enso shares are listed on Nasdaq Helsinki (STEAV, STERV) and Nasdaq Stockholm (STE A, STE R). In addition, the shares are traded in the USA as ADRs (SEOAY). storaenso.com   STORA ENSO OYJ 

Swisscom selects Ericsson Security Manager

Ericsson (NASDAQ: ERIC) has been selected by Swisscom, the leading telecommunications service provider in Switzerland, for its market-leading Ericsson Security Manager solution. Ericsson Security Manager will provide increased security automation, visibility and control for Swisscom Security Operation Center to address the increasing security management needs of the service provider. The new deal includes automation of security compliance management and basic security analytics. Philippe Vuilleumier, Head of Group Security, Swisscom, says: “Continuing our strong partnership and collaboration with Ericsson, we are deploying Ericsson Security Manager in our datacenter in Switzerland while simultaneously developing the solution further through progressive and agile collaboration. Ericsson Security Manager is improving the security baseline automation and security analytics in our Security Operations Center, strengthening our activities to protect our own critical infrastructure.” Åsa Tamsons, Senior Vice President and Head of Business Area Technologies & New Businesses, Ericsson, says: “Security is a cornerstone of Swisscom’s business. Ericsson Security Manager will transform the security management of Swisscom’s mobile network and in the future support new use cases in the telecommunications industry, while addressing the ever-increasing security requirements.” More information on Ericsson Security Manager can be found here.  NOTES TO EDITORS FOLLOW US: Subscribe to Ericsson press releases here . www.twitter.com/ericssonwww.facebook.com/ericssonwww.linkedin.com/company/ericsson MORE INFORMATION AT:Ericsson Newsroom  media.relations@ericsson.com(+46 10 719 69 92) investor.relations@ericsson.com(+46 10 719 00 00) About Ericsson Ericsson enables communications service providers to capture the full value of connectivity. The company’s portfolio spans Networks, Digital Services, Managed Services, and Emerging Business and is designed to help our customers go digital, increase efficiency and find new revenue streams. Ericsson’s investments in innovation have delivered the benefits of telephony and mobile broadband to billions of people around the world. The Ericsson stock is listed on Nasdaq Stockholm and on Nasdaq New York. www.ericsson.com Ericsson at Mobile World Congress 2019 Join or follow Ericsson at MWC 2019 in Barcelona from February 25 to 28 and experience the future of 5G and IoT innovation. We will present unique insights on 5G business opportunities and showcase use cases that enhance service providers’ business and customer experiences. Take the opportunity to learn more about the latest trends and technology shaping the ICT industry, now and in the future. Join us live and online at www.ericsson.com/mwc

Correction: Stora Enso’s Annual Report 2018 published

Correction: Links to the reports were wrong Stora Enso’s Annual Report 2018 has been published at storaenso.com/annualreport2018 . The Annual Report 2018 consists of four sections: Strategy, Sustainability, Financials and Governance. Strategy explains how our transformation is progressing and how we create value as a renewable materials company, highlighting key events from all divisions. Sustainability covers Stora Enso’s social, environmental, and economic sustainability performance. Financials consists of the report of the Board of Directors and the financial statements, Stora Enso in capital markets, and our tax footprint. The non-financial reporting according to the Finnish Accounting Act is included in the report of the Board of Directors. The official audited financial statements in Finnish and a Swedish translation can be downloaded at storaenso.com/annualreport2018 . Governance covers Stora Enso’s governance policy, practices, and actions as well as remuneration in 2018. An English translation of the Parent Company Financial Statements for 2018 can be downloaded at the group’s website at storaenso.com/en/download-centre . For further information, please contact:Ulrika Lilja, EVP, Communications, tel. +46 72 221 9228 Investor enquiries:Ulla Paajanen, SVP, Investor Relations, tel. +358 40 763 8767  Part of the bioeconomy, Stora Enso is a leading global provider of renewable solutions in packaging, biomaterials, wooden constructions and paper. We believe that everything that is made from fossil-based materials today can be made from a tree tomorrow. Stora Enso has some 26 000 employees in over 30 countries. Our sales in 2018 were EUR 10.5 billion. Stora Enso shares are listed on Nasdaq Helsinki (STEAV, STERV) and Nasdaq Stockholm (STE A, STE R). In addition, the shares are traded in the USA as ADRs (SEOAY). storaenso.com   STORA ENSO OYJ 

The subscription period in Nustay’s new share issue prior to listing at Spotlight Stock Market begins today

Press release, Nustay A/S: Mathias Lundoe Nielsen, Founder and CEO of Nustay, comments: “Our vision is simple – to provide smart access to the best prices for all hotels and rental properties in the world in a single search. We have a very strong foundation in the company with a highly developed technical platform up-and-running – and this together with our exceptionally strong team and the agreements we already have in place, makes Nustay an interesting investment proposition according to me. We have a unique position as a new player in the hotel OTA market with a radically different approach that puts the customers’ personal preferences and low prices first. With this approach, we believe that we can attract a large number of customers and take a sizable part of the market for online hotel bookings in the future. With that, I want to welcome you as a shareholder in Nustay – the world’s smartest platform for finding hotel rooms at the cheapest prices.” About the new share issue and listing at Spotlight Stock Market Nustay is now conducting a new share issue of approximately DKK 21.3 million before issue costs, prior to a planned listing at Spotlight Stock Market. The capital that Nustay is provided with through the new issue is primarily intended to finance marketing of the company’s hotel booking platform to facilitate Nustay’s continued growth. The new share issue is also intended to finance other operating expenses and provide a spread in ownership to build a wide base of ambassadors and potential new customers. During 2019 and forward, Nustay’s revenue is expected to increase significantly as more budget is allocated towards online performance marketing activities. Furthermore, Nustay aims to launch a new customer loyalty program, a mobile app, and to launch additional hotels and holiday homes on its platform. Offering in summary · Subscription period: February 14th – March 5th, 2019. · Subscription price: DKK 7,20 per share. · Subscription post: The minimum subscription is 500 shares, corresponding to 3 600 DKK. · Issue volume and minimum limit for implementation: The offer comprises a maximum of 2 962 777 shares, equivalent to approx. DKK 21.3 million. The minimum limit for the new share issue’s implementation is approx. DKK 13,9 million, approx. 65 percent of the total issue volume. · Number of shares before new share issue: 15 257 888 shares. · Valuation (pre-money): Approximately DKK 110 million, corresponding to approximately SEK 151 million. · Subscription commitments: Nustay has received subscription commitments of approximately DKK 12 million, a total of approximately 56 percent of the issue volume. · Listing at Spotlight Stock Market: The share in Nustay is planned to be listed on Spotlight Stock Market. The trading is planned to commence on March 22nd, 2019. Investor meetings In connection with the IPO, Nustay will present its business and future plans at a number of investor events. See schedule below for details. Participation is free of charge. Date and Event Place RegistrationtimeFebruary Investor Nordnet Registration is made at19, meeting in BankHavneholmen www.sedermera.se February Investor Scandic Registration is made at21, meeting in Klara,Slöjdgatan www.sedermera.se February Webinar in The webinar will No registration25, Helsinki be broadcast beforehand is necessary201917:00 together with online– Nordnet at Sedermera’s and18:00 Nordnet’s websites  February Investor Nordnet Registration is made at26, breakfast in BankAkersgata www.sedermera.se February Webinar in The webinar will No registration27, Copenhagen be broadcast beforehand is necessary201916:00 together with online– Nordnet at Sedermera’s and16:45 Nordnet’s websites Financial advisor, legal advisor and Selling Agent Sedermera Fondkommission is acting as financial advisor and issuing agent to Nustay in connection with the IPO and the planned listing at Spotlight Stock Market. Legal advisor is Markets & Corporate Law. Nordnet Bank AB will act as nordic Selling Agent in the IPO. For further information about the IPO and the listing, please contact: Sedermera Fondkommission Telephone: +46 (0) 40-615 14 10 E-mail: info@sedermera.se Website: www.sedermera.se For further information about Nustay, please contact:         Mathias Lundoe Nielsen, Founder and CEO, Nustay A/S Telephone: +45 22 91 94 99 E-mail: mln@nustay.com Website: www.nustay.com About Nustay Nustay is a Danish company within the hotel booking market that offers its customers a new booking concept. Nustay has a vision of becoming the best and most disruptively innovative hotel booking platform in the world. The company’s innovative and advanced hotel booking platform has been under development since 2014 and is today online, active and has proven its ability to handle customers all over the globe. Nustay is an Online Travel Agency that delivers personalised hotel deals for each registered user depending on the preferences of the user and the type of stay. Nustay differs itself from its competitors – current OTA market actors such as Booking.com and Hotels.com – by combining the best and most important aspects of existing online booking – a large hotel inventory, a great booking experience and lower prices than its competitors. - Nustay A/S, 14/02/19

Year-end report January-December 2018

October – December 2018 ·  Net sales increased to SEK 603 million (578) ·  Operating profit before depreciation decreased to SEK 5 million (29) ·  Operating profit decreased to SEK -85 million (17) ·  Revaluation of goodwill amounts to SEK -76 million (0) ·  Non-recurring items in operating profit amounted to SEK -82 million (-5) ·  Earnings after tax amounted to SEK -123 million (8) ·  Revaluation of deferred tax assets amounts to SEK -17 million (0) ·  Earnings per share amounted to SEK -0.58 (0.03) ·  Cash flow after investing activities amounted to SEK -6 million (27) ·  The work to refinance Bong’s bond has been finalized January – December 2018 ·  Net sales increased to SEK 2,220 million (2,095) ·  Operating profit before depreciation decreased to SEK 71 million (91) ·  Operating profit decreased to SEK -52 million (45) ·  Revaluation of goodwill amounts to SEK -76 million (0) ·  Non-recurring items in operating profit amounted to SEK -77 million (-5) ·  Non-recurring items in the finance net amounted to SEK -11 million (0) ·  Earnings after tax amounted to SEK -148 million (-9) ·  Revaluation of deferred tax assets amounts to SEK -17 million (0) ·  Earnings per share amounted to SEK -0.71 (-0.06) ·  Cash flow after investing activities amounted to SEK -65 million (40) Bong is one of the leading providers of envelope products in Europe and also offers solutions for distribution and packaging of information, advertising materials and lightweight goods. Important growth areas in the Group are packaging within retail and e-commerce and the envelope market within Eastern Europe. The Group has annual sales of approximately SEK 2.2 billion and about 1,400 employees in 12 countries. Bong has strong market positions in most of the important markets in Europe and the Group sees interesting possibilities for continued development. Bong is a public limited company and its shares are listed on Nasdaq Stockholm (Small Cap). For further information, please contact Kai Steigleder, CEO for Bong AB.  Tel (switchboard) 46 44-20 70 00    This is information that Bong AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 16.00 CET on 14 February 2019. 

Exel Composites Plc’s Financial Statements Release 2018: “Strong order intake in Q4”

Q4 2018 in brief ·  Order intake increased by 35.8% to EUR 29.1 million (Q4 2017: 21.4). ·  Revenue increased by 19.2% to EUR 26.7 million (22.4). ·  Adjusted operating profit amounted to EUR 0.8 million (1.3), which is 2.9% of revenue (5.9%). ·  Net cash flow from operating activities was EUR 0.5 million (2.7). ·  Earnings per share amounted to EUR -0.14 (0.08). Q1-Q4 2018 in brief ·  Order intake increased by 16.4% to EUR 100.8 million (2017: 86.5). ·  Revenue increased by 12.0% to EUR 96.6 million (86.3). ·  Adjusted operating profit amounted to EUR 5.0 million (6.3), which is 5.2% of revenue (7.3%). ·  Net cash flow from operating activities was EUR 0.9 million (4.9). ·  Earnings per share amounted to EUR 0.03 (0.36). Dividend proposal The Board of Directors proposes that a dividend of EUR 0.18 (0.30) per share be paid for the financial year 2018. Outlook for the full year 2019 Exel Composites expects revenue and adjusted operating profit to increase in 2019 compared to 2018. President and CEO, Riku Kytömäki Exel Composites ended 2018 on a strong note. In the fourth quarter both order intake as well as revenue increased significantly. Growth was driven by the Construction & Infrastructure customer segment, predominantly supported by the wind energy industry. This industry now also represents Exel’s largest client, a position which has been held by a client from the telecommunications industry for the past ten years. During 2018 the competitive situation in the telecommunications industry, especially in China, changed significantly, driven by geopolitical factors such as trade barriers and export tariffs. Other Applications customer segment also grew in the fourth quarter, driven by the contribution of the acquired Diversified Structural Composites, DSC. Revenue in the Industrial Applications customer segment was impaired by lower volumes in telecommunications. From a regional perspective, revenue in the region Rest of the World increased significantly in the fourth quarter supported by the North American DSC and by increased export from other Exel units to the American market. Revenue increased also in the Asia-Pacific region driven by the contribution of Nanjing Jianhui. The revenue decrease in Europe reflected lower volumes in telecommunications. All in all, Exel’s global market position improved significantly during the year 2018. Adjusted operating profit decreased in the fourth quarter, as volume growth in wind energy was not enough to compensate for the impaired profitability mainly related to sales mix in some of the Group’s manufacturing units. The turnaround and integration of DSC continues according to plan and in the fourth quarter of 2018 the operating profit of DSC improved clearly from the third quarter of 2018. During 2018 we initiated a cost reduction program to improve Group profitability. The implementation of the program continues as planned with the aim to optimize Exel Composites’ manufacturing footprint in Europe, to improve the profitability and cost efficiency in the DSC business and to drive further synergy savings between the company’s two manufacturing units in China, among other things. Early 2019 we announced the closing of Exel’s manufacturing unit in Voerde, Germany, and conducted co-determination negotiations in Finland, in addition to other cost savings measures. The annual savings target of the Group-wide cost savings program is EUR 3 million, expected to be fully effective in 2020. I am convinced that we have taken important steps to improve profitability and created a platform for long-term profitable growth. I look forward to 2019 with confidence. Consolidated key figures EUR thousand 1.10. 1.10. Change, 1.1. 1.1.-31.12. Change, -31.12. -31.12. % -31.12. 2017 % 2018 2018 2017Order intake 29,108 21,433 35.8 100,757 86,531 16.4Order backlog 1) 23,685 17,126 38.3 23,685 17,126 38.3Revenue 26,711 22,414 19.2 96,608 86,255 12.0Operating profit -1,194 1,389 -186.0 2,217 6,081 -63.5% of revenue -4.5 6.2 2.3 7.1Adjusted operating 768 1,327 -42.1 5,018 6,319 -20.6profit 2)% of revenue 2.9 5.9 5.2 7.3Profit for the -1,606 956 -267.9 386 4,212 -90.8periodNet cash flow from 534 2,708 -80.3 868 4,856 -82.1operatingactivitiesReturn on capital -8.3 12.3 4.4 14.8employed, %Net gearing, % 96.3 30.3 96.3 30.3Earnings per share -0.14 0.08 0.03 0.36Equity per share, 2.18 2.44 -10.5 2.18 2.43 -10.2EUREmployees on 677 562 20.6 647 532 21.7averageEmployees at end of 675 568 18.8 675 568 18.8period ¹ As per the end of the period.² Excluding material items affecting comparability, such as restructuring costs, impairment losses and reversals, and costs related to planned or realized business acquisitions or disposals. For more information, please refer to the paragraph “Change in Exel Composites’ financial reporting terminology” of the Half-year Financial Report published on 21 July 2016. Financial reporting and Annual General Meeting 2019 Exel Composites publishes the following financial reports in 2019: · Financial Statements Release 2018: 15 February 2019 · Business Review January - March: 3 May 2019 · Half Year Financial Report January - June: 23 July 2019 · Business Review January - September: 30 October 2019 Annual Financial Report, Corporate Governance Statement and Remuneration Statement for 2018 will be published on 28 February 2019 in electronic format at the company’s website www.exelcomposites.com. The Annual General Meeting will be held on Thursday 21 March 2019 at 10:00 at Scandic Marina Congress Center at the address of Katajanokanlaituri 6, Helsinki, Finland. Financial results briefing Exel Composites will hold a financial results briefing regarding the financial statements on Friday 15 February 2019 at 12:30 EET at Scandic Hotel Simonkenttä’s Roba meeting room (address Simonkatu 9, Helsinki, Finland). Exel Composites’ Financial Statements Release January – December 2018 is available in full in pdf format as an attachment to this release. The report and the related presentation shall also be available at the company’s website under the Investor section. Vantaa, 15 February 2019 Exel Composites PlcBoard of Directors

Finnair Group Financial Statements Release 2018

Finnair Plc                          Financial Statement Release            15 February 2019 at 9.00 am. EET Finnair carried a record number of passengers in Q4; full-year comparable operating profit totalled 169.4 million euros  October–December 2018  ·  Revenue increased by 5.8% to 683.1 million euros (645.3)*. ·  Available seat kilometres (ASK) grew by 9.0%. ·  Passenger load factor (PLF) was 76.9% (-3.4 percentage points). ·  Comparable operating result was 9.2 million euros (22.9). Operating result was 55.9 million euros (23.5). ·  Net cash flow from operating activities was 37.5 million euros (92.6), and net cash flow from investing activities was -49.5 million euros (-85.6).** ·  Unit revenue (RASK) decreased by 2.9%. Unit revenue at constant currency decreased by 2.4%. ·  Unit cost (CASK) decreased by 0.7%. Unit cost at constant currency excluding fuel decreased by 4.3%. ·  Earnings per share were 0.29 euros (0.11). January–December 2018  ·  Revenue increased by 10.4% to 2,834.6 million euros (2,568.4)*. ·  Available seat kilometres (ASK) grew by 14.8%. ·  Passenger load factor (PLF) was 81.8% (-1.5 percentage points). ·  Comparable operating result was 169.4 million euros (170.4). Operating result was 207.5 million euros (224.8). ·  Net cash flow from operating activities was 383.1 million euros (382.3), and net cash flow from investing activities was -194.0 million euros (-157.5).** ·  Unit revenue (RASK) decreased by 3.9%. Unit revenue at constant currency decreased by 2.6%. ·  Unit cost (CASK) decreased by 3.2%. Unit cost at constant currency excluding fuel decreased by 6.2%.   ·  Earnings per share were 1.08 euros (1.23). ·  The Board of Directors proposes to the Annual General Meeting that a dividend of 0.274 euros per share be distributed for 2018. *     Unless otherwise stated, comparisons and figures in parentheses refer to the comparison period, i.e. the same period last year.  **   In Q4, net cash flow from investing activities includes 2.3 million euros of investments in money market funds or other financial assets maturing after more than three months. In January–December, these increased in net terms by 81.8 million euros. These redemptions are part of the Group’s liquidity management.   Outlook Guidance on 15 February 2019: Global airline traffic is expected to continue growing in 2019. Finnair expects increased competition as capacity is added, particularly on routes linking Europe with Asia as well as in short-haul traffic. The slowdown in the economy of Finnair’s key markets and the continued uncertainties surrounding global trade, including from Brexit, could impact the demand for air travel and cargo. Finnair plans to increase its capacity by approximately 10 per cent in 2019, down from its 14.8 per cent capacity growth in 2018. This growth is mainly focused on the Asian market. Revenue is expected to grow at a somewhat slower pace than capacity in 2019. In line with its disclosure policy, Finnair will issue guidance on its full-year comparable operating result as part of its half-year report in July. CEO Topi Manner: The year 2018 was Finnair’s third year of accelerated growth, but it also had a different side to it. In the first half of the year, a favorable demand environment supported our rapid and profitable growth in both passenger traffic and travel services. However, in the second half of the year, competition intensified especially on certain European routes. In addition, the price of jet fuel temporarily spiked and the future growth rate of the global economy became more uncertain. Our full-year traffic growth – a 14.8% increase in capacity and an 11.6% increase in number of passengers to 13.3 million – resulted in a growth of 10.4% in revenue, with a total revenue of 2.8 billion euros. Our full-year comparable operating result was 169.4 million euros, thus remaining at the previous year’s level (170.4).  We continued investments that our renewal requires. Even if our operating result weakened towards the end of the year, our long-term target continues to be profitable, sustainable growth. Our market environment also has more uncertainty than a year ago, as the growth in global economy seems to soften. Our goal is to create value for our shareholders, customers and employees alike. Therefore, it is important that we take care of our profitability so that we can develop in all these areas and create value in the more challenging environment we operate in. In practice this means that we invest into items that are key for our future, we question our way of working in a healthy manner, we develop our productivity and react to changes in external environment. At the same time, we continue to develop our customer experience and people experience in long-term. As the new CEO, I have seen how passionate both our customers and our people are about Finnair. This forms a strong foundation on which to build Finnair’s future together. I want to thank our customers for the trust they have placed in Finnair, and all Finnair employees for the good performance in 2018. Dividend policy and the Board’s proposal for the distribution of profit  The aim of Finnair’s dividend policy is to pay, on average, at least one-third of the earnings per share as a dividend over an economic cycle. The aim is to take into account the company’s earnings trend and outlook, financial situation and capital needs in the distribution of dividends. In 2018, earnings per share were 1.08 euros (1.23). Finnair Plc’s distributable equity amounted to 392,868,533.76 euros on 31 December 2018. The Board of Directors proposes to the Annual General Meeting that a dividend of 0.274 euros per share be distributed for 2018.  Financial Reporting in 2019 The publication dates of Finnair’s financial reports in 2019 are the following:  Interim Report 1 January – 31 March 2019:                     24 April 2019 Half-year report 1 January – 30 June 2019:                     17 July 2019 Interim Report 1 January – 30 September 2019: 22 October 2019  FINNAIR PLCBoard of Directors Briefings  Finnair will hold a results press conference on 15 February 2019 at 11:00 a.m. and an analyst briefing at 12:30 p.m. at its office located at Tietotie 9. An English-language telephone conference and webcast will begin at 2:30 p.m. Finnish time. The conference may be attended by dialling your local access number +358 9 7479 0361 (Finland), 0200 880 389 (Sweden), 0800 358 6377 (UK) or +44 (0)330 336 9105 (all other countries). The confirmation code is 9344771. To join the live webcast, please register at: https://slideassist.webcasts.com/starthere.jsp?ei=1231175   For further information, please contact:  Chief Financial Officer Pekka Vähähyyppä, tel. +358 9 818 8550, pekka.vahahyyppa@finnair.com Director, Financial Communications Mari Reponen, tel. +358 9 818 2037, mari.reponen@finnair.com IR Analyst, Kasper Joukama, tel.+358 9 8181 2004, kasper.joukama@finnair.com

Telia Company comments the ruling from the Stockholm district court

Telia Company’s involvement in this court case has been about which country the disgorgements from the Uzbek business will be paid to – the Netherlands, Sweden or the U.S. Today’s ruling means that USD 208.5 million will be paid to the Netherlands or the U.S. The amount to be paid will not have a financial effect for Telia Company since it was included in the global settlement that Telia Company reached in 2017 to pay fines and disgorgements in an aggregate amount of USD 965 million to the concerned authorities regarding historical transactions in Uzbekistan. The disgorgements amounted to USD 417 million, whereof USD 208.5 million already has been paid to the US Securities and Exchange Commission (SEC).    “The ruling does not change our position that the settlement in 2017 was in the best interest for Telia Company and our shareholders. The recently concluded court case and Telia Company’s settlement with the US and Dutch authorities partly concern the same events, but they have been tried according to different legal frameworks – US and Dutch laws for the Company and Swedish law for the former employees. It is not unusual that an event is tried under different laws in different countries and that the outcome may differ,” says Jonas Bengtsson, Group General Counsel at Telia Company.     Telia Company cooperated with US and Dutch authorities in 2014-2017. The Company concluded that these countries’ legislations were applicable and accepted responsibility for actions which were in violation of those legal frameworks.    “I welcome that the district court now has announced its ruling. Even if Telia Company has not been part of the criminal proceedings involving three former Telia employees, it has of course affected the Company. It is part of a long process which started already in 2012. Our ambition during this entire process has been to cooperate as transparently as possible with the authorities involved. The entry into Uzbekistan which began in 2007 has had very serious consequences for Telia Company and for individuals alike. The Company took its responsibility when it entered into a global resolution in September 2017, for actions which had violated US and Dutch legislations. I hope that today’s ruling will bring an end to a painful and costly chapter in Telia Company’s history,” says Marie Ehrling, Chair of the Board of Telia Company.        For more information, please contact our press office +46 771 77 58 30, visit our Newsroom  or follow us on Twitter @Teliacompany .       We’re Telia Company, the New Generation Telco. Our approximately 20,000 talented colleagues serve millions of customers every day in one of the world’s most connected regions. With a strong connectivity base, we’re the hub in the digital ecosystem, empowering people, companies and societies to stay in touch with everything that matters 24/7/365 - on their terms. Headquartered in Stockholm, the heart of innovation and technology, we’re set to change the industry and bring the world even closer for our customers. Read more at www.teliacompany.com